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Background: The Department of Health has identified interventions to manage alcohol misuse, smoking
and overweight, delivered by community pharmacists, as public health priorities.
Objectives: To systematically review the effectiveness of community pharmacy interventions to manage
alcohol misuse, smoking cessation and weight loss; to explore if and how age, sex, ethnicity and
socioeconomic status moderate effectiveness; and to describe how the interventions have been organised,
implemented and delivered.
Data sources: Ten electronic databases were searched: Applied Social Sciences Index and Abstracts;
Cumulative Index to Nursing and Allied Health Literature; EMBASE; International Bibliography of the Social
Sciences; MEDLINE; NHS Economic Evaluation Database; PsycINFO; Social Science Citation Index; Scopus;
and the Sociological Abstracts from inception to May 2014. There was no restriction on language or
country. Supplementary searches included website, grey literature, study registers, bibliographies and
contacting experts.
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Review methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines
were followed. Any type of intervention of any duration based in any country and in people of any age
was included. The review included interventions set in a community pharmacy and delivered by the
pharmacist or the wider pharmacy team. Randomised controlled trials, non-randomised controlled trials,
controlled before-and-after studies and interrupted time series studies were included. Data extraction and
quality assessment were conducted independently for each study by two reviewers. Meta-analysis and
narrative synthesis were also conducted.
Results: The searches identified over 14,000 records, of which 24 studies were included. There were two
alcohol, 12 smoking cessation, five weight loss and five multicomponent interventions that included
pharmacotherapy and lifestyle changes in participants with diabetes mellitus, dyslipidaemia or hypertension.
Nine of the studies were UK based; seven of the studies were rated ‘strong’ for quality. All studies were
of adults. Pharmacy-based smoking cessation interventions including behavioural support and/or nicotine
replacement therapy are effective and cost-effective in helping adults to stop smoking, particularly when
compared with usual care. The pooled odds ratio of the intervention effects for smoking cessation was
1.85 (95% confidence interval 1.25 to 2.75). It is currently unknown which specific types of smoking
cessation interventions are the most effective. There was insufficient evidence for the effectiveness
of community pharmacy-based brief alcohol interventions. Evidence suggests that pharmacy-based
weight-loss interventions are as effective as similar interventions in other primary care settings, but not as
effective or cost-effective as commercially provided weight management services based in community
settings. None of the five multicomponent studies demonstrated an improvement compared with control
for anthropometric outcomes in participants with comorbidities, but they did show improvement in
measures associated with the comorbidities. Very few studies explored if and how sociodemographic or
socioeconomic variables moderated the effect of interventions. In two studies based in areas of high
deprivation, where participants chose the intervention, the sociodemographic characteristics of participants
differed between intervention settings. There were also differences in recruitment, attendance and
retention of participants by type of setting. The evidence suggests that a distinct group of people might
access pharmacies compared with other settings for alcohol management, smoking cessation and weight
loss. There is insufficient evidence to examine the relationship between behaviour change strategies and
effectiveness; or evidence of consistent implementation factors or training components that underpin
effective interventions.
Limitations: The information reported in the publications of included studies did not allow us to assess in
detail if and how age, sex, ethnicity and socioeconomic status moderate effectiveness, or to describe how
the interventions had been organised, implemented and delivered.
Conclusions: Community pharmacy interventions are effective for smoking cessation. Evaluations of
interventions to manage alcohol misuse and obesity, set within the community pharmacy, are needed. The
effect of community pharmacy interventions on health inequalities is unclear. Future research in this area is
warranted, and trials should include the assessment of age, sex, ethnicity, socioeconomic status and
contextual factors, and present analysis of how these factors moderate effectiveness.
Study registration: This study is registered as PROSPERO CRD42013005943.
Funding: The National Institute for Health Research Public Health Research programme.
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Plain English summary
A lcohol misuse, smoking and obesity are public health priorities; poorer and more vulnerable peopleare more likely to have a problem with alcohol, smoking and being overweight. Most people live near
a pharmacy, and pharmacies are often found in poor areas and open long hours. Pharmacies may therefore
be a useful place to help those people most in need and people who may not visit other health-care
settings, such as doctors’ surgeries or primary care centres.
We found 24 studies that compared a pharmacy-based intervention with doing nothing or another type of
intervention that could have also been set in a pharmacy or elsewhere. We found that smoking cessation
studies set in pharmacies help adults to stop smoking, especially when compared with doing nothing.
Not enough studies of interventions for alcohol misuse have been conducted to draw conclusions.
Pharmacy-based weight loss interventions helped adults to lose about the same amount of weight as
similar interventions led by nurses in doctors’ surgeries, but not as much as commercial weight
management services. Studies that aimed to help people control their diabetes mellitus, and reduce their
cholesterol or blood pressure by better management of their medicines and by making changes to their
lifestyle, were effective but did not help these people to lose weight at the same time.
Hardly any of the studies looked at whether or not the different characteristics of people, such as their
income, made a difference to how well the interventions worked or how fair these interventions are across
the whole population.
DOI: 10.3310/phr04020 PUBLIC HEALTH RESEARCH 2016 VOL. 4 NO. 2
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xvii

Scientific summary
Background
Excessive alcohol intake, smoking and obesity are three of the most significant modifiable risk factors for
morbidity and mortality in the UK. The rates of excessive alcohol intake, smoking and obesity are all
greater in lower socioeconomic groups, significantly contributing to overall inequalities in health. Within
the UK, community pharmacies may be an ideal setting in which to deliver health-care interventions to
reduce risk factors for disease. Community pharmacies are easily accessible and widely distributed, often in
areas of highest deprivation, and many are open long hours. Community pharmacists and the wider
pharmacy team have the potential to deliver health-care interventions to those hardest to reach and
arguably those most in need. In so doing, these interventions may reduce the socioeconomic inequalities in
the prevalence and treatment of modifiable risk factors for relevant diseases. The Department of Health
has identified interventions to manage alcohol misuse, smoking and overweight, delivered by community
pharmacists, as public health priorities. We currently do not know the overall effectiveness of these
community pharmacy-delivered interventions. This systematic review examines the effectiveness of such
interventions and the findings are of relevance to those responsible for policy and practice in England and
the UK, and many countries that are trying to tackle alcohol misuse, smoking and obesity, where one
option is to deliver interventions through community pharmacies.
Objectives
1. To assess the effectiveness of community pharmacy interventions on health and health behaviours in
relation to alcohol misuse, smoking cessation and weight management.
2. To explore if, and how, socioeconomic status (SES), sex, ethnicity and age moderate the effect of
these interventions.
3. To describe how the interventions included in this review have been organised, implemented
and delivered.
Review methods
A systematic review was conducted on the effectiveness of community pharmacy interventions for alcohol
misuse, smoking cessation and weight management using the principles outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins JPT, Green S. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011).
Interventions
The examined interventions were set in a community pharmacy and delivered by the pharmacist or the
wider pharmacy team. Any type of intervention of any duration based in any country and in people of any
age was included. Interventions led by the pharmacist or the wider pharmacy team that took place outside
the community pharmacy setting were excluded.
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Study designs
All types of controlled trials were included, such as randomised controlled trials (RCTs) and
non-randomised controlled trials (nRCTs), controlled before-and-after studies, interrupted time series
and repeated measures studies.
Search strategy
Ten electronic databases were searched from inception to May 2014: Applied Social Sciences Index and
Abstracts, Cumulative Index to Nursing and Allied Health Literature, EMBASE, International Bibliography of
the Social Sciences, MEDLINE, NHS Economic Evaluation Database, PsycINFO, Social Science Citation Index,
Scopus and the Sociological Abstracts. We did not exclude papers on the basis of country, language
or publication date. The electronic database searches (written by HM with advice from LS) were
supplemented with searches of websites, grey literature, research registries and bibliographies, and by
contacting experts.
Outcomes
Interventions for alcohol consumption and smoking cessation had to report a behavioural outcome to be
included (e.g. quit rates or change in alcohol intake, respectively). Weight loss interventions had to report
an anthropometric outcome to be included [e.g. change in weight or body mass index (BMI)]. Secondary
outcomes included any differential effects of the interventions by sociodemographic status (age, ethnicity,
sex) or SES (as measured by education, income, occupation, social class, deprivation or poverty). Data
on the organisation, implementation and delivery of interventions were also extracted.
Data extraction and quality appraisal
The initial screening of titles and abstracts was conducted by three reviewers (CLO, HM and SS); the
screening of full papers was conducted by two reviewers (CLO and TB). Data extraction was conducted
independently by two reviewers using a piloted electronic data extraction form (combination of AT,
CLO, CS, HM, LN, LS, SS and TB). The methodological quality of the included studies was appraised
independently by two reviewers using the Effective Public Health Practice Project Quality Assessment Tool
for Quantitative Studies (CLO and TB). Any discrepancies were resolved through discussion between the
authors and, if consensus was not reached, with the project lead (CS). Behaviour change, organisation
and service delivery, and implementation, was appraised by one reviewer (CS) and checked by another
(FS or LS for behaviour change, TB for organisation and service delivery and CB for implementation).
Analysis and synthesis
Narrative synthesis was conducted for all the included interventions. Owing to limited data and the
heterogeneity of the studies it was possible to conduct meta-analyses (AK, checked by Julian Higgins) only
for the smoking cessation studies.
SCIENTIFIC SUMMARY
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Results
The searches identified over 19,000 records, of which 24 studies were included. There were two alcohol
misuse interventions, 12 smoking cessation interventions, five weight loss interventions and five
multicomponent interventions that included pharmacotherapy and lifestyle changes in participants with
comorbidities including dyslipidaemia, hypertension and diabetes mellitus.
Nineteen were RCTs, three were nRCTs and two were controlled before-and-after studies. Nine studies
were conducted in the UK, four in the USA, two each in Australia, South America and Spain, and one
each in Canada, Denmark, Japan, Thailand and the Netherlands. All studies were of adults. Three studies
adopted a targeted approach to addressing inequality, recruiting a majority of participants from areas of
high deprivation. Three smoking cessation interventions were targeted at the pharmacy staff as well as
customers; the remaining 21 studies were targeted at pharmacy customers alone. Intervention components
varied considerably across the 24 studies; length of study ranged from 5 to 56 weeks. In terms of global
quality assessment, seven studies were rated ‘strong’, six studies were rated ‘moderate’ and 11 studies
were rated ‘weak’.
There was insufficient evidence for the effectiveness of community pharmacy-based brief alcohol
interventions; evidence from the two trials included in this review suggests a lack of effectiveness.
Twelve studies evaluated the effectiveness of community pharmacy-based smoking cessation interventions.
Ten RCTs were included in a meta-analysis, grouped by whether the pharmacy-based intervention was
compared with an active control or usual-care group. The effect was significant for pharmacy-based
interventions compared with usual care, with significant heterogeneity. The pooled odds ratios were 1.21
[95% confidence interval (CI) 0.86 to 1.71] and 2.56 (95% CI 1.45 to 4.53) for the active control and
usual care, respectively. Pharmacy-based smoking cessation interventions including behavioural support
and/or nicotine replacement therapy (NRT) are effective and cost-effective in stopping adults smoking,
particularly compared with usual care. There is insufficient evidence to say which specific type of smoking
cessation intervention is most effective.
Five studies evaluated the effectiveness of community pharmacy-based weight loss interventions. None of
the weight loss studies demonstrated a statistically significant improvement in the pharmacy-based
intervention groups compared with the control for any anthropometric outcome. However, the types of
interventions were heterogeneous and all of the comparison groups were other active interventions that
took place in or out of the pharmacy setting. Pharmacy-based weight loss interventions appear to be as
effective as similar interventions in other primary care settings but not as effective or cost-effective as
commercially provided weight management services in community settings.
Five studies evaluated multicomponent interventions (pharmacotherapy and lifestyle changes) compared
with usual care in participants with comorbidities, including diabetes mellitus, dyslipidaemia and hypertension.
None of the studies demonstrated a significant improvement compared with the control for BMI or weight,
but all studies did show a significant improvement in the relevant primary outcomes of glycaemic control,
lipids and blood pressure.
No study assessed the differential effects of any measure of SES; therefore, the impact of any of the
interventions on health inequalities is unknown. The most common behaviour change strategy used in
the included interventions was the transtheoretical model (stages of change). The majority of included
interventions were implemented within the political context of extending the pharmacists’ public health
role. In terms of sustainability, a number of studies highlight that reimbursement is needed to the
pharmacist for providing the intervention in order for it to be sustainable.
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Limitations
Despite the attention that was paid to extracting and summarising contextual factors including the
organisation, implementation and delivery of interventions, the intervention content, mechanisms and
procedures in most of the included papers were described in little detail. The reporting of implementation
factors was poorly reported, particularly stakeholder involvement (consultation and collaboration) in the
planning or during the delivery of the intervention, which was reported in only a few studies. The lack
of contextual information limits the potential for knowledge implementation and replication of the
interventions under review.
Conclusion
Summary of results
Twenty-four relevant studies of pharmacy-delivered interventions were identified; most of the evidence was
focused on smoking cessation interventions. There was insufficient evidence to assess the effectiveness of
pharmacy-based interventions for alcohol management. Pharmacy-based smoking cessation interventions,
including behavioural support and/or NRT, are effective and cost-effective in helping adults to stop
smoking, particularly compared with usual care. Pharmacy-based weight loss interventions appear to be
as effective as similar interventions in other primary care settings, but not as effective or cost-effective as
commercially provided weight management services in community settings. No study assessed the
differential effects of any measure of SES; therefore, the impact of any of the interventions on health
inequalities is unknown.
Implications for public health
Evidence from this review suggests that pharmacies are feasible settings in which to deliver health
promotion-type interventions. Our review has demonstrated that pharmacy-based interventions are
effective and cost-effective in helping adults to stop smoking compared with usual care. The evidence
demonstrates a range of types of smoking cessation interventions that are feasible within community
pharmacies, including behavioural support and/or NRT, but not which specific types of interventions
and components are the most effective. More evidence is needed to assess the effectiveness of
pharmacy-based interventions for alcohol and weight management.
Nine of the 24 studies were conducted in the UK and are generalisable to the UK pharmacy context. We
do not know if, and how, these interventions impact on health inequalities. There is also insufficient
evidence to examine the relationship between behaviour change strategies and effectiveness, or evidence
of consistent implementation factors or training components that underpin successful interventions. In
terms of sustainability, a number of studies highlighted that reimbursement is needed to the pharmacist
for providing the intervention in order for it to be sustainable.
Recommendations for research
This review shows that there is a dearth of evaluations that assess the effectiveness of pharmacy-based
interventions for alcohol management. The overall quality of the included studies suggests that more
research is required to improve recruitment and retention of participants to pharmacy-based interventions.
More information is also required about pharmacist training and the experience of those delivering
the training, the behaviour change strategies employed, resources required and the sustainability of
pharmacy-based interventions. Future pharmacy-based interventions, and evaluations of them, should be
robustly designed, particularly with regard to contextual factors, including the organisation, implementation
and delivery of interventions. They should also be sufficiently powered to detect small changes in
behavioural outcomes and any associated equity effects.
SCIENTIFIC SUMMARY
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Chapter 1 Background
Policy context
A number of agencies and countries, including the World Health Organization (WHO) and the Department
of Health (DH) for England, have set a clear agenda for the future of public health. This agenda is focused
on improving the healthy life expectancy of the population and, where possible, reducing or removing
threats to this aim.1,2 One strand within this agenda is to create accessible, multidisciplinary networks of
public health professionals who work within communities and provide services to address key public health
issues, health inequalities, and ultimately improve health and well-being. Worldwide, community pharmacies
may be an important component of this agenda; WHO acknowledges that community pharmacies and their
staff are easily accessible and, as such, could play a key role in public health initiatives. Interventions that aim
to reduce obesity, smoking rates and alcohol misuse, led by community pharmacists and other service
providers, have been identified by the DH as public health priorities.3,4 Indeed, it is thought that the key
characteristic through which community pharmacy-based public health interventions may have a positive
impact on health equity relates to their access and acceptability.
Excessive alcohol intake, smoking and obesity are three of the most significant modifiable risk factors for
morbidity and mortality in middle- and high-income countries.5,6 Conditions that are caused or exacerbated
by these risk factors include cardiovascular disease, type 2 diabetes mellitus, liver disease and lung cancer.
Socioeconomic inequalities in the prevalence and treatment of these conditions are major contributors to
overall inequalities in health and well-being.
The number of alcohol-related deaths in the UK is increasing and has almost doubled since 1991; higher
rates of excessive alcohol intake and alcohol-related deaths are reported in those living in areas of social
deprivation.7 In addition, for men in unskilled low-paid occupations, the rate of alcohol-related mortality is
around 3.5 times greater than in those in managerial and professional occupations. For women, this figure
is even higher, with those in unskilled low-paid occupations at around 5.7 times greater risk of alcohol-
related mortality than those in managerial and professional occupations.8 In the UK, the highest number of
preventable deaths are attributable to smoking,9 with approximately half of all life-long smokers dying
prematurely, losing on average about 10 years of life.10 It is estimated that up to 86,500 preventable
deaths each year can be attributed to smoking in the UK.11 In the UK, smoking rates declined to around
21% in 2007 and have since plateaued;12 smoking rates are greatest in low socioeconomic groups.13 The
prevalence of obesity in both children and adults remains relatively high in the UK compared with most
other European countries,14,15 particularly in areas of social deprivation. The prevalence of obesity in
women living in the UK is highest among those living in areas of social deprivation, but the association in
men is less clear.16
Existing relevant reviews were unable to assess the effectiveness of community pharmacy-delivered alcohol,
smoking and weight management interventions because of a limited evidence base.17–19 However, more
interventions have been carried out since these reviews were conducted and the evidence base requires
updating. In 2008, the DH2 stated it was crucial to develop ‘a sound evidence base that demonstrates how
pharmacy delivers effective, high quality and value for money services’, and this systematic review aims to
respond to this requirement.
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Community pharmacies
Community pharmacies in the UK are often the most accessible and available health-care provider to the
community, and higher numbers of community pharmacies are found in areas of high social deprivation. In
England, there are over 10,500 community pharmacies, distributed across urban and rural areas,11 allowing
the public to access health care without an appointment. These community pharmacies are open at
convenient times, including evenings and weekends, allowing access for people who work a wide range of
hours. This situation has consistently improved in recent years in England, with policy drives to improve
access to medicines, including the promotion of ‘100-hour pharmacies’, which must open 100 hours per
week for every week of the year.2 Eighty-nine per cent of the population in England can access a
pharmacy from home within a 20-minute walk. Importantly, in areas of highest deprivation, this value
increases to almost 100%.20 Estimates vary with regard to the reach of the community pharmacy network,
but it is thought to be relatively high: a survey published in 2008 found that 95% of the population of
Scotland make at least one visit during any 1 year.21
Many community pharmacies now offer smoking cessation services and a few offer alcohol reduction and
weight management services.22 Currently, six local pharmaceutical committees (LPCs) have weight
management services, 14 LPCs have alcohol services and there are 81 stop smoking services (some LPCs
have more than one service covering different areas). These services are delivered by pharmacists,
pharmacy technicians and counter assistants. The specific types of interventions are wide-ranging and
include two main approaches: pharmaceutical related [e.g. supplying nicotine replacement therapy (NRT)
for smoking cessation] and non-pharmaceutical related (e.g. providing advice on behaviour change
strategies), or a combination of both approaches. At present, many of these services are commissioned by
the local authority according to local need: all services are delivered to an agreed framework specification
that allows for variations in the delivery of the service at a local level.
Summary
Excessive alcohol intake, smoking and obesity are three of the most significant modifiable risk factors for
morbidity and mortality in the UK. The rates of excessive alcohol intake, smoking and obesity are all
greater in lower socioeconomic groups, significantly contributing to overall inequalities in health.
Within the UK, community pharmacies are potentially the ideal setting in which to deliver health-care
interventions to reduce risk factors for disease. Community pharmacies are easily accessible; they are
widely distributed, often in areas of highest deprivation, and many are open long hours. The unique access
characteristics of community pharmacies may be more attractive to individuals who cannot, or choose not
to, access conventional health-care providers. In addition to conventional health-care provision, community
pharmacists can provide opportunistic health care. Community pharmacists can play a significant role in
improving risk factors for disease through modifying health behaviours, such as through the management
of alcohol consumption, smoking cessation and weight loss. All these factors taken together indicate
that community pharmacists and the wider pharmacy team have the potential to deliver health-care
interventions to those hardest to reach and arguably those most in need, and in so doing may reduce the
socioeconomic inequalities in the prevalence and treatment of modifiable risk factors for disease.
The DH has identified interventions aimed at managing alcohol, smoking and weight, delivered by
community pharmacists as public health priorities. We currently do not know how effective such
community pharmacy-delivered interventions are. This systematic review assesses the effectiveness of such
interventions and is of relevance to those responsible for policy and practice in many countries that are
trying to tackle obesity, smoking and alcohol misuse, where one option is to deliver interventions through
community pharmacies. Specifically, this review aims to help those commissioning public health services in
the UK to determine which pharmacy-delivered interventions are effective, good quality and value
for money.
BACKGROUND
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Objectives
1. To assess the effects of community pharmacy interventions on health and health behaviours in relation
to alcohol misuse, smoking cessation and weight management.
2. To explore if and how socioeconomic status (SES), sex, ethnicity and age moderate the effect of
the interventions.
3. To describe how the interventions included in the review have been organised, implemented
and delivered.
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Chapter 2 Methods
The review was carried out using the principles outlined in the Cochrane Handbook for SystematicReviews of Interventions Version 5.1.0.23 The review protocol is published in BioMed Central’s
Systematic Reviews24 and is registered with the International Prospective Register of Systematic Reviews
(PROSPERO; registration number: CRD42013005943). A study advisory group that comprised patients,
pharmacists and researchers with expertise in alcohol, smoking and obesity guided the research. The
review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA)25,26 and Template for Intervention Description and Replication recommendations.27
Interventions
The review included any type of intervention based in any country and in people of any age. The review
included interventions that focused on alcohol misuse, smoking cessation and weight management.
As there was no restriction on the type of intervention, interventions could include multiple lifestyle
interventions that encompassed more than one component (e.g. smoking cessation and weight
management). There was no restriction on the type of participant and so interventions could include
participants with comorbidities such as cardiovascular disease or type 2 diabetes mellitus. There was no
restriction on the type of comparator and could include a non-active control/usual care, or another type of
active intervention set inside or outside the community pharmacy; the comparator could be an identical
intervention carried out in a setting other than the community pharmacy. There was no restriction on
study duration.
The setting of interest was the community pharmacy, which was defined as a pharmacy set in the
community that is accessible to all and not based in a hospital, clinic or online. The participants could be
recruited from outside the community pharmacy setting as long as the intervention was carried out from
the community pharmacy. The intervention had to be led by the community pharmacist or the wider
pharmacy team comprising the pharmacist, pharmacy assistant and/or pharmacy technician; however, the
intervention could also include other deliverers as part of a multidisciplinary team. Interventions led by the
pharmacist or the wider pharmacy team that took place outside the community pharmacy were excluded.
Table 1 details the study eligibility criteria.
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Study design
From the results of our initial scoping search it was anticipated that there would be insufficient evidence
from randomised controlled trials (RCTs) alone and so all studies with a control group were included.
Using the Cochrane Effective Practice and Organisation of Care study design criteria,28 the types
of study design included in the review were as follows: RCTs, non-randomised controlled trials (nRCTs),
controlled before-and-after studies (CBAs), interrupted time series and repeated measures studies.
Before-and-after studies without a control group and all cross-sectional studies were excluded because it is
impossible to attribute causation from such study designs.
Evidence from uncontrolled studies was excluded from this review, but has been identified for possible
future research. Throughout the screening process, any reference that appeared to be an uncontrolled
before-and-after study that otherwise seemed to fit the inclusion criteria were identified. It was considered
important to identify these types of studies, which cannot inform issues of effectiveness but may inform
future areas of research around issues such as the recruitment and retention of participants and the
demographic and SES of participants accessing community pharmacy-based settings.
TABLE 1 Study eligibility criteria
Aspect of
study design Eligibility criteria Examples and additional clarification
Population People of all ages and in any country Could include participants with comorbidities
such as cardiovascular disease or type 2 diabetes
mellitus
Intervention Community pharmacy-delivered interventions for
alcohol reduction, smoking cessation or weight loss
Could include multiple lifestyle interventions that
encompassed more than one component
Comparator Non-active control/usual care, or another type of
active intervention
Could be carried out in a community pharmacy
or in another setting
Outcome Behavioural outcome (e.g. quit rates, change in
alcohol intake). For weight loss interventions,
studies had to report an anthropometric
outcome (e.g. weight, BMI, waist-to-hip ratio)
No other limits (could be self-reported, observed,
measured)
Setting A community pharmacy was defined as a
pharmacy set in the community which is accessible
to all and not based in a hospital, clinic or online
Participants could be recruited from outside of
the community pharmacy setting as long as the
intervention was carried out from the community
pharmacy
Provider Had to be led by the community pharmacist or the
wider pharmacy team comprising the pharmacist,
pharmacy assistant and/or pharmacy technician
Could also include other deliverers as part of a
multidisciplinary team
Study design All studies with a control group (RCTs, nRCTs,
CBAs, ITS and repeated measures studies)
No limit on study duration
BMI, body mass index; CBA, controlled before-and-after study; ITS, interrupted time series; nRCT, non-randomised
controlled trial; RCT, randomised controlled trial.
METHODS
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Search strategy
Ten electronic databases were searched (host sites given in parenthesis): MEDLINE (via Ovid), EMBASE
(via Ovid), Cumulative Index to Nursing and Allied Health Literature (NHS Evidence Health Information
Resources), PsycINFO (NHS Evidence Health Information Resources), Social Science Citation Index
(Thomas Reuters’ Web of Science), Applied Social Sciences Index and Abstracts (via Cambridge Scientific
Abstracts), International Bibliography of the Social Sciences (via EBSCOhost), Sociological Abstracts (via
Cambridge Scientific Abstracts), Scopus (Elsevier) and the NHS Economic Evaluation Database (via the NHS
Centre for Reviews and Dissemination).
Two reviewers developed the electronic searches (HJM and LS) using medical subject headings and text
words using terms for pharmacy, alcohol, smoking cessation and weight. During development of the
search we used the studies that were identified as relevant in our previous scoping search as a cross-check
to see if the search strategy identified the same studies, this acted as a method of checking the sensitivity
of the search strategy. All databases were searched from inception (e.g. MEDLINE starts in 1946) to
May 2014. The MEDLINE search is detailed in Appendix 1. There was no restriction on publication date
or language.
In order to capture all relevant evidence, various supplementary approaches were used to identify additional
published, unpublished and ongoing studies. The electronic database searches were supplemented with
website (Google) and grey literature searches (OpenGrey, Social Care Online, Prevention Information &
Evidence eLibrary and Nexus UK). The International Standard Registered Clinical/Social Study Number registry
and the National Research Register were also searched. The bibliographies of all included studies were hand
searched; experts in the field were contacted as well as authors of ongoing studies.
Outcomes
The primary outcomes of this review were behavioural outcomes; a causal modelling framework29 was
used to conceptualise behavioural outcomes. The framework contains four categories: (1) determinants
of behaviour; (2) behavioural outcomes; (3) physiological and biochemical outcomes; and (4) health
outcomes. Interventions for smoking cessation and alcohol consumption had to report a relevant
behavioural outcome in order to be included (e.g. quit rates and change in alcohol intake, respectively).
For weight loss interventions, studies had to report an anthropometric outcome (physiological) to be
included [e.g. weight, body mass index (BMI), waist-to-hip ratio]. There were no other restrictions on study
inclusion by type of outcome. Outcomes that were measured, observed or self-reported were included.
The secondary outcomes of this review were any differential effects of the interventions by sociodemographic
status (age, ethnicity, sex) or SES (as measured by education, income, occupation, social class, deprivation
or poverty), or interventions that were targeted at disadvantaged groups.
Contextual data on the organisation, implementation and delivery of interventions were extracted using
the methodological tool for the assessment of the implementation of complex public health interventions
in systematic reviews developed by Egan et al.30 for the workplace and adapted by Bambra et al.31 for
obesity interventions. Examples of components of the organisation, implementation and delivery of
interventions include theoretical underpinning and strategies used to change behaviour; implementation
context; consultation and/or collaboration process; sustainability; stakeholder support; staff training and
quality assurance; experience of the intervention team; and resources and other intervention-related costs.
The Behaviour Change Wheel32 and the Nuffield Intervention Ladder33 were chosen to broadly describe the
interventions by grouping and classifying the policy categories and intervention functions. We also provide
a brief description of the theoretical models which underpinned the interventions and the behaviour
change strategies used within each intervention, mostly paraphrasing the original papers.
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Data extraction and quality appraisal
The initial screening of titles and abstracts was conducted by three reviewers (CM, HM and SS). The
screening of full-text papers was conducted by two reviewers (CM and TB) with any disagreement or
uncertainty about inclusion resolved through discussion with two other reviewers (AT and CS). Data
extraction and quality assessment was conducted independently for each study by two reviewers (from AT,
CM, CS, HM, LN, LS, SS and TB). The data extraction form is detailed in Appendix 2. Data were extracted
on the study characteristics, service provider characteristics, outcomes, demographic and socioeconomic
variables, and costs.
The quality of the included studies was appraised using the Effective Public Health Practice Project Quality
Assessment Tool for Quantitative Studies34 (see Appendix 3), which is recommended by the Cochrane
Public Health Review Group.35 Any discrepancies in the data extraction or quality assessment were either
resolved through discussion or ultimately referred to a third reviewer for final assessment (TB). The quality
assessment was used within the narrative synthesis to highlight variations between studies.
Analysis and synthesis
Owing to the heterogeneity of the studies, it was possible to conduct meta-analyses for the smoking
cessation studies only. The analyses were performed using the R package meta (The R Foundation for
Statistical Computing, Vienna, Austria). The smoking data were analysed using a binomial–normal
random-effects model. In order to explain the observed heterogeneity between studies, four different
meta-regression models were fitted, accounting for whether an active control group or usual care was used,
duration of the intervention and the global quality assessment ratings. Q-statistics and the percentage of
heterogeneity between studies were reported for each metaregression model. The optimum metaregression
model was chosen using a minimum Akaike information criterion. Where meta-analysis could not be
performed, as was the case with the weight data, the change data were described using a bar chart.
Owing to the limited available data and lack of informative priors, the planned analysis as described in the
protocol24 was not performed in R instead of Stata (StataCorp LP, College Station, TX, USA) or WinBUGS
(MRC Biostatistics Unit, Cambridge, UK) for the same reason. A funnel plot for the smoking cessation RCTs
was carried out to indicate (but not diagnose) the possible presence of publication bias: intervention
effect estimates from individual studies were plotted on the horizontal axis and the standard error of the
intervention effect estimate was plotted on the vertical axis. A triangular region was plotted, within which
95% of studies would be expected to lie in the absence of both biases and heterogeneity.23 Narrative
synthesis was conducted for all the included interventions.
Studies eligibility
The titles and abstracts of 14,011 records were screened for inclusion; 13,939 were excluded because
inclusion criteria were not met. Inclusion criteria were all types of controlled trials set in a community
pharmacy and delivered by the pharmacist or the wider pharmacy team with a focus on alcohol misuse,
smoking cessation and weight management. Any type of intervention of any duration based in any
country and in people of any age was included. Seventy-two records were obtained as full-text articles
because on initial screening it appeared these records might fit the inclusion criteria. Twenty-four studies
were finally included and full references are listed in Appendix 4. An additional three studies are ongoing
and are listed in Appendix 5.
The process of inclusion and exclusion of studies is detailed in Figure 1. Of the 72 full-text articles that
were screened, eligibility was unclear in 10 articles,36–45 and this was resolved through discussion among
reviewers (AT, CO, CS, TB). Uncertainty mainly arose regarding whether the intervention was set in a
community pharmacy or led by pharmacy staff, or the outcomes (e.g. where studies reported composite
METHODS
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measures or where outcomes specific to the pharmacy-based element could not be picked out).
The reasons for the exclusion of papers at the full-text stage (n= 40) are detailed in Appendix 6.
Fifty-four studies that otherwise appear to fit the inclusion criteria were identified as uncontrolled
before-and-after studies; these references are listed in Appendix 7.
UK alcohol service evaluations
Our initial scoping search of the literature revealed a dearth of information from controlled studies of
community pharmacy alcohol screening and brief intervention services. Therefore, a search was undertaken
to identify any uncontrolled evaluations undertaken in the UK of community pharmacy alcohol screening
and brief advice interventions.
Additional searches for these types of evaluations were carried out between March 2014 and July 2014
and included contacting (1) commissioners of such services; (2) providers of such services; and (3) experts
in the academic community who have published in this field. Commissioners included all local authorities
in England and all health boards in Scotland and Wales were contacted. The head of the Pharmaceutical
Services Negotiating Committee (PSNC) was contacted. Key individuals responsible for commissioning
alcohol services were contacted in NHS Scotland and NHS Wales. Providers including LPCs in England were
contacted through the PSNC. An advert was taken out in the PSNC newsletter, which was then e-mailed
to all LPCs. Similarly, Community Pharmacy Wales and Community Pharmacy Scotland were also contacted
Records after duplicates removed
(n = 14,011)
Records identified through
database searching
(n = 19,321)
Additional records identified
 through other sources
(n = 4)
Studies included
from 29 papers (n = 24)
• Alcohol, n = 2
• Smoking, n = 12
• Weight, n = 5
• Multicomponent, n = 5
Records screened
(n = 14,011)
Records excluded
(n = 13,939)
Full-text articles
assessed for eligibility
(n = 72)
Full-text articles 
excluded
(n = 40)
Ongoing studies (n = 3)
Studies included in 
quantitative synthesis
(meta-analysis)
 (n = 10)
FIGURE 1 The PRISMA flow diagram for studies.
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by e-mail. An advert was also taken out in The Pharmaceutical Journal asking for any evaluations in
relation to community pharmacy and alcohol interventions to be sent to the research team. The
Pharmaceutical Journal is sent to all pharmacists who are affiliated with the Royal Pharmaceutical Society
(≈30,000 pharmacists) in the UK. Experts in the field including academics who have previously published in
this area were contacted; information was also requested through Twitter (Twitter, Inc., San Francisco, CA,
USA) and LinkedIn (LinkedIn, Mountain View, CA, USA). Authors were contacted of relevant conference
abstracts from the Royal Pharmaceutical Society Conference (2010–14 inclusive), the Academic Health
Services Research and Pharmacy Practice Conference (2010–14 inclusive) and the International Network on
Brief Interventions for Alcohol and Other Drugs (2010–13 inclusive).
The results from these types of evaluations are reported separately and alongside the synthesis of
effectiveness results from the included controlled interventions. Because these reports are not published in
peer-reviewed journals and are uncontrolled service evaluations, they were not formally quality assessed
(unlike the effectiveness interventions).
METHODS
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Chapter 3 Results
Study characteristics
Tables 2–5 provide study characteristics for each type of intervention focus (alcohol, smoking, weight and
multicomponent, respectively). Twenty-four studies were included in this review (29 papers). There were
two alcohol interventions,46,48 12 smoking cessation interventions,44,45,49–53,55–60,63 five weight-loss
interventions39,64–67 and five multicomponent interventions that included pharmacotherapy and lifestyle
changes in participants with comorbidities including dyslipidaemia (n= 1 study),71 hypertension72 and type 2
diabetes mellitus (n= 3 studies).68–70 Four studies had multiple publications, one smoking cessation study had
an English63 and a Danish73 publication; another smoking cessation study49 had two additional publications
including a paper on cost-effectiveness51 and a paper on shorter-term follow-up.50 Another smoking
cessation study60 had an additional publication on cost-effectiveness.61 One multicomponent intervention
had an English72 and a Spanish publication.74 We extracted data from all these additional publications with
the exception of the Danish73 and the Spanish publication.74 Three smoking cessation interventions52,55,60
appeared to be targeted at pharmacy staff as well as clients; the remaining 21 studies were targeted at
pharmacy clients alone. There were 19 RCTs,44–46,48,52,53,55,57–60,63,64,66–68,70–72 three nRCTs39,56,69 and two
CBAs.49–51,65 There were 22 published journal articles39,44–46,49–53,55–60,63,64 and two reports.48,65 Nine studies
were conducted in the UK,46,48–51,56,65,66,68 four in the USA,39,44,52,64 two each in Australia,45,53 South America69,71
and Spain,69,70 and one each in Canada,55 Denmark,63 Japan,59 Thailand67 and the Netherlands.57
Seventeen studies recruited participants within the community pharmacy; other recruitment settings included
hospital/primary care units, via telephone and a community health centre. The intervention setting was always
a community pharmacy (for at least one intervention group); the types of pharmacies included single outlets,
small chains and large chains. Pharmacies were set in rural, urban and a combination of both geographical
settings. The number of pharmacies included within each study ranged from 1 to over 200. Participant
sample size ranged from 28 to around 7000, resulting in approximately 14,000 service users in total.
All studies reported participant demographic characteristics and some reported socioeconomic details at
baseline. Twenty-three studies reported age and sex, 13 studies reported education levels; seven studies
reported ethnicity, two studies reported income, four studies reported employment/occupation and three
studies reported marital status. Five studies (one alcohol management, two smoking cessation and two
weight loss) reported the SES of participants using versions of deprivation scores. One smoking cessation
study reported a ‘socioeconomic group score’ which was a composite measure of education levels, single
parent status, housing status, employment status, sickness, free prescription eligibility and deprivation.
All studies were of adults and the mean age ranged from 24.2 to 67.4 years. Participants in a study of a
photoageing intervention were much younger (mean age 24.2 years) than the majority of the participants
because this intervention was specifically targeted at smokers aged between 18 and 30 years. In terms
of sex, across all the studies there was a majority of female participants. Across all the studies the
percentage of females ranged from 36% to 93%; however, when the weight loss trials were excluded,
the percentage of females ranged from 36% to 69%. In the weight loss studies the majority of
participants (> 70%) were female. There were two exceptions, both smoking cessation studies: one
Japanese study59 reported 18.5% females (5/27) and in one US study44 99% were male; this reflected the
target population, which comprised tobacco-chewing participants, who tend to be predominantly male.
The majority of participants in five44,48,52,66,68 out of the seven studies44,46,48,52,65–67 that reported ethnicity
were white. In one weight loss intervention, four-fifths of participants were from black and ethnic minority
groups. In one alcohol intervention46 based in the inner London Borough of Hammersmith and Fulham,
20% of participants were Asian, black, mixed, Chinese or other.
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Three studies49–51,65,66 appeared to adopt a targeted approach to addressing inequality, recruiting a majority
of participants from areas of high deprivation. All three studies compared a pharmacy-based setting with
other settings. Bauld et al.49–51 compared smoking cessation services that were group-based in the
community with one-to-one pharmacy-based services; both services were attended by a larger proportion
of women than men. The smaller number of clients who attended the group service were older, slightly
more affluent (although still a relatively deprived group) and more likely to be women. Bush et al.65
compared a weight management programme set in pharmacies versus the same programme set in general
practitioner (GP) surgeries. GP surgery participants tended to be older than pharmacy participants and
ethnic composition of the two groups differed significantly. The mean Index of Multiple Deprivation (IMD)
score of participants at GP surgeries and pharmacies was 43.8 and 43.3, respectively. Jolly et al.66
compared a range of NHS and commercial weight loss programmes including a pharmacy-based
intervention; 73.4% of participants were from the two most socioeconomically disadvantaged quintiles of
the population. The mean IMD score of participants in the GP surgery and pharmacy arms were 32.2 and
35.1, respectively; higher IMD scores indicate greater deprivation.
Eligibility criteria for participants in the two alcohol interventions46,48 included a minimum score that
indicated possible harmful or hazardous alcohol consumption but not alcohol dependence. Eligibility
criteria for participants in the smoking cessation interventions consisted of measures of nicotine
dependence, which varied across the interventions. Four studies52,57–59 reported the baseline number of
cigarettes smoked per day, and this ranged between 20 and 23 cigarettes per day for three studies;52,58,59
and one study reported a baseline of 42 cigarettes per day.58 Another four studies reported only
Fagerström scores (scored 0–10, with higher scores reflecting a greater dependence on nicotine),
which ranged from 3 in a group of young adults with a mean age of 24 years53 to around 6 for
three studies.45,60,63
The degree of overweight or obesity varied across the five weight loss interventions; all interventions
specified a minimum BMI at baseline and the mean BMI ranged from 27.7 kg/m2 to 44.9 kg/m2.39,67
Intervention components varied considerably across all 24 studies and specific study intervention details are
reported alongside the individual study results. Duration of follow-up (from baseline to end) ranged from
5 to 56 weeks. Where the duration of a study is referred to, this is defined as from baseline to final
follow-up.
In terms of outcomes, both the alcohol interventions used self-reported questionnaires to evaluate change
in alcohol behaviours. Half (6/12) of the smoking cessation interventions relied on self-reported change in
smoking behaviours45,55,57,59,60,63 and half used biochemical measures44,49–53,56,58 [carbon monoxide (CO) or
cotinine levels] to validate change in smoking behaviours. All five of the weight loss interventions39,64–67
and all five multicomponent interventions67–72 (pharmacotherapy plus lifestyle changes) measured
weight. Five studies assessed health status or quality of life.39,46,65,68,70 Eight studies reported
cost outcomes.48,49–51,56,60,65,66,69
Only four studies assessed whether or not certain demographic variables moderated the effect of
interventions; all four studies48,60,65,66 assessed the differential effects of sex and one of these studies also
assessed age.65 No study assessed the differential effects of any measure of SES. Few studies used
regression analysis to assess the influence of demographic or socioeconomic variables on change from
baseline, in other words as potential predictors of outcomes within intervention groups or to
explain retention.
Funding sources were stated in 16 studies;44–46,48–52,55,58,60,63–68,70 the types of funding sources included
academic research bodies, health-related institutions, commercial organisations and pharmaceutical
companies, with some studies receiving funding from a combination of different types of sources.
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Study quality
Twenty-four studies39,44–46,48–53,55–60,63–72 were assessed for quality [three ongoing studies (see Appendix 5)
were not quality assessed] using six criteria: (1) selection bias; (2) study design; (3) confounders; (4) blinding;
(5) data collection methods; and (6) withdrawals/dropouts. Each study was given an overall (global) rating
based on the ratings for the six criteria (Table 6).
TABLE 6 Quality assessmenta
Study
Quality criteria
Global
rating
Selection
bias
Study
design Confounders Blinding
Data
collection
methods
Withdrawals
and dropouts
Alcohol
Dhital et al., 201546 Moderate Strong Strong Moderate Moderate Moderate Strong
Watson and
Stewart, 201148
Weak Strong Weak Moderate Moderate Weak Weak
Smoking cessation
Bauld et al., 201149
Bauld et al., 200950
Bauld et al., 200951
Weak Moderate Strong Moderate Strong Weak Weak
Bock et al., 201052 Weak Strong Moderate Moderate Strong Strong Moderate
Burford et al.,
201353
Moderate Strong Strong Weak Strong Moderate Moderate
Costello et al.,
201155
Weak Strong Strong Weak Moderate Weak Weak
Crealey et al.,
199856
Weak Strong Weak Moderate Moderate Weak Weak
Hoving et al.,
201057
Moderate Strong Strong Moderate Strong Moderate Strong
Howard-Pitney
et al., 199944
Moderate Strong Weak Strong Strong Strong Moderate
Maguire et al.,
200158
Moderate Strong Weak Weak Strong Strong Weak
Mochizuki et al.,
200459
Moderate Strong Strong Moderate Moderate Moderate Strong
Sinclair et al., 199860 Moderate Strong Strong Moderate Strong Moderate Strong
Sonderskov et al.,
199763
Moderate Strong Strong Moderate Moderate Strong Strong
Vial et al., 200245 Weak Strong Strong Weak Moderate Moderate Weak
Weight loss
Ahrens et al., 200364 Moderate Strong Strong Weak Strong Weak Weak
Bush et al., 201165 Moderate Moderate Weak Moderate Strong Weak Weak
Jolly et al., 201166 Weak Strong Strong Moderate Strong Moderate Moderate
Malone and
Alger-Mayer 200339
Moderate Strong Weak Moderate Strong Weak Weak
Phimarn et al.,
201367
Moderate Strong Strong Moderate Strong Strong Strong
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Selection bias
None of the studies was assessed as ‘very likely’ to have a representative study sample because participants
were not obtained from randomly selected samples. Therefore, none of the studies was assessed as
‘strong’ for selection bias. In 13 studies39,52,56–59,64,65,67–69,71,72 the reviewers could not tell what percentage
of selected individuals agreed to participate. Ten studies44–46,53,55,60,63,66,70 reported sufficient information,
in two of which55,63 80–100% agreed to participate; in three studies44,53,60 60–79% agreed to participate
and in five studies45–46,48,66,70 < 60% agreed to participate. In one study of the NHS Stop Smoking
Service49–51 it was not applicable to assess the percentage of selected participants agreeing to participate,
because smokers self-referred and did not require an invitation to access the services. Overall, in terms of
selection bias, 16 studies39,44,46,53,57–60,63–65,67,69–72 were ‘somewhat likely’ (scoring moderate) and eight
studies45,48–52,55,56,66,68 were ‘not likely’ (scoring weak) to have representative study samples.
Study design
Nineteen studies were RCTs,44–46,48,52,53,55,57–60,63,64,66–68,70–72 three studies39,56,69 were nRCTs and two
studies49–51,65 were CBAs. All 21 RCT/nRCT designs were classed as ‘strong’ for quality and the two
CBAs were classed as ‘moderate’. In two studies48,60 the pharmacies were ‘randomised’ rather than
individual participants.
Confounders
Fifteen studies45,46,49–51,53,55,57,59,60,63,64,66–70 were classed as ‘strong’ for confounding, either because it was
reported that there were no statistically significant baseline differences between the groups or because
most differences were controlled for in the analyses. In some studies, even when groups were reported as
comparable at baseline, potential confounders were adjusted for in subsequent analyses. One study52
scored ‘moderate’ for confounding, as it controlled for some baseline differences in the analyses. Eight
studies39,44,48,56,58,65,71,72 were classed as ‘weak’ for confounding, either because it was not clear if there were
baseline differences, or because there were baseline differences and it was not clear if confounders
had been controlled for in the analyses, or < 60% of baseline differences were controlled for in
subsequent analyses.
TABLE 6 Quality assessmenta (continued )
Study
Quality criteria
Global
rating
Selection
bias
Study
design Confounders Blinding
Data
collection
methods
Withdrawals
and dropouts
Multicomponent interventions (pharmacotherapy and lifestyle changes)
Diabetes mellitus – type 2
Ali et al., 201268 Weak Strong Strong Moderate Strong Strong Moderate
Correr et al.,
201169
Moderate Strong Strong Weak Moderate Weak Weak
Fornos et al.,
200670
Moderate Strong Strong Moderate Strong Strong Strong
Dyslipidaemia
Paulos et al.,
200571
Moderate Strong Weak Weak Strong Weak Weak
Hypertension
Zaragoza-Fernandez
et al., 201272
Moderate Strong Weak Moderate Moderate Strong Moderate
a ‘Weak’ is weak quality, ‘moderate’ is moderate quality and ‘strong’ is strong quality, with weak being the least desirable
and strong being the most desirable.
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Blinding
One study44 reported that both the outcome assessors and the participants were blinded to the study
intervention and was classed as ‘strong’ for blinding. Sixteen studies39,46,48–52,56,57,59,60,63,65–68,70,72 were classed
as ‘moderate’ for blinding. In most of these cases, either the assessors were not aware of the intervention
and it was not clear if the participant was aware or vice versa. One study46 clearly stated that outcome
assessors were blinded and participants were not. Another study60 reported that pharmacists were aware
of the intervention status but participants were not. Another study63 reported that blinding of participants
had failed. Seven studies45,53,55,58,64,69,71 were classed as ‘weak’ for blinding because both the outcome
assessor and the participants were aware of the intervention.
Data collection methods and tools
Fifteen studies39,44,49–53,57,58,60,64–68,70,71 report using valid and reliable data collection tools and were classed as
‘strong’ and nine studies45,46,48,55,56,59,63,69,72 reported using valid data collection tools; however, reliability was
not explicitly reported and these studies were classed as ‘moderate’. It should be noted that as well as the
robustness of the data collection tools, the outcome data varied in terms of the type of outcome (e.g.
behavioural or clinical) and how it was measured (e.g. self-reported, observed or biochemically confirmed).
Withdrawals and dropouts
Eight studies44,52,58,63,67,68,70,72 reported a follow-up rate of 80% or more participants and were classed as
‘strong’, and seven studies45,46,53,57,59,60,66 reported a follow-up of 60–79% participants and were classed as
‘moderate’. Eight studies followed up < 60% of participants, and in one study71 dropouts were not
reported; these nine studies were classed as ‘weak’.
Global rating
In terms of overall quality assessment, seven studies46,57,59,60,63,67,70 were rated ‘strong’, six studies44,52,53,66,68,72
as ‘moderate’ and 11 studies39,45,48–51,55,56,58,64,65,69,71 as ‘weak’. These quality ratings and the individual
quality criteria of which they are composed should be borne in mind when evaluating the
effectiveness data.
Intervention integrity
Thirteen studies44–46,52,55,57,58,60,63,65,66,69,72 reported measuring consistency of the intervention; however,
sometimes this included only compliance rather than whether or not the intervention was carried out in a
consistent manner (Table 7). One smoking cessation study60 used both quantitative and qualitative methods
to evaluate the training of the pharmacists and the process of the intervention from the perspectives of both
pharmacy personnel and participants; another smoking cessation study58 interviewed pharmacists to gain
insight into the process of the intervention. An alcohol intervention study48 used follow-up focus groups to
explore the actual experience of the service. Very few studies incorporated a process evaluation. In the
majority of studies it was unclear whether or not the intervention was carried out as intended.
Three studies53,57,70 reported on the issue of contamination; one study57 reported that contamination of the
control group was possible (may have received a similar intervention from external sources). Another
study70 reported the possibility of cross-contamination between study groups because participants were
randomised within pharmacies. The final study53 reported on measures used to avoid contamination of
groups: participants were randomised according to treatment being used that week at the pharmacy by
week of attendance.
Appropriate analysis
Eight studies46,53,55,66–68,70,72 reported the power of the study samples, at either 80% or 90%, one68 of which
was powered for the studies primary outcome of glycated haemoglobin (HbA1c) percentage rather than the
outcomes of this review (alcohol behaviour, smoking cessation or weight reduction). It was unclear if
10 studies44,49–52,56–58,63,64,69,71 were sufficiently powered as power was not reported. Six studies39,45,48,59,60,65
were not sufficiently powered to detect significant differences in treatment effect between groups. One
study55 comprised > 7000 participants and was assumed to be sufficiently powered.
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Six studies39,44,53,57,58,66 conducted intention-to-treat (ITT) analyses (all randomised participants were
assessed at final follow-up). Eleven smoking cessation studies44,45,49–53,55,57–60,63 carried out analyses with the
assumption that those lost to follow-up had not stopped smoking. Another four studies39,46,64,66 imputed
data for those lost to follow-up; Jolly et al.66 used three types of analyses: (1) completers only; (2) ‘baseline
observation carried forward’; and (3) ‘last observation carried forward’. One alcohol study46 performed
sensitivity analysis, carrying baseline values forward for people with missing follow-up scores. Eight
studies48,65,67–72 performed completer analyses only; however, the size of these studies varied, as did the
percentage dropout. Three studies52,68,72 had a very low dropout rate, at less than 12%, and in two
studies,65,69 using completer analysis only, dropout was very high (40% in one case69 and 93% in the
other65), increasing the potential for attrition bias. In one study48 there was substantially higher attrition of
intervention participants (78%) than of control subjects (67%).
Given that participants were nested within pharmacies, few studies used hierarchical modelling techniques
to adequately adjust for potential pharmacy- or pharmacist-level effects on individual participant outcomes.
Twenty studies39,44–46,52,53,55–59,63,64,66–72 randomised individual participants to groups; one study70 randomised
participants within pharmacies. The two studies48,60 that randomised pharmacy settings (rather than
individual participants) accounted for clustering within the analyses. Another two studies55,57 accounted for
between-pharmacy variance using multilevel analyses in order to understand whether or not variability in
participant outcomes existed between pharmacies. One alcohol study46 tested within-group changes in
Alcohol Use Disorders Identification Test (AUDIT) scores from baseline to follow-up using a generalised
linear mixed model with fixed effects for group and time (nested within group) and random effects for
pharmacist and participant (nested within pharmacist). Another study66 performed secondary analyses of
commercial weight loss programmes compared with primary care-based programmes (including pharmacy)
and adjusted for clustering of participants within the intervention groups. One study52 adjusted for
pharmacist and pharmacist sex in the analyses. The number of pharmacies within the studies ranged from
1 to over 200; seven studies52,56,64,67,68,71,72 used three or fewer pharmacies, which may limit the
generalisability of the results.
Implementation of interventions
Implementation was evaluated using the tool30,31 for the assessment of the implementation of complex
public health interventions in systematic reviews; this tool covered three key domains: organisation,
implementation and delivery of interventions. In addition, the Behaviour Change Wheel32 and the Nuffield
Intervention Ladder33 were used to broadly describe the interventions by grouping and classifying the
policy categories and intervention functions.
Implementation
More details on implementation are reported in Appendix 9. Contextual subsections included political,
economic, social and managerial factors. Interventions were categorised as ‘political’ if the primary purpose
for developing and testing the intervention was the national political drive to extend the public health
role of community pharmacies. Interventions were categorised as ‘economic’ if the primary purpose for
developing and testing the intervention was to assess whether existing services could be delivered at a
lower cost in pharmacies (and usually by pharmacists and pharmacy staff) than in other settings or by
other service providers. Interventions were classed as ‘social’ if the primary purpose for developing and
testing the intervention was to assess the reach of services to those most in need in pharmacies compared
with similar services in other settings and offered by other service providers. Interventions were classed as
‘managerial’ if the primary purpose for developing and testing the intervention was to assess whether or
not existing services set in pharmacies and delivered by pharmacists could be delivered equally effectively
by pharmacy assistants.
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The implementation context of the majority of interventions (n= 16) included in this systematic review
was political.39,45,46,48–52,55,58,60,63–67,69,70 For two of these 16 studies, the authors also performed a cost
analysis.49–51,61 The implementation context of three studies was economic.53,56,69 For the remaining
five included studies, the interventions had no specific implementation context.
Very few studies reported any degree of consultation or collaboration with stakeholders as part of the
planning process or during delivery of the intervention. Watson and Stewart48 conducted focus groups
with pharmacists and members of the public during the planning stages of their brief alcohol intervention,
and their views and suggestions were incorporated into the intervention. Pharmacists were consulted in
the planning of another brief alcohol intervention regarding an acceptable and feasible training period.46
In two studies44,49–51 health authority staff provided assistance, but it is not clear whether or not this related
to the implementation of the intervention. The study by Hoving et al.57 collaborated with a national charity
on smoking and health, and together they developed the intervention.
The study by Costello et al.55 was nested within a ‘host’ study called Smoking Treatment for Ontario
Patients (STOP), which collaborated with different community and regional partners in many different ways
during the planning and delivery of the intervention, including tertiary care centres, public health units,
mass distribution, community pharmacies, community health centres, STOP on-the-road workshops with
primary health units, internet-based enrolment, family health teams and family physicians.
The issue of sustainability is particularly interesting for the interventions included in this review. In the majority
of interventions, regardless of their target behavioural outcome, pharmacists received reimbursement for
providing the intervention. The authors of a number of the studies highlighted that reimbursement to the
pharmacist for providing the service is necessary in order for the intervention to be sustainable.55,58
Organisation and delivery
More details on the organisation and delivery of interventions are reported in Appendix 10. All of the
included studies were set in community pharmacies, although the nature of these varied in some countries.
Twenty-one of the 24 interventions were delivered by the resident pharmacy staff; three smoking cessation
interventions used other deliverers. One smoking cessation intervention53 was delivered by a research
pharmacist employed by the local university, who delivered the intervention at all sites, and another
smoking cessation intervention was delivered by a Master of Science student.45 One smoking cessation
intervention involved the postal delivery of a computer-generated letter.57
Of the 21 interventions delivered by resident pharmacy staff, it was clear that most studies (n= 17)
included standardised staff training, although this was usually brief (ranging from 2 hours to 2 days).
Two of these studies, one of smoking cessation and one of quitting chewing tobacco, mentioned they also
included role-play as part of the training44,52 and two weight loss studies reported that they also included
‘practical tasks’ as part of the training.66,67
Of the four interventions delivered by resident pharmacy staff that did not include standardised staff
training, we only had the abstract in English for one smoking cessation study59 at the time of writing this
report. Another smoking cessation study63 included no mention of staff training but did state that the
pharmacy staff were given instructions from the pharmaceutical company regarding procedures. The
pharmacists responsible for delivering a weight management programme in another study64 did not receive
any training, but were expected to carry out self-directed learning to prepare themselves to be able to
counsel patents in dietary advice. Of note, in this study, a registered dietitian reviewed the dietary plan
developed by the pharmacist before it was used with the patients, and was consulted as needed during
the study. The weight management study by Zaragoza-Fernandez et al.72 did not mention any
staff training.
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In terms of quality assurance, one alcohol reduction study provided a 2-hour evening follow-up training
session during the intervention to address challenges and share learning across the pharmacists who were
delivering the intervention.46 In two smoking cessation studies,56,58 a researcher visited the pharmacists after
the group training session to provide support and to address any queries they had in implementing the
training. In one smoking cessation study that was organised by a pharmaceutical company63 the company
contacted pharmacies at least once a week during the intervention. In a multicomponent study of people
with type 2 diabetes mellitus,70 pharmacists had regular contact with the research team during the study
and attended clinical sessions where results on drug-related problems were presented and discussed.
All studies reported information about the experience of the person/staff who delivered the intervention.
In all cases this was the resident pharmacist, the research pharmacist or the pharmacy staff team (including
the pharmacists and pharmacy technician/assistant). However, in most cases it was unclear who developed
the intervention. Information on resources was documented for some of the studies, but the level of
detail was variable. Seven studies (one alcohol reduction,48 four smoking cessation49–51,53,56,61 and two
weight loss65,66) included a cost analysis (see Table 12).
Behaviour change
More details on the theoretical basis and behaviour change strategies of interventions are reported in
Appendix 8. Fifteen studies44–46,48–52,55–58,60,65–67,70 reported the behaviour change strategy, model and/or
theory of the intervention. A number of these studies reported using multiple behaviour strategies, models
and/or theories. The most commonly reported was the transtheoretical (stages-of-change) model, which
was reported by six studies,44,45,56,58,60,66 followed by motivational interviewing which was reported by five
studies.48,52,56,58,66,67 In addition, one intervention was informed by the I-change model,57 and another by the
theory of planned behaviour.67 Nine studies39,53,59,63,64,68,69,71,72 did not report using any type of behavioural
counselling or support as part of the intervention.
The Behaviour Change Wheel32 and the Nuffield Intervention Ladder33 are both mainly descriptive models
with broad aggregations and classifications on intervention strategies. These approaches were chosen as
the descriptions available in included studies did not allow for coding specific aspects of theory and
strategy used in the included interventions. Using the Behaviour Change Wheel32 the intervention
functions of the majority of interventions identified in this review were ‘education’ and ‘enablement’.
In addition, interventions that included the provision of NRT or commercial weight loss programmes or
products, free of charge, were also deemed to include the intervention function ‘incentivisation’. One
smoking cessation intervention, which included the use of face-ageing software,53 was deemed to include
the intervention function ‘persuasion’. One weight loss intervention,64 which included the use of meal
replacements, was deemed to include the intervention function ‘restriction’.
Using the policy category of the Behaviour Change Wheel32 all of the interventions were categorised as
‘service provision’. Six of these interventions also included ‘communication/ marketing’.44,57,58,64,65,70 One
intervention included computer-generated individually tailored advice in the form of a letter,57 and the
other five interventions used various marketing recruitment strategies such as the involvement of the local
press and supermarkets. No other policy categories were identified.
Using the Nuffield Intervention Ladder33 most interventions included in this review were coded as ‘enable
choice’.46,48–53,56–60,65–72 Those interventions which included the provision of NRT or commercial weight loss
programmes or products, free of charge, were coded as ‘guide choice – incentives’.44,45,52,55,63,66 Two
interventions that lacked any detail about advice given, apart from the provision of educational
information, were coded as ‘provide information’.39,69 The meal replacement intervention64 for weight loss
was coded as ‘restriction’.
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Motivation/aim
All of the included studies clearly described the motivation (aim) behind the intervention investigated.
Details can be found in Tables 2–5.
Follow-up and evaluation
All studies included information on follow-up response rate/retention (see Tables 2–5). However, in terms
of implementation, there was very little useful information in the included studies. Six studies (four
smoking cessarian49–51,53,56,60,61 and two weight management65,66) included some form of economic
evaluation, but only one included a process evaluation.63 One study included interviews and focus groups
with the deliverers and participants which provided useful implementation information.48
Intervention delivered as intended
None of the studies reported details about whether or not the intervention was delivered as intended,
for example by observation of sessions, quality control audits, staff and researcher records. However,
some studies included methods that were put in place to improve quality assurance (examples include
standardised training and protocols/manuals, practice ‘role-play’ sessions with feedback, regular meetings
with trainers/supervisors/more experienced members of the intervention team during the intervention).
More information on methods to improve quality assurance is provided in Appendix 10.
Differential effects
The differential effects of the interventions, by age, sex, ethnicity or SES of the participants, are discussed
within the main results section (see Differential effects by demographic or socioeconomic factors and see
Table 13). In summary, very few of the studies included in this review reported the differential effects of an
intervention by demographic variables and none evaluated any moderating effect of SES.
Effects of interventions
Study outcomes are summarised in Tables 8–11 for each type of intervention focus (alcohol, smoking,
weight and multicomponent). Costs are summarised in Table 12. Demographic and socioeconomic
variables are summarised in Table 13. See Appendix 11 for detailed outcomes for all studies.
Alcohol interventions
There were two RCTs of brief alcohol interventions in adults compared with usual care or leaflet-only
control; global ratings were strong for one study46 and weak for the other.48 Table 8 summarises the
results. Pharmacist training was provided in both studies. Both studies reported using behaviour change
strategies and involved one-to-one contact with the pharmacist. Dhital et al.46 encouraged self-directed
behaviour change; the intervention included reflection and feedback of the AUDIT score.
Behavioural outcomes
Both studies had change in alcohol consumption as the primary outcome; however, different tools were
used in each. Eligibility criteria for both studies were scores that indicated ‘possible harmful or hazardous
alcohol consumption, but not alcohol dependence’ [indicated by an AUDIT score of 8–19 or a Fast Alcohol
Screening Tool (FAST) score of 3–16]. One RCT46 used the AUDIT and reported a baseline AUDIT score of
11.93 and the other RCT48 used the FAST and reported 29.2% scoring ≥ 3 at baseline.
At 12 weeks there was no evidence in effectiveness of community pharmacist delivery of brief alcohol
intervention. The AUDIT total change score did not differ significantly between the two groups and did not
change significantly between baseline and follow-up in either the intervention or control group. The
12-week AUDIT between-group difference adjusted for pharmacist, sex, age, ethnicity and education was
–0.57 [95% confidence interval (CI) –1.59 to 0.45].
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There was no significant difference between FAST score for the intervention group compared with control
at 3 or 6 months and adjusted for baseline FAST. The 6-month FAST between-group difference was –1.84
(95% CI –4.49 to 0.82). At 6 months there was substantially lower follow-up of intervention clients (22.2%)
than of control clients (33.3%).
Meta-analysis
There were insufficient data to conduct meta-analyses.
Costs
One RCT48 reported on staff costs and training costs associated with the brief alcohol intervention.
A baseline estimate used training costs annuitised (converted to a yearly rate) over 3 years and staff costs
based on fee payment to participating pharmacies. Economic data were derived from financial records
maintained by the research team and from pharmacy logs. The overall cost for delivering the brief alcohol
intervention was £70.90, based on an average of 10 people screened for each brief alcohol intervention
delivered. The costs were particularly sensitive to the staff time cost, the number of clients screened per
pharmacy and the number of clients screened per brief intervention delivered. In addition, the time taken
to deliver the brief intervention was very variable.
Differential effects by demographic or socioeconomic factors
Neither study evaluated differential effects by demographic or socioeconomic factors. One study48 reported
change in FAST scores by sex; however, the numbers of participants were very small and the study was not
powered to detect differences between the two groups.
UK service evaluations
Seventeen UK alcohol service evaluations were identified (see Appendix 12 for further details). All of the
evaluations focused on alcohol screening and/or brief intervention. The number of pharmacies involved
in the evaluations ranged from 4 to 240. The evaluation period (where reported) ranged from 8 weeks
to 9 months. The service was delivered by pharmacists, technicians and support staff. The number of
participants ranged from 30 to 2479. The majority of the services used either the AUDIT, AUDIT –
Consumption or FAST. One evaluation used a ‘Drinkaware kit’78 that offered three resources [a plastic
half-pint measuring glass, a cardboard wheel showing units and a booklet (which contained a drink diary)].
The length of the follow-up period was often not reported; where reported, it ranged from 2 weeks to
8 months. Some evaluations have followed up patients, but rather than ascertain alcohol consumption
using the original screening tool, have explored patients’ alcohol intake from a qualitative perspective,
which makes comparisons regarding change in alcohol consumption difficult. Other evaluations have
followed up patients and have focused on satisfaction of the original intervention, rather than explore how
alcohol consumption has changed. Of the evaluations found, only those done on a small scale have
followed up patients using the original screening tool; the follow-up rates were also low with respect to
the initial numbers accessing the services.
The evaluations do, however, show that community pharmacy is an appropriate place to screen patients
and offer brief advice in relation to alcohol misuse. Indeed, of the evaluations obtained so far, over 50,000
patients have been screened in a community pharmacy setting – with over 20,000 reported as harmful or
hazardous drinking. Significantly, a small proportion of these patients have been referred on to specialised
alcohol services owing to intake that may suggest alcohol dependence. These results demonstrate the
potential reach of the community pharmacy network.
Few evaluations reported the type of people accessing these services; one evaluation79 reported that service
users who were female and aged over 60 years of age were more likely to access the service. Significantly,
males had higher AUDIT scores than females and patients from more deprived areas had higher AUDIT scores.
This evidence suggests that these types of services have the potential to reach those most in need.
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It is not clear whether or not the screening and/or brief advice provided in the pharmacy setting reduces a
patient’s consumption of alcohol over time. In addition, for the three main screening tools used in the
community pharmacy, it was not clear which is the most appropriate to use in relation to patient outcome.
A summary of the evidence for alcohol interventions is provided in Box 1.
Smoking cessation interventions
There were 10 RCTs,44,45,52,53,55,57–60,63 one nRCT56 and one CBA49–51 of smoking cessation interventions in
adults. Table 9 summarises the results. Follow-up ranged from 5 weeks to 12 months. Quit rates within
the pharmacies ranged from < 1% to 56%. Global ratings for studies varied: four studies57,59,60,63 were
rated strong, three moderate44,52,53 and five weak.45,49–51,56,58
Eleven smoking cessation studies44,45,49–53,55,57–60,63 carried out analyses with the assumption that those lost
to follow-up had not stopped smoking. Details of the type of analysis used to measure effectiveness
were not reported in one study.56 Some studies also included completer analyses; however, we focus on
results from the largest data set within each study and on the longest follow-up. Numbers of participants
ranged from 2859 to approximately 7000,55 with the majority of studies including between 300 and
600 participants. Half (6/12) of the smoking cessation interventions relied on self-reported change in
smoking behaviours45,55,57,59,60,63 and half used biochemical measures (CO or cotinine) to validate change in
smoking behaviours.44,49–53,56,58
Of the 12 smoking cessation studies, 10 included NRT (in either the intervention or control group or
both).44,45,49–51,55,56,58–60,63 Eleven of the studies44,45,49–53,55–60 included some form of behavioural support/
advice/counselling. There was only one study63 which specifically reported that no psychological or
behavioural support was added to the pharmacological treatment.
In terms of the component which is evaluated, seven studies52,55–60 evaluated some form of behavioural
support, four of which compared behavioural support with a non-active control that received usual
care.52,57,58,60 In two studies,56,59 the behavioural support component was evaluated as an ‘additional’
element; the participants also received NRT in both the intervention and control arms. Another study55
compared 1 week of NRT then fortnightly pharmacy visits for NRT plus three sessions of brief behavioural
counselling with 5 weeks NRT at the initial pharmacy visit plus one session of brief behavioural counselling
at the initial visit.
Four studies44,52,56,63 evaluated a NRT component: one study compared NRT with placebo NRT,63 another
study compared NRT with non-active control56 and two studies assessed NRT as an additional element
(i.e. the participants also received behavioural support in both the intervention and control arms).44,52 Three
studies evaluated behavioural support plus NRT compared with non-active usual care.45,52,56 Two studies
evaluated the effect of the setting of the intervention; one study assessed behavioural support plus NRT
provided in a hospital outpatient setting compared with pharmacy setting.45 One study compared
individual pharmacy-based behavioural support plus NRT with group support provided in a community
setting.49–51 One study53 evaluated the effect of a photoageing intervention in which both the intervention
and control groups received pharmacist advice.
BOX 1 Summary of evidence for alcohol interventions
l There was insufficient evidence for the effectiveness or cost-effectiveness of community pharmacy-based
brief alcohol interventions.
l It is not clear whether or not the UK alcohol screening services provided in the pharmacy setting reduce a
patient’s consumption of alcohol over time.
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Behavioural outcomes
Eight studies45,52,53,56–58,60,63 evaluated an active pharmacy-based intervention in comparison with a
non-active or usual-care control condition; five52,53,56,58,63 showed significant improvements compared with
control. Five studies evaluated an additional element to an intervention:44,52,55,56,59 the additional elements
included NRT in two studies44,52 and behavioural counselling/advice in another three studies.55,56,59
One study52 showed significant improvements with the addition of NRT to tailored counselling and one
study showed significant improvements with the addition of behavioural support to NRT.56
Only two studies compared pharmacy-based setting with another setting. Bauld et al.49–51 compared
one-to-one pharmacist support with group-based smoking cessation clinics based in the community.
All pharmacy clients had NRT, 84% of the group clients had NRT and the remaining 16% of the group
clients received oral medication. The participants chose the service, rather than being assigned by study
investigators. The group-based service attracted fewer clients but was significantly more effective than the
pharmacy-based service in terms of the proportion of participants who were not smoking at 12 months
(6.3% vs. 2.8%), determined using validated measures. However this study was observational only and
the effectiveness results should not be directly compared in any formal manner. Vial et al.45 compared
pharmacy counselling with outpatient counselling and there was no significant difference in smoking
cessation between the groups.
A RCT52 of training pharmacists to provide a tailored counselling service with and without NRT compared
with a non-randomised control group that received observation only showed a significant increase in
validated 7-day point prevalence at 6 months (28% for counselling and NRT, 15% for counselling only,
8% for control).
One RCT53 compared the addition of a computer-generated photoageing service (demonstrating the
detrimental effects on facial physical appearance of smoking) with standard smoking cessation advice in a
pharmacy. The photoageing intervention was more effective than the control based on the proportion of
participants (young people with a mean age of 24 years) who were not smoking at 6 months [13.8%
(n= 11/80) vs. 1.3% (n= 1/80)], determined using CO-validated measures. This difference between groups
remained statistically significant after adjustment for small differences between groups in sex and
nicotine dependence.
Another RCT55 evaluated three sessions of pharmacist counselling to one session based on the 5-A model
for brief behavioural counselling in addition to both groups receiving 5 weeks of free NRT. There was no
significant difference between intervention groups for self-reported 7-day point prevalence at 5 weeks,
controlling for covariates [odds ratio (OR) 0.96, 95% CI 0.86 to 1.08]. At 5 weeks, the self-reported 7-day
point prevalence was 17.5% for participants receiving three sessions of counselling and 18% for those
receiving just one session. Approximately 50% of ‘three-session’ participants completed all three sessions,
and among these participants quit rates were significantly higher than among the group of ‘one-session’
participants (27.7% vs. 18%).
Computer-generated tailored advice, compared with a thank-you letter,57 did not increase self-reported
6-month abstinence in participants recruited from Dutch pharmacies (quit rates < 1% in either group).
The pharmacists were involved only in making the questionnaires available to customers.
One study44 evaluated the addition of 6 weeks of free NRT (compared with placebo NRT) to pharmacist
advice and support in participants who were tobacco chewers. Validated abstinence rates were relatively
high at the 6-month follow-up but not significantly different between groups (38% for NRT group vs.
34% for placebo group).
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A RCT58 evaluated the Pharmacist Action on Smoking (PAS) model compared with ad hoc smoking
cessation advice in UK pharmacies; over 80% in each group also received NRT. The PAS intervention
significantly increased validated smoking cessation compared with control at 12 months (14.3% vs. 2.7%).
A small Japanese study59 evaluated the additional effect of initial and follow-up cessation advice to nicotine
gum (plus advice on usage). Both interventions appeared to increase cessation but it was not reported if
there was a significant improvement from baseline to follow-up. There was no significant difference
between groups in self-reported cessation at 3 months (45.5% vs. 31.2%).
A UK RCT60 compared training pharmacists and pharmacy assistants in the stages-of-change model of
smoking cessation with standard professional pharmacist care. Intervention participants were significantly
more likely than control participants to purchase an ‘anti-smoking’ product. The intervention was
associated with a favourable non-significant trend at 9 months, but this was based on self-reported
abstinence, and pharmacists were willing to participate before randomisation. Self-reported continued
abstinence at 9 months was 12% in the intervention group versus 7.4% in the control group.
A Danish study63 evaluated the effect of two different strengths of over-the-counter nicotine patches
compared with placebo. No psychological or behavioural support was added to the pharmacological
treatment. Self-reported point prevalence included participants who had one episode of smoking
(< 6 days). Those smoking ≥ 20 per day at baseline were randomised to 21-mg patches or placebo; those
smoking < 20 per day at baseline were randomised to 14-mg patches or placebo. At 26 weeks the
intervention was effective compared with placebo for those smoking ≥ 20 per day at baseline
(11% vs. 4.2%) but not for lighter smokers (22.7% vs. 18.4%).
One RCT45 compared 16 weeks of nicotine patches plus weekly counselling delivered by pharmacies with
the same treatment delivered in a hospital outpatient clinic; a minimal intervention control group received
written and verbal information at baseline only. Participants were all former inpatients of a respiratory
unit and the intervention commenced while participants were inpatients then continued after discharge
(as either outpatient- or pharmacy-based treatment). Seven-day point prevalence, but not continuous
abstinence, was significantly different in favour of the pharmacy- and outpatient-based intervention
compared with control intervention at the 12-month follow-up. Self-reported continuous abstinence at
12 months was 19% in the pharmacy-based group versus 24% in the outpatient group and 4.6% in the
control group.
A cost-effectiveness study56 carried out in two pharmacies in Northern Ireland compared a behavioural
intervention based on the PAS model with a nicotine gum-only control. Another control group comprised
participants who expressed a wish to stop smoking and who were chosen on the basis that they matched,
in terms of age, sex, social status and disease status, those in the behavioural intervention group. The
study was a cost-effectiveness analysis and did not report many participant details. At 6 months there
was a statistically significant difference in cessation rates between intervention and control patients. The
6-month CO-verified abstinence was 46% in the intervention group versus 6% in the control group
receiving only nicotine gum and 0% in the control group that expressed a wish to stop smoking.
Metaregression and meta-analysis
Table 14 shows the results of metaregression for the smoking interventions. In model 1, we fitted a
random-effects model including all 10 RCTs. The pooled OR for the intervention effects was 1.85 (95% CI
1.25 to 2.75), an indication of positive effect of the interventions on participants smoking cessation. However,
there was 72% unexplained differences between the studies. In model 2, we fitted a metaregression model
accounting for whether a study had active control or usual care. The pooled ORs were 1.21 (95% CI 0.86 to
1.71) and 2.56 (95% CI 1.45 to 4.53) for the active control and usual care, respectively. As expected, there
was a bigger effect for usual care than for the active control. The proportion of unexplained heterogeneity
reduced to 52%. In model 3, we accounted for whether a study had active control or usual care and also
the duration of the interventions; the unexplained heterogeneity reduced to 27.2% with a non-significant
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Q-statistic test (10.99; p< 0.2026). In model 4, we accounted for quality rating. The quality rating does not
appear to contribute much to the model after accounting for intervention duration and whether a study had
active control or care as usual.
The meta-analysis results by study groups (active control or usual care) and the overall pooled ORs, are
presented in Figures 2 and 3, presents the same meta-analysis results by quality ratings. There is
asymmetry in the funnel plot in Figure 4, which may be a reflection of publication bias. In the absence of
bias, the plot should approximately resemble a symmetrical (inverted) funnel; however, Figure 4 shows
a gap in one corner of the graph, which could indicate the presence of bias, including publication bias,
with smaller studies without significant effects not being published. Such a pattern is compatible with
publication bias, on the assumption that smaller studies with uninteresting effects are withheld from
publication. However, the funnel plot must be interpreted with caution, taking into account that it
contains only 11 studies which just exceeds the recommended study size threshold (n= 10) for creating
such plots.23
Costs
The CBA49–51 included a cost-effectiveness analysis, using validated quit rates for an economic evaluation of
both the annual and the lifetime cost-effectiveness of the pharmacy- and group-based interventions in
comparison with a baseline ‘self-quit’ scenario. At 52 weeks, the group service achieved a higher quit rate
(6.3%) than the pharmacy service (2.8%) but was more intensive and required greater overhead costs.
The Markov model estimated the potential lifetime outcomes in terms of cost per quality-adjusted life-year
gained. The lifetime analysis resulted in an incremental cost per quality-adjusted life-year of £4800 for the
group support and £2600 for pharmacy one-to-one counselling. Cost per pharmacy-based client was £79
based on a 0.025 probability of a 52-week quit. The paper reports that both services were considered to
be highly cost-effective despite relatively low quit rates.
One RCT61 included a cost-effectiveness analysis using self-reported continued abstinence at 9 months
(12% in the intervention group vs. 7.4% in the control group). Costs included those borne by the health
service and pharmacies, but also by clients (societal perspective). Training costs included organising and
operating costs of the training sessions and trainees’ out-of-pocket expenses, including staff costs and
travel plus lost leisure time. Cost to the client included NRT and counselling time. Cost to the pharmacy
covered training and counselling time. Any NRT purchased was a cost of the intervention to the client
(total cost per user for NRT was £47.53). Cost to the NHS comprised organising and operating costs,
pharmacy travel expenses and promotional materials and client documentation. The cost of producing
one additional successful attempt to quit smoking by using intensive rather than standard pharmaceutical
support was £300 or £83 per life-year.
TABLE 14 Metaregression
Model Variables AICa Q-statisticb (quantile; p-value) cI2
1 – 27.63 35.78; p< 0.0001 72.0%
2 Active control (or usual care) 26.21 18.73; p< 0.0276 52.0%
3 Active control+ intervention duration 23.69 10.99; p< 0.2026 27.2%
4 Active control+ intervention duration+ global rating 26.07 8.14; p< 0.2277 26.3%
AIC, Akaike information criterion.
a Smallest AIC value indicates the most optimum model for the data.
b Q-statistic test for the significance of heterogeneity between studies.
c I2 quantifies the percentage of unexplained heterogeneity between the studies.
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A RCT53 of a photoageing intervention assessed the cost-effectiveness from a health sector perspective, in
terms of the incremental cost per additional quitter and per additional lifetime quitter. Direct costs over
and above providing standard cessation advice were calculated based on the time taken to provide the
service and the cost to a pharmacy of purchasing tokens to use the online software to photoage
participants. Potential cost offsets were based on the quit benefits model, which is a tool developed in
Australia to predict the difference in health-care costs of smokers and non-smokers for males and females
by age group after 10 years’ follow-up.
In the intervention group, 22 of 80 participants (27.5%) reported quitting, with 11 of 80 participants
(13.8%) confirmed by CO testing. The difference between groups was significant even after adjustment
for baseline differences. The incremental cost-effectiveness ratio (ICER) was AU$46 per additional quitter,
or the equivalent of AU$74 per additional lifetime quitter. Cost offsets of AU$2144 from a reduction in
the health-care costs of quitters resulted in the intervention potentially generating net total cost savings of
AU$1778. The mean cost of implementing the intervention was estimated at AU$5.79 per participant. The
mean cost that participants indicated they were willing to pay for the digital ageing service was AU$20.25
[standard deviation (SD) AU$15.32], which was more than the actual costs.
A cost-effectiveness study56 conducted in two pharmacies in Northern Ireland compared a behavioural
intervention group based on the PAS model with a nicotine gum-only control group. The 46% quit rate of
the intervention study was not used for cost-effectiveness analysis: a 10% quit rate was used to reflect
the participants who entered stage 3 of the PAS programme (i.e. those who set a quit date) and who
remained abstinent at 12 months. Various assumptions were also made, including uptake by pharmacies,
recruitment of participants, natural cessation rate and relapse rates. The cost-effectiveness of the PAS
model was therefore measured in terms of cost per life-year gained for all patients who entered stage 3
of the PAS programme. The main cost-effectiveness analysis indicated that costs ranged from £196.76
to £351.45 per life-year saved for men, and from £181.35 to £772.12 per life-year saved for women,
depending on age at intervention. Given the baseline assumptions and on the basis of a 45-year-old
smoker, the cost per successful intervention was £509.60. The PAS model appears effective and, if the
PAS smoking cessation programme were to be offered routinely by community pharmacists throughout
Northern Ireland, it would be cost-effective.
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Differential effects by demographic or socioeconomic factors
Five smoking cessation studies44,49–51,53,55,60 reported examining demographic and/or socioeconomic
characteristics as potential predictors of outcomes within intervention groups. One study was rated strong
for global quality,60 one was rated moderate44,53 and three were rated weak.49–51,55
Bauld et al.49–51 compared smoking cessation services that were group based in the community with
one-to-one pharmacy-based services; at 52 weeks, group-based clients were more likely to quit than
pharmacy clients. Older people were more likely to quit in either the pharmacy-based or the group-based
service, higher SES was associated with long-term abstinence for pharmacy clients. Sex did not predict
quitting in either the pharmacy-based or the group-based service.
In another smoking cessation study of a photoageing intervention,53 there were no associations between
change in Fagerström score (measures nicotine dependence) and age or sex in the control group. However,
for the intervention group, age (but not sex) was significantly associated with a change in score. Older
participants were significantly less likely to reduce their score than younger participants, suggesting that the
intervention may have a greater effect on the younger participants. However, it should be noted that
participants in this trial only included an age range of 18–30 years.
Another RCT55 evaluated three sessions of pharmacist counselling to one session based on the ‘5-A’ model
for brief behavioural counselling in addition to both groups receiving 5 weeks of free NRT. Bivariate
analyses showed that, among three-session completers, both younger and employed individuals were
more likely to be abstinent than older and unemployed participants. A study that evaluated the addition of
free NRT (vs. placebo NRT) to pharmacist support for tobacco chewers44 examined the active patch group
for predictors of relapse: older chewers were less likely to relapse. A UK RCT,60 comparing trainee
pharmacists and pharmacy assistants in the stages-of-change model of smoking cessation with standard
professional pharmacist care, reported that trends in outcome (in favour of the intervention) were not
affected by age, sex or IMD of the participants.
One smoking cessation study reported on demographic or socioeconomic characteristics as potential
predictors of outcomes between intervention groups. A Danish study63 compared the effect of two
different strengths of over-the-counter nicotine patches and placebo. There were no differences in
smoking cessation rates between men and women according to starting dose and treatment.
A summary of the evidence for smoking cessation interventions is provided in Box 2.
Weight loss interventions
Five interventions were designed to evaluate weight loss (three RCTs,64,66,67 one nRCT39 and one CBA65)
interventions in adults. Table 10 summarises the results. All but one study included advice regarding diet
and physical activity; the other study39 included low-fat dietary advice within an intervention designed to
improve adherence to orlistat therapy.
Three studies65–67 compared a pharmacy-based intervention with interventions in various other settings,
including commercial weight loss programmes set in community venues, primary care settings such as GP
practices, primary care units and outpatient clinics. One study64 compared a meal replacement diet with a
conventional low-calorie diet (identical recommended total daily calorie intake); both interventions were set
in a pharmacy. One small study39 assessed the added value of community pharmacy support for obesity
management in addition to orlistat and an outpatient nutrition programme.
Meta-analysis
There were insufficient data to conduct meta-analyses and so the weight data are described in Figure 5.
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BOX 2 Summary of evidence for smoking cessation interventions
l Twelve studies of varied quality evaluated the effectiveness of community pharmacy-based smoking
cessation interventions.
l Pharmacy-based smoking cessation interventions including behavioural support and/or NRT are effective
and cost-effective in helping adults to stop smoking, particularly when compared with usual care. A total of
10 RCTs were included in a meta-analysis; the pooled OR of the intervention effects for smoking cessation
was 1.85 (95% CI 1.25 to 2.75). The pooled OR was 1.21 (95% CI 0.86 to 1.71) for intervention vs. active
control and 2.56 (95% CI 1.45 to 4.53) for intervention vs. usual care.
l Accounting for the type of comparator and the duration of the interventions reduced the unexplained
heterogeneity to 27.2%, with a non-significant Q-statistic test (10.99; p< 0.2026).
l Four smoking cessation studies included cost outcomes, but the methods of cost-effectiveness analyses
differed, making comparisons difficult. However, three UK pharmacy-based interventions appeared
cost-effective, despite relatively low quit rates in one case and a non-significant trend for cessation rates in
another case. An Australian study appeared cost-effective (and effective) in increasing quit rates among
young adults who were exposed to the detrimental effects on facial physical appearance of smoking using
a computer-generated simulation.
l The evidence was too heterogeneous to evaluate which specific types of smoking cessation interventions
are the most effective or cost-effective.
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FIGURE 5 Bar chart of weight change from baseline to follow-up by treatment group. P, pharmacist;
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Behavioural outcomes
Three studies65–67 reported BMI, three studies64,65,67 reported waist circumference (WC) and all five
studies39,64–67 reported weight. The largest improvement in BMI59 was –1.3 kg/m2; for WC it was –8.1 cm64
and for weight it was –5.6 kg.64 None of the studies demonstrated a significant difference in favour of the
pharmacy-based intervention compared with the control for any anthropometric outcome.
One UK RCT66 compared eight groups [Weight Watchers™ (WeightWatchers.co.uk Ltd, Maidenhead, UK),
Slimming World™ (Miles-Bramwell Executive Services Ltd, Alfreton, UK), Rosemary Conley™ (Rosemary Conley
Online Ltd, Steyning, UK), Size Down (a NHS community-based group), GP, pharmacy, participants’ own choice
and an exercise-only control group]. All except the GP and pharmacy groups exhibited significant weight loss
between baseline and 1-year follow-up. At 1 year, only the Weight Watchers group had significantly greater
weight loss than the control group (mean 2.5 kg, 95% CI 0.8 kg to 4.2 kg). The commercial programmes
(Weight Watchers, Slimming World and Rosemary Conley) achieved significantly greater weight loss than the
primary care programmes (general practice and pharmacy-based interventions). At 1 year, the difference was
1.6 kg (0.3 kg to 2.9 kg; p= 0.06) in the adjusted model. Mean weight loss at 1 year, with baseline value used
for imputation, was 0.8 kg (SD 4.7 kg) for primary care and 2.5 kg (SD 6.2 kg) for commercial programmes.
In one CBA study65 comparing diet and physical activity in a pharmacy with a GP-based intervention, in
both groups BMI, WC and weight appeared to be reduced at follow-up. Statistical significance, either from
baseline to follow-up or between groups, was not reported; there was very high attrition in this study
(93%). In this CBA, the participants chose the service rather than being assigned by study investigators
and, consequently, may have been a relatively more motivated sample.
In two studies,39,64 both the intervention and ‘control’ groups lost a significant but similar amount of
weight between baseline and follow-up; participants in both the meal replacement and low-calorie diet
groups64 lost a similar amount of weight (both based in the pharmacy) as those treated with orlistat on
an outpatient basis,39 with or without additional pharmacy-based support. In one study,67 there was no
significant loss of weight between baseline and follow-up in either the intervention or control group.
Costs
Two studies reported costs.65,66 The CBA65 study reported that it was unclear which provider type (pharmacy or
GP) delivered the programme more cost-effectively because of different cost-effectiveness results at different
time points. Attendance rates on the programme were consistently better among pharmacy participants than
among GP surgery participants. Direct costs included training, initial test and appointments. Providers were
reimbursed £300 for undergoing 2 days of training once they had recruited six participants and then £30 for
the initial assessment of each participant and £10 for each consultation after the initial assessment.
The total cost of delivering the My Choice Weight Management Programme was £50,200. Total costs
were higher among GP providers (£26,970) than among pharmacy providers (£23,230). This difference can
be explained by the remuneration structure for the intervention, as payments were based on the number
of sessions hosted (number of sessions hosted by GPs= 1735; pharmacy= 1447).
Costs per participant were higher through pharmacies (£126.90) than through GPs (£100.60). This was
true throughout the course of the intervention, but the gap in costs between pharmacy and GP providers
narrowed and there was no statistically significant difference in costs between providers among
participants attending the final session. Again, the difference in costs is a result of the larger number
of participants recruited by GPs. It is important to note that the demographic and socioeconomic
characteristics of the pharmacy and GP groups differed significantly: GP participants tended to be older
than pharmacy participants and the ethnic composition of the two groups differed significantly.
The cost-effectiveness of the intervention is measured in terms of costs per kilogram weight loss and costs per
1% weight loss and ICER at session 12 and session 15. The differences between providers were statistically
significant; among participants attending session 12, the cost per kilogram weight loss was £57.00, with costs
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being higher among pharmacy providers (£74.80) than among GP providers (£43.40). Among participants
attending session 15 (final session), the opposite pattern was observed, with the costs of both measures being
lower among pharmacy providers than among GP providers (although these differences were not statistically
significant). At session 12 each extra kilogram weight loss per participant would cost £8.29 through pharmacy
providers. Conversely, at session 15, each extra kilogram of weight loss per participant would cost £2.91
through GP providers. At the end of the intervention the ICER favoured the pharmacy.
Jolly et al.66 evaluated the direct costs to the primary care trust of each programme and of sending out
invitation letters from practices. These included the costs of the provider’s service and the cost of the
searches in general practice, invitation letters and provision of call centre support. The cost of the call
centre that co-ordinated the service as an average per person, based on the cost of staff employed over a
12-month period and the number of clients who used the service over this time period. Costs to the
participants were not included, nor were any training costs for providers.
Assuming that participants randomised to the most successful intervention continued to have a BMI
1.3 kg/m2 less throughout life, then the cost per life-year saved was approximately £77. These benefits are
not discounted and are based on many assumptions. The authors conclude that commercial organisations
provide a more effective service at lower cost than primary care providers (GPs and pharmacists).
One-to-one primary care-based programmes, including pharmacy-based programmes, were ineffective and
most costly to provide (both £112.73 per participant based on a pool of 70 participants each).
Differential effects by demographic or socioeconomic factors
Two studies recruited participants from areas with high levels of socioeconomic deprivation.65,66 The mean
IMD score of participants in the GP surgery and pharmacy arms of the Lighten Up trial66 was 32.2 and
35.1, respectively. The study authors report that the characteristics of the participants reflected the
population of the primary care trust well, with 23.5% of the participants being in the bottom 10% of
socioeconomic deprivation, which is similar to that for the primary care trust, and 13% of participants
being from a minority ethnic group, which is slightly lower than the local prevalence of 18%. The mean
IMD score of participants attending the My Choice Weight Management Programme65 at GP surgeries and
pharmacies was 43.8 and 43.3, respectively. Higher IMD scores indicate higher deprivation.
The Lighten Up trial66 evaluated a range of weight loss programmes in community and primary care
settings; participants who were lost to follow-up tended to be younger than those who were followed up,
but they were similar in terms of BMI, sex, ethnicity and IMD score.
The same two weight loss studies reported examining demographic and/or socioeconomic characteristics
as potential predictors of outcomes within intervention groups.65,66 Bush65 compared a weight
management programme set in pharmacies versus the same programme set in GP surgeries and reported
there were no statistically significant relationships between age, sex, IMD quintile or ethnicity and
percentage weight loss at session 12 within pharmacy or GP surgery participants. In a study of weight loss
programmes in various community and primary care settings, sex had no effect on weight loss.66
These two weight loss studies reported examining demographic and/or socioeconomic characteristics as
potential predictors of outcomes between intervention groups.65,66 In a study of weight loss programmes in
various community and primary care settings there was no statistically significant interaction between sex
and the type of weight loss programme.66
Bush et al.65 compared a weight management programme set in pharmacies versus the same programme set
in GP practices. Female participants who followed a programme based in a GP practice lost a significantly
larger proportion of their initial weight than those following a pharmacy-based programme, and participants
aged 40–49 years lost a greater proportion of their initial weight at GP providers than at pharmacy providers.
A summary of the evidence for weight loss interventions is provided in Box 3.
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Multicomponent interventions (pharmacotherapy and lifestyle changes)
Five studies evaluated the effects of pharmacotherapy (medicines management) plus lifestyle advice in
participants with comorbidities including type 2 diabetes mellitus,68–70 dyslipidaemia71 and hypertension.72
Table 11 summarises the results. Global quality ratings varied among the studies; one was rated strong,70
two were rated moderate68,72 and two were rated weak.69,71
Type 2 diabetes mellitus
There were three studies (two RCTs68,70 and one nRCT69) of interventions in adults with type 2 diabetes
mellitus. In the nRCT,69 four pharmacies were assigned to intervention and two pharmacies were assigned
to control; in addition, the pharmacists were willing to participate before randomisation. Two studies68,70
included lifestyle advice as well as pharmacotherapy, for example counselling in acute and chronic
complications of diabetes mellitus, lifestyle (physical activity, healthy diet and smoking cessation), regular
foot inspections, and correct use of drugs and self-monitoring of blood glucose. One study69 reported that
the intervention included ‘patient education’, but no further details were reported. The studies were
conducted in Brazil,69 Spain70 and the UK;68 the UK study was a small pilot study. All three studies had
glycaemic control as the primary outcome and BMI was also a primary outcome in one study.68
All three studies used completer analyses; dropout was minimal in two studies, but 60% in one study,69 which
may have biased results. Follow-up duration was 12–13 months. Baseline BMI ranged from 28 kg/m2 to 32 kg/m2.
The small UK study68 demonstrated significant reductions in BMI in the intervention group as compared
with no significant changes in the control group from baseline to follow-up, but no significant difference
between groups at follow-up (–3.86 kg/m2 vs. –1.09 kg/m2, respectively). The intervention was also
associated with significant improvement in HbA1c percentage, systolic blood pressure and blood glucose
level as compared with the control group after the period of 12 months. Changes in lipids were mixed;
triglycerides were non-significantly lower in the intervention group than in the control group. Low-density
lipoprotein, high-density lipoprotein and total cholesterol levels were significantly higher in the intervention
group than in the control group.
After 12 months of pharmacotherapy and patient education,69 BMI and WC remained similar in the
intervention and control groups (–0.2 kg/m2 vs. 0.3 kg/m2, respectively for BMI). However, the intervention
significantly improved glycaemic control, with participants in this group experiencing a greater reduction in
HbA1c and fasting capillary glycaemia than those in the control group. The intervention was cost-effective
in terms of costs per patient to reduce HbA1c values by 1%; however, there was 60% dropout.
BOX 3 Summary of evidence for weight loss interventions
l Five studies evaluated the effectiveness of community pharmacy-based weight loss interventions. The types
of interventions were heterogeneous and the evidence limited; therefore, meta-analysis was not
carried out.
l None of the studies demonstrated a significant difference in favour of the pharmacy-based intervention
compared with control for any anthropometric outcome.
l Two studies reported cost-effectiveness; the costs associated with primary care interventions were broadly
similar in the two studies. Cost-effectiveness varied at different time points and was influenced by the
number of participants recruited (which differed by primary care setting). Commercial organisations
provided a more effective service at lower cost than primary care providers.
l Two studies recruited participants from areas with high levels of socioeconomic deprivation. In one study
there was no difference in effectiveness by sex. In another study, where participants chose the intervention
which varied by setting, there was variation in effectiveness by setting according to demographic
characteristics (age and sex).
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After 12 months of pharmacotherapy and lifestyle advice,70 BMI was reduced in the intervention group,
but not the control group (–0.9 kg/m2 vs. –0.3 kg/m2, respectively); however, BMI was not significantly
different between groups. In the intervention group there were significant improvements in HbA1c levels,
fasting blood glucose levels, total cholesterol levels and systolic blood pressure.
Dyslipidaemia
One small RCT71 set in one pharmacy in Chile evaluated pharmacotherapy plus lifestyle modification in
adults with dyslipidaemia. Lifestyle modification included changes in eating habits, increase in physical
activity and decrease in or cessation of other risk factors such as alcohol intake, smoking and
excess weight.
At the end of the 16-week programme, weight within the intervention group decreased an average of
1.0 kg, while in the control group the average weight increased by 1.1 kg. There was a significant decrease
in BMI of 0.4 kg/m2 in the intervention group from baseline to follow-up. It is assumed that BMI remained
similar to baseline in the control group (data not reported). Baseline BMI and weight were not reported
and the analysis is based on completers only; it is not clear how many participants entered the study.
Cholesterol and triglycerides improved significantly from baseline to follow-up in intervention participants
and there was no significant change in control participants.
Hypertension
One RCT72 compared a diet and physical activity intervention with usual care in hypertensive participants
not controlled by antihypertensive medication despite compliance. There was no significant improvement
in BMI or weight from baseline to follow-up in either the intervention or control groups. However, the
main aim of this study was to improve control of hypertension rather than promote weight loss; the diet
and physical activity intervention did significantly reduce blood pressure in intervention participants
between baseline and the 8-week follow-up.
Differential effects by demographic or socioeconomic factors
None of the studies reported a differential effect by demographic or socioeconomic factors. One study of
participants with type 2 diabetes mellitus69 reported that the percentage of female dropouts was
significantly higher than the percentage of female completers (female/male dropouts were 73/27% and
female/male completers were 53/47%).
A summary of the evidence for multicomponent interventions is provided in Box 4.
BOX 4 Summary of evidence for multicomponent interventions
l Five studies evaluated multicomponent interventions (pharmacotherapy and lifestyle changes) compared
with usual care in participants with comorbidities (diabetes mellitus, dyslipidaemia and hypertension).
l None of the studies demonstrated a significant improvement in anthropometric outcomes compared with
control but they did show significant improvement in the relevant primary outcomes of blood pressure,
glycaemic control and lipids.
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Chapter 4 Discussion and conclusions
The objectives of the review were (1) to assess the effectiveness of community pharmacy interventionson health and health behaviours in relation to alcohol misuse, smoking cessation and weight
management; (2) to explore if and how SES, sex, ethnicity and age moderate the effect of these
interventions; and (3) to describe how the interventions included in this review have been organised,
implemented and delivered. All three objectives have been met in terms of the extent to which the state
of the evidence enabled us to do so. The extent to which objective 1 has been met is much stronger than
the extent to which objectives 2 and 3 have been met. In order to satisfactorily meet objectives 2 and 3,
more evidence is required from robust interventions that explore if and how SES, sex, ethnicity and age
moderate intervention effects and report how such interventions are organised, implemented and delivered.
Objective 1: to assess the effectiveness of community
pharmacy interventions on health and health behaviours in
relation to alcohol misuse, smoking cessation and
weight management
There was insufficient evidence for the effectiveness and cost-effectiveness of community pharmacy-based
brief alcohol interventions. Evidence from two trials suggests lack of effectiveness. It is not clear whether or
not the UK alcohol screening services or brief advice provided in the pharmacy setting reduces a patient’s
consumption of alcohol over time. UK alcohol screening services demonstrate that the community
pharmacy is an appropriate place to screen patients for alcohol misuse.
Twelve studies evaluated the effectiveness of community pharmacy-based smoking cessation interventions.
Pharmacy-based smoking cessation interventions, including behavioural support and/or NRT, are effective
and cost-effective in helping adults to stop smoking, particularly when compared with usual care;
however, there was heterogeneity between the studies. Four smoking cessation studies reported
cost-effectiveness analyses, but the methods differed and this made comparisons difficult. However,
three UK pharmacy-based interventions appeared cost-effective, despite relatively low quit rates.
Five studies evaluated the effectiveness of community pharmacy-based weight-loss interventions and did
not demonstrate significant between-group differences in weight. However, the majority of these studies
were comparing a pharmacy-based intervention with another active intervention either within the pharmacy
or in another setting. One UK RCT, Lighten Up, compared eight groups (Weight Watchers, Slimming World,
Rosemary Conley, a NHS community-based group called Size Down, GP, pharmacy, participants’ own
choice and an exercise-only control group). At 1 year, participants in only the Weight Watchers programme
had significant weight loss compared with the control group and this intervention was associated with the
highest attendance rate. Mean weight loss at 1 year was 0.8 kg (SD 4.7 kg) for primary care (GP and
pharmacy) and 2.5 kg (SD 6.2 kg) for commercial programmes (Weight Watchers, Slimming World,
Rosemary Conley). Two weight-loss trials reported on cost-effectiveness. The pharmacy-based arm of
Lighten Up was not cost-effective compared with commercial programmes. Another study reported costs
for two primary care-based weight-loss services (GP and pharmacy) and the costs were broadly similar to
that of the pharmacy-based programme in the ‘Lighten Up’ trial.
Five studies evaluated multicomponent interventions (pharmacotherapy and lifestyle changes) compared
with usual care in participants with comorbidities (diabetes mellitus, dyslipidaemia, hypertension). None of
the studies demonstrated a significant improvement compared with control for anthropometric outcomes,
but they did show significant improvement in the relevant primary outcomes of blood pressure, glycaemic
control and lipids.
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Objective 2: to explore if and how socioeconomic status, sex,
ethnicity and age moderate the effect of these interventions
None of the studies examined the differential effects of any measure of SES. Three studies (one smoking
cessation63 and two weight loss studies65,66) examined the differential effects of demographic variables.
The smoking cessation study reported no differential effect by sex. One weight loss study reported no
differential effect by sex.66 The other weight loss study reported isolated statistically significant differences
in weight loss between participants attending the intervention in pharmacies and GPs; for example, female
participants attending a GP lost a larger proportion of their initial weight than females attending a
pharmacy.65 Similarly, participants aged 40–49 years lost a greater proportion of their initial weight at GP
providers than at pharmacy providers.
The significance of these differences in terms of inequalities is unclear; participants chose the service they
wanted to attend and the demographics of participants differed significantly between the two settings.
Another smoking cessation study shows demographic and socioeconomic differences between participants
who self-select treatment by setting. This evidence suggests that the people accessing pharmacies are
different from those attending other settings for alcohol management, smoking cessation and weight loss.
Some studies examined demographic and/or socioeconomic factors at recruitment stage, as potential
predictors of outcomes within group, and/or to explain differences in retention. Although these studies
cannot inform if and how these interventions might impact on inequalities, they can help to inform how
interventions can be targeted to improve access, success and retention. The UK alcohol service evaluations
suggest that these types of services have the potential to reach those most in need.
Objective 3: to describe how the interventions included in this
review have been organised, implemented and delivered
Few studies reported detailed information about the behaviour change strategies employed to deliver the
interventions in order to enable more specific coding of the interventions. The most common behaviour
change strategy used in the included interventions was the transtheoretical model (stages of change).
The majority of included interventions were implemented within the political context of extending the
pharmacists’ public health role. The overall poor descriptions of intervention content, mechanisms and
procedures in most of the included papers limit the potential for knowledge implementation and
replication of the interventions under review.
There was insufficient detailed information to examine any potential relationships between intervention
effectiveness and behaviour change strategies, and whether or not any patterns existed between effective
interventions and implementation components such as pharmacist training or resource intensity. The
reporting of stakeholder involvement (consultation and collaboration) in the planning or during the
delivery of the intervention was particularly poor (only reported in two studies). In terms of sustainability,
a number of studies highlight that reimbursement is needed to the pharmacist for providing the
intervention in order for it to be sustainable.
Strengths and limitations
In terms of the strengths and limitations of the included studies, a thorough and robust search of the
literature was carried out to ensure that all types of community pharmacy-delivered alcohol, smoking and
weight management interventions were captured. However, only 24 controlled studies were identified, of
which 19 were RCTs. Most of the studies focused on smoking cessation interventions and there were only
two interventions for alcohol misuse. No restriction was placed on the types of interventions included
within the review; this meant that five included studies focused on disease states rather than health
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behaviours. These multicomponent interventions addressed a variety of lifestyle factors in adults receiving
pharmacotherapy for comorbidities including type 2 diabetes mellitus, dyslipidaemia and hypertension.
Evidence from these studies is specific to these subgroups of participants.
The purpose of this review was to evaluate the effectiveness of pharmacy-delivered interventions in three
behaviour-related areas (alcohol, smoking and weight), which are each relevant for public health and
have a clear evidence base for interventions outside pharmacy settings. Alcohol consumption and
smoking cessation are both health behaviours (as well as outcomes), whereas obesity is an outcome, and
intervention can target dietary or physical activity behaviours, or both. Therefore, the effectiveness of
weight interventions cannot be directly compared with interventions to reduce alcohol consumption or for
smoking cessation.
This review was primarily a review of effectiveness and not a review of economic evaluations. Any cost
outcomes that were reported within the included studies were assessed; however, the methods of
cost-effectiveness analyses differed between the included studies, making comparisons difficult. Some of
the economic analyses modelled predicted costs of health care as well as observed costs. In addition,
assumptions are made on modelling (such as weighing a certain amount less throughout life or how many
people will relapse and start smoking again over the life course), which should be borne in mind when
assessing the evidence.
Within the protocol it is reported that different types of interventions would not be combined within a
meta-analysis. However, owing to the relatively small number of included RCTs and the mix of intervention
types we felt that it was appropriate as a ‘first step’ to group together the smoking cessation studies that
included behaviour support and/or NRT. The primary research objective was to assess the effectiveness of
any type of intervention which is delivered and based within a community pharmacy setting. Therefore,
by grouping all intervention types together in a meta-analysis, we can begin to assess the effectiveness of
interventions based within the community pharmacy. There was, however, insufficient evidence to say
which specific type of smoking cessation intervention is most effective.
In terms of the strengths and limitations of the included studies, two were pilot studies and, although
they met the eligibility criteria, these types of studies are inherently different from full trials. Pilot studies do
not aim to be sufficiently powered or to have the procedures fully developed, unlike full trials. Quality
assessment might not reflect the inherent difference in aims between these types of study designs, and
this should be borne in mind when comparing the evidence.
An area of ongoing debate among triallists is about the unit of randomisation in RCTs, that is whether
or not it is more appropriate to randomise a cluster, in this case pharmacies, as opposed to randomising
the individual pharmacy client. This is particularly relevant to behaviour change interventions within the
pharmacy practice setting. Of the 19 included RCTs, 17 randomised individual pharmacy clients and only
two randomised pharmacies. It could be argued that cluster RCT design more accurately reflects the real
world and strengthens the external validity of a study, making the evidence more relevant.
In terms of intervention fidelity, we assessed whether or not the consistency of interventions was measured,
whether or not the interventions were delivered as intended and if it was likely that contamination occurred.
In the vast majority of included studies it was not possible to assess fidelity, as these measures were not
reported. In studies in which participants using the same pharmacy were randomised to intervention or control
groups, there is an increased risk of contamination. This was the case for many of the studies included in this
review, yet, despite this, only two of the trials reported on the possibility of cross-contamination between
intervention and control groups. Lack of reported information of intervention fidelity limited the review, in
terms of assessing the strength of any causal relationships between intervention components and outcomes.
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The review is strengthened by the attention paid to contextual factors including the organisation,
implementation and delivery of interventions. Attention was paid to extracting information about
pharmacist training, which will be particularly useful to policy-makers. Few studies reported detailed
information about the behaviour change strategies employed to deliver the interventions, in order to
enable more specific coding of the interventions; the Behaviour Change Wheel and intervention ladder
approaches were therefore chosen to broadly describe the interventions. The overall poor descriptions in
most of the included studies, of intervention content, mechanisms and procedures, limits the potential for
knowledge implementation and replication of the interventions under review.
This review included only process evaluations that were included within the trial papers; we did not search
for papers from the included studies that separately reported process evaluations. Many studies have also
been done on processes outwith evaluations. A new search would be required to systematically capture
all the evidence from trials that have published work on contextual findings around the organisation,
implementation and delivery of pharmaceutical care service by community pharmacies. Therefore, we refer
to process evaluations only to describe how the included interventions have been organised, implemented
and delivered. Given the paucity of reported process data from the included interventions, it is important
that future interventions clearly report contextual factors.
Conclusions
There is insufficient evidence to assess the effectiveness of pharmacy-based interventions for alcohol
management; however, the evidence does show that community pharmacies can be appropriate places
to screen patients for alcohol misuse. Pharmacy-based smoking cessation interventions, including
behavioural support and/or NRT, are effective and cost-effective in stopping adults smoking, particularly
when compared with usual care. Evidence suggests that pharmacy-based weight loss interventions are as
effective as similar interventions in other primary care settings but not as effective or cost-effective as
commercially provided weight management services in community settings. Very few studies explored if
and how sociodemographic or socioeconomic variables moderated interventions effects. The information
reported in the studies shed very little light on how best to organise, implement and deliver interventions
in the pharmacy setting.
Implications for public health
Our review has found a relatively small international evidence base; more evidence is needed to assess the
effectiveness of pharmacy-based interventions for alcohol and weight management. Nine studies were
conducted in the UK,46,48–51,56,58,60,65,66,68 and so the study findings should be generalisable to the UK
pharmacy context. Our review has demonstrated that pharmacy-based interventions are effective and
cost-effective in helping adults to stop smoking. The review supports the commissioning of smoking
cessation services in a community pharmacy setting.
The evidence shows a range of types of smoking cessation interventions that are feasible within community
pharmacies, including behavioural support and/or NRT, but not which specific types of interventions and
components are the most effective. A range of type of interventions in various different settings is required
to suit different adults who want to manage their alcohol intake, stop smoking or lose weight. Evidence
from this review suggests that pharmacy-based interventions for smoking cessation are suitable as part of a
suite of interventions.
The review has shown that is feasible to recruit patients to an alcohol screening intervention within a
community pharmacy setting, but there is insufficient evidence of the effectiveness of such screening and
brief intervention and whether or not this reduces a patient’s alcohol consumption over time. What is not
known, however, is the outcome for patients who are identified as hazardous/harmful drinkers within a
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community pharmacy and referred to other branches of health care (e.g. a GP or rehabilitation centre).
Given the reach of the community pharmacy network, and that our review has shown it is feasible to
recruit patients in this setting, it would be prudent to explore referral options for adults who screen
positive for hazardous/harmful drinking.
There is a lack of evidence regarding the effect of pharmacy-based interventions on health inequalities.
Very few studies targeted disadvantaged population groups; these types of studies can provide useful
information about recruitment and retention of these high-risk groups. Given the potential reach of the
community pharmacy network, more work is needed to ascertain how commissioning smoking cessation
services may impact on inequalities in health. Inequalities in relation to interventions can result from both
differential uptake of pharmaceutical services and differential effectiveness by demographic and SES.
This review concentrates on differential effectiveness by demographic and SES (and found little evidence
reported) but acknowledges that inequalities in uptake are an equally important contribution to health
inequalities. Pharmaceutical needs assessments80 include evaluation of the level of access to community
pharmacies, the specific needs of individual localities and uptake of services compared with other regions,
but not differential uptake. Evidence from weight management programmes based in community
pharmacies shows that middle-aged women are more likely to join. A 2000 postal survey81 in a stratified
random sample of 10,000 adults aged ≥ 35 years in North Staffordshire, UK, showed that female sex and
older age were independently associated with collection of a prescription medicine. Female sex, younger
age and higher social class were independently associated with over-the-counter purchase, while female
sex and smoking were independently associated with seeking advice from the pharmacist.
Recruitment to pharmacy-based interventions may indicate possible differences in uptake of
pharmaceutical services. There is some evidence of differences in recruitment to community pharmacy
interventions according to sex. Across all the studies there was a majority of female participants recruited
and this was the more pronounced within the weight loss studies. It is unclear how this might impact on
the willingness of men to use weight loss services in pharmacies. More research is needed about whether
or not access to community pharmacies, and uptake of their services, differs by sociodemographic and
socioeconomic characteristics.
The authors are not aware of any other reviews which directly compare public health interventions across
different primary or community health-care settings. This review attempts to do just that by including
studies that compared a pharmacy-based intervention group with interventions based in other settings.
However, only five of the included studies compared a pharmacy setting with another setting (two smoking
cessation and three weight loss interventions). One smoking cessation study compared pharmacy with an
outpatient setting and found no significant difference between groups for smoking cessation. Another
smoking cessation study found that the NHS group-based service set in the community attracted fewer
clients but was significantly more effective in stopping smoking at 12 months than the pharmacy-based
service. Three weight loss studies compared different settings, GP, primary care units and pharmacy settings
appeared to be of equal effectiveness, which was less than that of commercial services based in
the community.
A direct comparison between public health interventions in different settings is difficult because of
differences in the characteristics of the participants and the context in which the interventions are
delivered. There are many other factors in addition to effectiveness that need to be considered, such as
recruitment and attendance, which appear to be comparable between GP surgeries and pharmacies but
better in community and commercial programmes. Current evidence shows that referral to commercial
weight loss providers is more effective than GP surgery- and pharmacy-delivered interventions. In the
choice arm of the Lighten Up trial,66 71 (71%) participants chose one of the commercial providers, 16 (16%)
chose the Size Down programme, three (3%) chose general practice and 10 (10%) chose pharmacy
provision. Women were more likely than men to choose one of the commercial providers [57 (81%)
women, compared with 14 (47%) men]. Among those randomised, the rate of participants not taking up
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the invitation to attend was twice as high for pharmacy as for commercial providers and only the minimal
contact control arm had lower uptake rate. In terms of programme attendance, pharmacy had the worst
attendance records of all arms.
As well as possible differential uptake of pharmaceutical services by demographic and socioeconomic
characteristics, there may be differential uptake relative to other community health-care settings such as
primary care. If a distinct group of people is accessing pharmaceutical services who would not access
services in other health-care settings even if effect sizes are smaller than in other settings, then public
health interventions within community pharmacies need to be considered as an option within a suite of
choices available for the general population that could positively impact on health inequalities at a
population level. However, we found an absence of evidence in this regard.
There is insufficient evidence to examine the relationship between behaviour change strategies and
effectiveness or evidence of consistent implementation factors or training components that underpin
effective interventions. More information is needed about pharmacist training and the experience of those
delivering the training, resources required and sustainability of pharmacy-based interventions.
Contextual factors are important when developing public health services in a community pharmacy
environment. One such important consideration is the changing landscape of health-care services and
the emphasis placed on expanding the role of community pharmacies. This has been acknowledged
internationally: the WHO has described qualities of a future pharmacist82 – one of whom is a care-giver.
Rather than using community pharmacies in their traditional role in dispensing and compounding
medication, there are drivers in policy to extend the role of community pharmacists. This is also evident in
the NHS, where the changing contract of community pharmacies is allowing pharmacists to become more
involved in patient-focused health-care service delivery. Recently there have been campaigns to use
community pharmacies to obtain certain health-care advice rather than other, perhaps more costly, primary
care services. Clearly, how the contract for these services is structured is an important factor in how these
services are implemented.
Another important factor in terms of service delivery is how patients perceive community pharmacies.
Recent evidence from a qualitative study83 suggests that patients will not ‘trust’ pharmacies to deliver
unfamiliar health-care services. Similarly, a systematic review undertaken by Eades et al.84 showed that,
despite the changing role of community pharmacies, most consumers did not expect a public health
service by a pharmacist; they also had mixed views on a pharmacist’s ability to provide such services. The
public’s perception of community pharmacies and the ability to provide public health services could be a
significant barrier towards implementation unless strategies are put in place to promote this.
The role of community pharmacies differs across the world, with many pharmacies still solely used as a
means of supplying medication. Although nine studies included in this review were UK based, there were
studies set in a further 10 countries, inside and outside Europe. It is probable that the uptake of pharmacy
services will be variable, based on consumers’ perceptions and experiences. The influences on people’s
choice of community pharmacy versus GP surgery, self-management or commercial provider are likely to
vary between countries where health care is delivered using different models. However, in view of the
changing role of pharmacy, the concept of ‘pharmaceutical care’ has been introduced. Although this relates
to the provision of drug therapy, it is associated with the outcomes of treating or preventing disease. This
term is recognised internationally and used throughout the world by policy-makers relevant to health care.
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Research recommendations
This review has prompted various suggestions for improvement, to contribute to a more useful and
rigorous evidence base, which will enable the translation of research findings into effective public health
approaches for managing alcohol, smoking and weight within the pharmacy setting.
l Surprisingly, a relatively large proportion of the research so far has been carried out in the UK, which
contributes to its generalisability to the UK pharmacy setting. However, the overall quality of the
24 included studies suggests that more research is required to improve recruitment and retention of
participants to pharmacy-based interventions.
l Only two studies evaluated the efficacy of pharmacy-based interventions in improving alcohol
management. Evaluations of interventions are required in order to assess the effectiveness of
pharmacy-based interventions for alcohol management.
l More research is needed about how an intervention may impact on inequalities in alcohol misuse,
smoking and obesity; and how this impact will be measured, in terms of socioeconomic variables and
ethnicity. None of the studies examined the effect of interventions across the SES gradient. In a few
cases where studies examined the differential effects of demographic variables, the significance of
these differences on health inequalities is unclear. Future studies will need to be sufficiently powered to
detect small changes and to measure equity effects of these small changes at a population level.
l The implementation tool was useful in extracting descriptive data across a wide range of factors.
However, it will need to be refined in the future, or a new tool developed, if it is to help gather more
insight into why an intervention might or might not work. Other methods of review, such as a realist
review, offer an alternative approach to synthesising information about implementation, and so any
refinement or new tool might benefit from taking this approach into account. However, as one of
the problems in our review, and in others that have assessed implementation, was the paucity of
information in the primary studies about implementation factors. Therefore, we recommend that
‘implementation reporting’ guidelines be developed within public health so that this important
information is included by researchers undertaking primary studies, in a more systematic way.
l This review identified little evidence about the reach of pharmacy-based interventions. Targeted
intervention studies provide some evidence that adults accessing pharmacies are a distinct subgroup
that may not access other primary care or commercial services. This evidence is derived from
participants who self-selected the intervention and setting. More research is required on the reach of
the pharmacy setting.
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Appendix 1 Search strategy
MEDLINE (via Ovid)
Searched: May 2014.
Date of search: from inception to May 2014.
Search strategy
# Search term
1 exp Community Pharmacy Services/
2 Pharmacies/
3 exp Pharmacists/
4 exp Pharmacists’ Aides/
5 Pharmacy/
6 chemist.tw.
7 (communit$ adj7 pharmac$).tw.
8 (office$ adj7 pharmacy$).tw.
9 ((pharmacy or pharmacist? or pharmacies) adj3 (community or counsel$ or advice or care)).tw.
10 (pharmacist? adj3 (front line or ’one to one’ or face to face)).tw.
11 (pharmacist? or pharmacy or pharmacies).tw.
12 ((pharmacist? or pharmacy) adj3 (aide or aides or assistant? or staff)).tw.
13 (Pharmacist? adj2 (care or delivered)).tw.
14 (pharmacist? adj3 (counsel$ or (patient? adj2 education$) or led or intervention? or public health or diagnos$)).tw.
15 or/1–14
16 exp Obesity/
17 exp Body Weight/
18 exp Body Weight Changes/
19 exp Weight Gain/ or exp Weight Loss/
20 (obese or obesity).tw.
21 overweight.tw.
22 weight.tw.
23 diet$.tw.
24 nutrition$.tw.
25 (physical$ adj activ$).tw.
26 exercise$.tw.
27 lifestyle$.tw.
28 (bmi$ or (body adj mass ind$)).tw.
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# Search term
29 (waist adj6 circumference$).tw.
30 ((weight adj2 (control or reduction) adj2 (advice or counsel$ or program$ or intervention?)) or (weight adj
manag$)).tw.
31 ((overweight or obese or obesity) adj4 (Advice or counsel$ or intervention? or program$)).tw.
32 or/16–31
33 exp Smoking/ or exp Smoking Cessation/
34 nicotine.tw.
35 cigarette$.tw.
36 (nicotine replacement therapy or NRT).tw.
37 smoking cessation.tw.
38 smok$.tw.
39 exp "Tobacco Use Cessation"/
40 exp Smoking Cessation/
41 (smoking cessation or (quit$ adj2 smok$)).tw.
42 ((reduce or reducing) adj3 (’tobacco use’ or cigarette? or smoking or addiction)).tw.
43 or/33–42
44 alcohol.mp.
45 exp Alcohols/
46 exp Alcohol Drinking/
47 exp Alcoholism/
48 exp Drinking Behavior/
49 (drink$).tw.
50 beer.tw.
51 wine.tw.
52 ethanol.tw.
53 drunk.tw.
54 (addict$ or (alcohol adj2 (abus$ or misus$))).tw.
55 alcohol$.tw.
56 drunk$.tw.
57 intoxicat$.tw.
58 or/44–57
59 32 or 43 or 58
60 (animals not humans).mp.
61 59 not 60
62 15 and 60
63 limit 62 to humans
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Appendix 2 Data extraction form
Project details
Author.
Year.
Project name.
Publication type.
Journal Volume (Issue) Pages.
Aims (rationale, theory or goal of the elements essential to the intervention).
Target population(s).
Country.
Intervention description (materials used and procedures).
Start date of project.
End date of project.
Date.
Reviewers initials of data extraction.
Cost to participant, pharmacy, local authority, or other organisation(s).
Throughput – number of participants per time period.
Resources (time, money, staff and equipment).
Theoretical basis/behaviour change techniques used.
Contact details.
Language.
Behaviour-change wheel.
Intervention function.
Behaviour-change wheel.
Policy category.
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Nuffield Intervention Ladder code.
Staff training and quality assurance.
Was consistency of intervention measured?
Was the intervention delivered as intended?
Is it likely contamination occurred?
Delivery fidelity
Experience of intervention team.
Project details notes (if required).
Implementation context notes.
Study information
Study Focus.
Smoking/Alcohol Study: Measure of behaviour?
Weight Study: Measure of weight? If no, stop extraction. If yes, add details on measures taken and
instruments used (including if validated). If no, stop extraction. If yes, add details on measures taken and
instruments used (including if validated).
Setting (should be community pharmacy).
Study Design Type RCT: allocated to different groups using methods that are random.
nRCT: allocated to different groups using methods that are not random.
CBA: observations are made before and after an intervention, both in a group that receives the
intervention and in a control group that does not.
Interrupted time series (ITS): observations are made at multiple time points before and after
an intervention.
RMS: a ITS study where measurements are made in the same individuals at each time point.
Before–After: must have at least 1 measure before and after (stop extraction, and keep in a pile).
Level of intervention (individual, community, societal).
Approach to targeting inequality (targeted or universal?).
Unit of randomisation/allocation.
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Unit of analysis.
Did the intervention deliverers receive any training related to the intervention, and if so, what?
Measure of inequality.
Sex, age, and individual or area-level measures of socioeconomic status (education, income, occupation,
social class, deprivation, poverty).
Population details
Population targeted.
Method of sampling (volunteer, random, stratified, etc.).
Ethnicity.
Study design.
Total population (number who could take part/approached).
Time between baseline and follow-ups.
Confounding from attrition/non response explored?
Adjustments?
Intention-to-treat?
Imputation of missing data?
Population details notes (if required).
% female (baseline sample).
Mean age (years) SD Median age (years) range.
Baseline recruitment rate (%).
Baseline sample size.
Final sample size.
Follow-up response rate (%) Sample size of final analysis.
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If data are reported in two groups:
If data are reported together:
% female (baseline sample).
Mean age (years) SD Median age (years) range.
Baseline recruitment rate (%).
Baseline sample size.
Final sample size.
Follow-up response rate (%) Sample size of final analysis.
Intervention/Group 1:
% female (baseline sample).
Mean age (years) SD Median age (years) range.
Baseline recruitment rate (%).
Baseline sample size.
Final sample size.
Follow-up response rate (%) Sample size of final analysis.
Control/Group 2:
Outcomes and results
Data collection methods.
Outcomes.
Outcome assessor(s) aware of intervention status?
Participants aware of research question?
Data collection tools valid?
Data collection tools reliable?
Results (evidence of effectiveness).
Acceptability to staff and customers.
Evidence of cost-effectiveness (where applicable).
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Set up and running costs.
Funding source and length/security of funding.
Outcomes and results notes (if required).
Stakeholder support.
Sustainability.
Implementation
A) Motivation (Why was the intervention implemented?).
B) Theoretical basis/behaviour change techniques used and staff training and quality assurance.
C) Implementation context Notes.
D) Experience of intervention team (planners/implementers).
E) Consultation and/or collaboration processes.
F) Was the intervention delivered as intended?
G) Sustainability.
H) Stakeholder support.
I) Resources (time, money, staff and equipment).
J) Differential effects.
Implementation score.
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Appendix 3 Quality assessment tool
Component ratings
(A) Selection bias
(Q1) Are the individuals selected to participate in the study likely to be representative of the
target population?
Very likely
Somewhat likely
Not likely
Can’t tell
(Q2) What percentage of selected individuals agreed to participate?
80–100% agreement
60–79% agreement
< 60% agreement
Not applicable
Can’t tell
RATE THIS SECTION STRONG MODERATE WEAK
See dictionary 1 2 3
(B) Study design
Indicate the study design
Randomized controlled trial
Controlled clinical trial
Cohort analytic (two group pre+ post)
Case-control
Cohort (one group pre+ post (before and after))
Interrupted time series
Other specify ____________________________
Can’t tell
Was the study described as randomized? If NO, go to Component C.
No Yes
If Yes, was the method of randomization described? (See dictionary)
No Yes
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If Yes, was the method appropriate? (See dictionary)
No Yes
RATE THIS SECTION STRONG MODERATE WEAK
See dictionary 1 2 3
(C) Confounders
(Q1) Were there important differences between groups prior to the intervention?
Yes
No
Can’t tell
The following are examples of confounders:
Race
Sex
Marital status/family
Age
SES (income or class)
Education
Health status
Pre-intervention score on outcome measure
(Q2) If yes, indicate the percentage of relevant confounders that were controlled (either in the design
(e.g. stratification, matching) or analysis)?
80–100% (most)
60–79% (some)
< 60% (few or none)
Can’t tell
RATE THIS SECTION STRONG MODERATE WEAK
See dictionary 1 2 3
(D) Blinding
(Q1) Was (were) the outcome assessor(s) aware of the intervention or exposure status of participants?
Yes
No
Can’t tell
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(Q2) Were the study participants aware of the research question?
Yes
No
Can’t tell
RATE THIS SECTION STRONG MODERATE WEAK
See dictionary 1 2 3
(E) Data collection methods
(Q1) Were data collection tools shown to be valid?
Yes
No
Can’t tell
(Q2) Were data collection tools shown to be reliable?
Yes
No
Can’t tell
RATE THIS SECTION STRONG MODERATE WEAK
See dictionary 1 2 3
(F) Withdrawals and drop-outs
(Q1) Were withdrawals and drop-outs reported in terms of numbers and/or reasons per group?
Yes
No
Can’t tell
Not applicable (i.e. one time surveys or interviews)
(Q2) Indicate the percentage of participants completing the study. (If the percentage differs by groups,
record the lowest.)
80–100%
60–79%
< 60%
Can’t tell
Not applicable (i.e. retrospective case–control)
RATE THIS SECTION STRONG MODERATE WEAK
See dictionary 1 2 3 Not applicable
DOI: 10.3310/phr04020 PUBLIC HEALTH RESEARCH 2016 VOL. 4 NO. 2
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103
(G) Intervention integrity
(Q1) What percentage of participants received the allocated intervention or exposure of interest?
80–100%
60–79%
< 60%
Can’t tell
(Q2) Was the consistency of the intervention measured?
Yes
No
Can’t tell
(Q3) Is it likely that subjects received an unintended intervention (contamination or cointervention) that
may influence the results?
Yes
No
Can’t tell
(H) Analyses
(Q1) Indicate the unit of allocation (circle one).
Community organization/institution practice/office individual
(Q2) Indicate the unit of analysis (circle one).
Community organization/institution practice/office individual
(Q3) Are the statistical methods appropriate for the study design?
Yes
No
Can’t tell
(Q4) Is the analysis performed by intervention allocation status (i.e. intention to treat) rather than the
actual intervention received?
Yes
No
Can’t tell
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Global rating
Component ratings
Please transcribe the information from
the grey boxes on pages 1–4 onto this
page. See dictionary on how to rate
this section. A SELECTION BIAS STRONG MODERATE WEAK
1 2 3
B STUDY DESIGN STRONG MODERATE WEAK
1 2 3
C CONFOUNDERS STRONG MODERATE WEAK
1 2 3
D BLINDING STRONG MODERATE WEAK
1 2 3
E DATA COLLECTION METHOD STRONG MODERATE WEAK
1 2 3
F WITHDRAWALS AND DROPOUTS STRONG MODERATE WEAK
1 2 3 Not applicable
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Appendix 4 List of included studies
Bold type indicates main study paper in cases of multiple study papers.
Ahrens RA, Hower M, Best AM. Effects of weight reduction interventions by community pharmacists.
J Am Pharm Assoc 2003;43:583–9.
Ali M, Schifano F, Robinson P, Phillips G, Doherty L, Melnick P, et al. Impact of community pharmacy
diabetes monitoring and education programme on diabetes management: a randomised controlled study.
Diabet Med 2012;29:e326–33.
Bauld L, Boyd KA, Briggs AH, Chesterman J, Ferguson J, Judge K, et al. One-year outcomes
and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led
cessation services. Nicotine Tob Res 2011;13:135–45.
Bauld L, Chesterman J, Ferguson J, Judge K. A comparison of the effectiveness of group-based and
pharmacy-led smoking cessation treatment in Glasgow. Addiction 2009;104:308–16.
Boyd KA, Briggs AH. Cost-effectiveness of pharmacy and group behavioural support smoking cessation
services in Glasgow. Addiction 2009;104:317–25.
Bock BC, Hudmon KS, Christian J, Graham AL, Bock FR. A tailored intervention to support pharmacy-based
counseling for smoking cessation. Nicotine Tob Res 2010;12:217–25.
Burford O, Jiwa M, Carter O, Parsons R, Hendrie D. Internet-based photoageing within Australian
pharmacies to promote smoking cessation: randomised controlled trial. J Med Internet Res 2013;15:e64.
Bush J, Langley CA, Patel A, Harvey JE. Evaluation of the Heart of Birmingham Teaching Primary Care Trust
(HoBtPCT) My Choice Weight Management Programme. Final Report. Birmingham: Aston University; 2011.
Correr CJ, Melchiors AC, Fernandez-Limos F, Pontarolo R. Effects of a pharmacotherapy follow-up in
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Appendix 8 Behaviour change
Study
Behaviour change
strategy used, and
theoretical basis, of
intervention delivered in
a community pharmacy
setting, where reported.
Plus same information
reported for the
comparison group(s)
(active and/or non-active
control)
Behaviour Change Wheel
Nuffield Intervention
Ladder codeIntervention function Policy category
Alcohol
Dhital et al.,
201546
Brief alcohol intervention
that was not motivational
interviewing, but rather
followed a structured
protocol influenced by the
motivational interviewing
approach delivered in a
10-minute discussion;
included reflection and
encouraged self-directed
behaviour change; feedback
of the AUDIT score was also
given
Comparison group:
a leaflet-only control
Education, enablement Service provision Enable choice
Watson and
Stewart, 201148
Brief alcohol intervention
based on motivational
interviewing
Comparison group: a
general lifestyle leaflet
control
Enablement, education Service provision Enable choice
Smoking cessation
Bauld et al.,
201149
Bauld et al.,
200950
Boyd et al.,
200951
12 weeks of medium-
intensity behavioural
counselling
Comparison group:
Maudsley hospital model
of 7 weeks of intense
group-based behavioural
support (not delivered in a
pharmacy setting, and
delivered by an ‘advisor’)
Education, enablement Service provision Enable choice
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Study
Behaviour change
strategy used, and
theoretical basis, of
intervention delivered in
a community pharmacy
setting, where reported.
Plus same information
reported for the
comparison group(s)
(active and/or non-active
control)
Behaviour Change Wheel
Nuffield Intervention
Ladder codeIntervention function Policy category
Bock et al.,
201052
All counselling approaches
are aligned with the 5 A’s
framework (ask, assess,
advise, assist, arrange
follow-up) which includes
counselling on motivational
issues. Pharmacists deliver
counselling, supported by EQ.
EQ is a software system that
provides individually tailored
feedback to patients who
smoke cigarettes, and
matches reports for the
pharmacist to help guide
cessation counselling.
Contents of the tailored
feedback address the
domains of motivation,
decisional making (pros and
cons of quitting smoking)
and perceived barriers to
quitting, smoking triggers/
cues, nicotine dependence
and effective smoking
cessation medications.
The tailored feedback also
addresses the relationship
between quitting smoking
and the experience of
potential negative affect
and/or depressive symptoms
Comparison group: two
intervention groups included
the same counselling
approaches (EQ); difference
was ± free nicotine patches.
The observation-only control
group included no
counselling
For either intervention
groups vs. control:
education, enablement
Service provision For EQ vs. control:
enable choice
For EQ+ patches vs.
EQ or control: guide
choice – incentives
(nicotine patches were
provided free as part of
the intervention)
Burford et al.,
201353
The intervention group
participants were digitally
photoaged by using the
internet-based APRIL face
ageing software so they
could preview images of
themselves as a lifelong
smoker and as a non-smoker
Comparison group: both
the intervention and
control groups received
‘standardised smoking
cessation advice’ from the
pharmacist
Education,
enablement,
persuasion
Service provision Enable choice
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Study
Behaviour change
strategy used, and
theoretical basis, of
intervention delivered in
a community pharmacy
setting, where reported.
Plus same information
reported for the
comparison group(s)
(active and/or non-active
control)
Behaviour Change Wheel
Nuffield Intervention
Ladder codeIntervention function Policy category
Costello et al.,
201155
Comparison of two
interventions that used
the same behavioural
counselling strategy. The
pharmacists used the ‘5-A’
model for brief behavioural
counselling (see Bock et al.
201052)
Comparison group: one
intervention used one
session and the other used
three sessions of the
behavioural counselling
Both intervention
groups: education,
enablement,
incentivisation
Service provision Both intervention
groups: guide choice –
incentives (NRT was
free as part of the
intervention)
Crealey et al.,
199856
PAS is a structured
intervention package based
on the stages-of-change
model and using motivational
interviewing. It is designed to
assist smokers to stop and to
motivate and support them to
stay stopped, delivered in a
one-to-one counselling format
with structured follow-up
(a pilot study for the Maguire
study listed below)
Theoretical model:
transtheoretical model (stages
of change)
Comparison group: matched
controls who did not receive
PAS
Education, enablement Service provision Enable choice
Hoving et al.,
201057
Computer-generated advice
in a 5- to 7-page coherent
letter individually tailored,
based on responses to a
baseline questionnaire.
Messages were selected
through a theory-based
algorithm to address aspects
relevant to the individual
participant (e.g. perceived
advantages and
disadvantages of smoking
cessation and anticipated
difficult situations to refrain
from smoking)
Theoretical model: I-change
model incorporating several
cognitive models such as the
transtheoretical model and
theory of reasoned action
Education, enablement Service provision,
communication/
marketing
Enable choice
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Study
Behaviour change
strategy used, and
theoretical basis, of
intervention delivered in
a community pharmacy
setting, where reported.
Plus same information
reported for the
comparison group(s)
(active and/or non-active
control)
Behaviour Change Wheel
Nuffield Intervention
Ladder codeIntervention function Policy category
Comparison groups: a
thank-you letter from a
pharmacist; computer-
generated advice in a letter
from a GP that was
individually tailored; a
thank-you letter from a GP
Howard-Pitney
et al., 199944
Behavioural treatment
comprising two visits to the
pharmacy, support calls and
self-help materials, including
a 23-page, self-help quitting
manual tailored for chewing
tobacco users. The major
sections in the manual took
the chewer through typical
stages in the quitting
process: getting ready, quit
date, dealing with urges,
and recovery or staying off
chew. [Note that it was
unclear whether or not this
intervention was based
on the transtheoretical
(stages-of-change) model]
Comparison group: same
behavioural treatment as
intervention, but they
received a placebo patch
rather than a nicotine patch
Both intervention
groups: education,
enablement,
incentivisation
Service provision,
communication/
marketing
Both intervention
groups (GP and
pharmacy): guide
choice – incentives
(NRT was free as part
of the intervention)
Maguire et al.,
200158
PAS is a structured
intervention package based
on the stages-of-change
model and using
motivational interviewing. It
is designed to assist smokers
to stop and to motivate and
support them to stay
stopped, delivered in a
one-to-one counselling
format with structured
follow
Theoretical model:
transtheoretical (stages-of-
change) model
Comparison group: matched
controls who did not receive
PAS
Education,
enablement,
Communication/
marketing,
service provision
Enable choice
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Study
Behaviour change
strategy used, and
theoretical basis, of
intervention delivered in
a community pharmacy
setting, where reported.
Plus same information
reported for the
comparison group(s)
(active and/or non-active
control)
Behaviour Change Wheel
Nuffield Intervention
Ladder codeIntervention function Policy category
Mochizuki et al.,
200459
Structured support from the
pharmacist (five times over
3 months)
Comparison group: ad-hoc
advice when asked for it by
participant
Education, enablement Service provision Enable choice
Sinclair et al.,
199860
Behavioural counselling in
smoking cessation based on
the stages-of-change model.
The intervention group also
received nicotine patches
Theoretical model:
transtheoretical (stages-of-
change) model
Comparison groups: same as
intervention but, after an
initial consultation with a
community pharmacist they
are followed up by a
research pharmacist in a
hospital outpatient clinic;
advice from pharmacists
who have not undergone
training in behavioural
counselling
Education, enablement Service provision Enable choice
Sonderskov
et al., 199763
The intervention did not
include any behavioural
support. The intervention
was nicotine patches
Comparison group: same as
intervention but placebo
patches
Enablement Service provision Guide choice –
incentives (nicotine
patches provided at
half the retail cost)
Vial et al.,
200245
Behavioural counselling in
smoking cessation based on
the stages-of-change model
Theoretical model:
transtheoretical (stages-of-
change) model
Comparison groups: minimal
intervention group who
were provided with written
material and advice only
Education, enablement Service provision Guide choice –
incentives (nicotine
patches were provided
at about half the retail
cost)
DOI: 10.3310/phr04020 PUBLIC HEALTH RESEARCH 2016 VOL. 4 NO. 2
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121
Study
Behaviour change
strategy used, and
theoretical basis, of
intervention delivered in
a community pharmacy
setting, where reported.
Plus same information
reported for the
comparison group(s)
(active and/or non-active
control)
Behaviour Change Wheel
Nuffield Intervention
Ladder codeIntervention function Policy category
Weight loss
Ahrens et al.,
200364
Meal replacements
Comparison group: normal
low-calorie diet
Education, enablement,
restriction
Service provision,
communication/
marketing
Restrict choice
Bush et al.,
201165
My Choice Weight
Management Programme
delivered ‘through’
pharmacies. Based on the
model used for the
Counterweight Project,
with weekly consultations.
Compared with the
Counterweight Project,
there was more focus on
goal-setting and the targets
and less focus on portion
control
Comparison group: same as
intervention but delivered
‘through’ GP surgeries
Education, enablement Service provision,
communication/
marketing
Enable choice
Jolly et al.,
201166
There were eight arms
(six interventions) in this
(Lighten Up) trial. Pharmacy
(pharmacist led, one to
one) was classed as the
intervention group for this
systematic review. The
theoretical basis of the
intervention was the
stages-of-change model
with use of motivational
interviewing. Predominant
behaviour change strategies
included goal-setting,
self-monitoring with food
diaries, hunger scale, waist
measurements and physical
activity. Participants were
encouraged to reward
themselves for success
Control: enablement
Dietetic, GP and
pharmacy: education,
enablement
WW, SW and RC:
education,
enablement,
modelling,
incentivisation
Service provision Dietetic, GP, pharmacy,
control: enable choice
WW, SW and RC:
guide choice –
incentives
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Study
Behaviour change
strategy used, and
theoretical basis, of
intervention delivered in
a community pharmacy
setting, where reported.
Plus same information
reported for the
comparison group(s)
(active and/or non-active
control)
Behaviour Change Wheel
Nuffield Intervention
Ladder codeIntervention function Policy category
Comparison groups
l WW (group):
predominant strategies
used to change behaviour
included stages of
change, food and activity
diaries, goal-setting, and
evaluation of progress.
Rewards are given for
every 3.2 kg (7 lb) lost and
for loss of 5% and 10%
of body weight
l SW (group):
predominant behaviour
change strategies used
included motivational
interviewing, weekly
weighing; group
support; and group
praise for weight loss,
new decisions and
continued commitment
even in the absence of
weight loss. Awards are
given for 3.2 kg (7 lb)
lost and loss of 10% of
body weight. Individual
support, if needed, uses
self-monitoring of food
and emotions, for and
against evaluations,
visualisation techniques,
and personal eating
plans. Theoretical
model: transactional
analysis, awareness
ego states
l RC (group): the
approach is based on
role modelling and
group support and uses
visualisation and
reframing to support
behavioural change.
Predominant behaviour
change strategies used
include rewards for
slimmers who maintain
or lose weight, slimmer
of the week, and
certificates for 3.2 kg
and 6.35 kg milestones.
Theoretical model: not
reported
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Study
Behaviour change
strategy used, and
theoretical basis, of
intervention delivered in
a community pharmacy
setting, where reported.
Plus same information
reported for the
comparison group(s)
(active and/or non-active
control)
Behaviour Change Wheel
Nuffield Intervention
Ladder codeIntervention function Policy category
NHS Size Down programme
(led by food advisers recruited
from the local community,
and trained by dietitians,
group). The theoretical
background was based on
the stages-of-change model.
The benefits of physical
activity, setting goals and
finding activities to fit into life
were discussed. Predominant
behaviour change strategies
used included goal-setting,
stages of change, and
self-monitoring with a food
diary. Theoretical model:
transtheoretical (stages-of-
change) model
GP practice (nurse led,
one to one): same as
intervention but different
setting
Control (12 free vouchers for
local leisure centre)
Or a choice of one of the
above
Malone and
Alger-Mayer,
200339
Pharmacists delivering
obesity management
(following a training course)
to patients prescribed orlistat
Comparison group: orlistat
plus usual care delivered by
the pharmacist (who had
not undertaken the training
course)
Education (but not
enablement because
no behavioural
component to sessions)
Service provision Provide information
(rather than enable
choice, because no
behavioural component
to sessions)
Phimarn et al.,
201367
Obesity counselling based
on a obesity handbook
comprising three parts:
(1) an informational section
which deals with healthy
diet, principles of calorie
intake, food groups, portion
size and exercise; (2) a
patient profile to record
personal information and
clinical outcomes; and (3) a
daily food record for patients
to record their daily meals
Education, enablement Service provision Enable choice
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Study
Behaviour change
strategy used, and
theoretical basis, of
intervention delivered in
a community pharmacy
setting, where reported.
Plus same information
reported for the
comparison group(s)
(active and/or non-active
control)
Behaviour Change Wheel
Nuffield Intervention
Ladder codeIntervention function Policy category
Theoretical model: theory of
planned behaviour
Comparison group: a routine
group-directed weight
management service
provided by staff in the
GP practice
Multicomponent interventions (pharmacotherapy and lifestyle changes)
Diabetes mellitus – type 2
Ali et al., 201268 Pharmacist-led patient
education, lifestyle
modification counselling and
diabetes mellitus monitoring
programme
Comparison group: usual
care
Education, enablement Service provision;
communication/
marketing
Enable choice
Correr et al.,
201169
‘Pharmacotherapy follow-up’
in pharmacies. The key and
differential component of
pharmacotherapy follow-up
compared with other
cognitive services (e.g.
medication review) is its
focus on assessing the
clinical outcomes resulting
from the process of use of
medicines, rather than
evaluating this process of
use, and thus ultimately
identifying certain
medication negative clinical
outcomes
Comparison group: usual
care
Education, enablement Service provision Enable choice
Fornos et al.,
200670
‘Pharmacotherapy follow-up’
in pharmacies. This was a
similar type of intervention
as Correr et al.69 but also
specifically included health
education by the pharmacist
with a view to achieving a
healthier lifestyle
Comparison group: usual
care
Education, enablement Service provision Enable choice
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Study
Behaviour change
strategy used, and
theoretical basis, of
intervention delivered in
a community pharmacy
setting, where reported.
Plus same information
reported for the
comparison group(s)
(active and/or non-active
control)
Behaviour Change Wheel
Nuffield Intervention
Ladder codeIntervention function Policy category
Dyslipidaemia
Paulos et al.,
200571
A pharmaceutical care
programme that provides
education in the areas of
medication compliance and
lifestyle modifications
Comparison group: usual
care
Education, enablement Service provision Enable choice
Hypertension
Zaragoza-
Fernandez et al.,
201272
‘Individualised health
education’
Comparison group: usual
care
Education (but not
enablement as no
behavioural component
to sessions)
Service provision Provide information
(rather than enable
choice, as no
behavioural component
to sessions)
EQ, Exper_Quit; RC, Rosemary Conley; SW, Slimming World; WW, Weight Watchers group.
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Appendix 9 Implementation
Study
Implementation
contexta
Consultation/collaboration
processes during planningb
Consultation/collaboration
processes during deliveryc Sustainabilityd,e
Alcohol
Dhital et al.,
201546
Political Pharmacists were consulted
in the planning of the trial
regarding an acceptable and
feasible training period
No information of relevance
was reported
No information of
relevance was
reported
Watson and
Stewart,
201148
Political Focus groups were convened
before (and after) the study
to (1) explore pharmacists’
perceptions of barriers and
facilitators to delivering the
intervention and (2) explore
with members of the
public their opinions/beliefs
about the intervention in
community pharmacy setting
No information of relevance
was reported
No information of
relevance was
reported
Smoking cessation
Bauld et al.,
201149
Bauld et al.,
200950
Boyd et al.,
200951
Political,
economic
The study authors
acknowledge the assistance
provided by NHS Greater
Glasgow and Clyde staff and
the study steering group, but
it is not clear where (or how)
they were involved during
planning
The study authors
acknowledge the assistance
provided by NHS Greater
Glasgow and Clyde staff and
the study steering group, but
it is not clear where (or how)
they were involved during
delivery
The authors do
not discuss the
sustainability of the
pharmacy-led
intervention, but
they do conclude
that it is appropriate
that different cost-
effective service
configurations, such
as pharmacy
services, are available
and can coexist to
offer smokers choice
and maximise
accessibility
Bock et al.,
201052
Political No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
Burford et al.,
201353
Economic No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
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Study
Implementation
contexta
Consultation/collaboration
processes during planningb
Consultation/collaboration
processes during deliveryc Sustainabilityd,e
Costello
et al., 201155
Political This study was nested within
a larger host study, that is
the STOP study. During
planning, the STOP
programme collaborated
with different community
and regional partners in
many different ways
including:
l tertiary care centres
l public health units
l mass distribution
l community pharmacies
l community health
centres
l STOP on-the-road
workshops with primary
health units
l internet-based enrolment
l family health teams
l family physicians
During intervention delivery,
the STOP programme
collaborated with different
community and regional
partners in many different
ways including:
l tertiary care centres
l public health units
l mass distribution
l community pharmacies
l community health
centres
l STOP on-the-road
workshops with primary
health units, internet-
based enrolment
l family health teams
l family physicians
Authors highlight
that reimbursement
is needed to the
pharmacist for
providing the service
in order for it to be
sustainable. (There
was no financial
reimbursement for
the pharmacists’
professional services
in this study)
They also state that
a secondary aim
of the study was
sustainability
through training of
pharmacists to
provide counselling
The authors state
that they look
forward to
maintaining their
existing partnerships
as well as building
new community
connections into the
future
Crealey et al.,
199856
Economic No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
Hoving et al.,
201057
No specific
implementation
context (study
focus was simply
on testing the
intervention)
The intervention was
developed by the University
of Maastricht in collaboration
with the Dutch Foundation
on Smoking and Health
(STIVORO for a smoke-free
future)
No information of relevance
was reported
No information of
relevance was
reported
Howard-
Pitney et al.,
199944
No specific
implementation
context (study
focus was simply
on testing the
intervention)
The study authors
acknowledge the assistance
provided by the Shasta
County Department of Public
Health and Tehama County
Health Agency, but it is not
clear where (or how) they
were involved during
planning
The study authors
acknowledge the assistance
provided by the Shasta
County Department of Public
Health and Tehama County
Health Agency, but it is not
clear where (or how) they
were involved during delivery
No information of
relevance was
reported
Maguire et al.
200158
Political No information of relevance
was reported
No information of relevance
was reported
Barriers emerging
from the qualitative
evaluation of this
intervention included
insufficient
remuneration for
pharmacists, which
would impact on
sustainability
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Study
Implementation
contexta
Consultation/collaboration
processes during planningb
Consultation/collaboration
processes during deliveryc Sustainabilityd,e
Mochizuki
et al., 200459
No specific
implementation
context mentioned
in the abstract
(English abstract
only)
No information of relevance
was reported in the abstract
No information of relevance
was reported in the abstract
No information of
relevance was
reported in the
abstract
Sinclair et al.
199860
Political,
economic
No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
Sonderskov
et al., 199763
Political The pharmaceutical company
(Ciba-Geigy) provided
instructions concerning trial
procedure during planning
The pharmaceutical company
(Ciba-Geigy) were in contact
with pharmacies once a week
during delivery
No information of
relevance was
reported
Vial et al.,
200245
Political No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
Weight loss
Ahrens et al.,
200364
Political No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
Bush et al.,
201165
Political No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
Jolly et al.,
201166
Political No information of relevance
for the pharmacy-led
intervention was reported
No information of relevance
for the pharmacy-led
intervention was reported
No information of
relevance for the
pharmacy-led
intervention was
reported
Malone and
Alger-Mayer,
200339
Political No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
Phimarn et al.,
201367
Political The intervention (in Thailand)
required a formal agreement
between a pharmacy and a
primary care unit
No information of relevance
was reported
No information of
relevance was
reported
Multicomponent interventions (pharmacotherapy and lifestyle changes)
Diabetes mellitus – type 2
Ali et al.,
201268
Political No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
Correr et al.,
201169
Economic No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
Fornos et al.,
200670
No specific
implementation
context
No information of relevance
was reported
No information of relevance
was reported
The authors
suggested that a
closer co-operation
between GPs and
pharmacists, than
was in place for this
study, for successful
implementation of
the intervention
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Study
Implementation
contexta
Consultation/collaboration
processes during planningb
Consultation/collaboration
processes during deliveryc Sustainabilityd,e
Dyslipidaemia
Paulos et al.,
200571
No specific
implementation
context
No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
Hypertension
Zaragoza-
Fernandez
et al., 201272
Political No information of relevance
was reported
No information of relevance
was reported
No information of
relevance was
reported
In the majority of cases, the information in this table was difficult to extract from the included studies, and we are
cognisant that a degree of interpretation was required. The information in this table was extracted by one reviewer
(Summerbell) and checked by a second (Brown).
a Does the study provide any useful contextual information relevant to the implementation of the intervention
(e.g. political, economic, social or managerial factors)? Note that information in the introduction/background sections to
included papers was most likely to inform the implementation context. Political: the primary purpose for developing
and testing the intervention was the national political drive to extend the public health role of community pharmacies.
Economic: the primary purpose for developing and testing the intervention was to assess whether or not existing services
could be delivered at a lower cost in pharmacies (and usually by pharmacists and pharmacy staff) compared with other
settings and service providers. Social: the primary purpose for developing and testing the intervention was to assess the
reach of services to those most in need in pharmacies compared with similar services in other settings and service
providers. Managerial: the primary purpose for developing and testing the intervention was to assess whether or not
existing services set in pharmacies and delivered by pharmacists could be delivered equally effectively by
pharmacy assistants.
b Is there a report of consultation/collaboration processes between managers, employees and any other relevant
stakeholders during the planning of stage?
c Is there a report of consultation/collaboration processes between managers, employees and any other relevant
stakeholders during the delivery of stage?
d What is the sustainability of the intervention? Strength of the institution implementing the intervention; integration
of activities into existing programmes/services/curriculum/etc.; training/capacity-building component; community
involvement/participation.
e In most studies, where relevant, pharmacists received reimbursement for providing the intervention.
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Appendix 10 Organisation and delivery of
interventions
Author
Type and location
of pharmacy
Staff training and quality
assurance
Experience of
intervention team
Resources and other
intervention-related
costsa
Alcohol
Dhital et al.,
201546
Community
Pharmacies in the
London Borough of
Hammersmith and
Fulham, London, UK
All trial pharmacists had been
trained over 3.5 hours (by lead
author) to deliver the intervention
protocol, including flexible use of
the discussion topics in ways
influenced by the counselling
approach of motivational
interviewing. In such a brief training
workshop it was not feasible to aim
to train the pharmacists in
motivational interviewing as this
approach requires ongoing
supervision of practice
Quality assurance: a 2-hour evening
follow-up training session was
arranged 7 weeks after the start of
the trial to address challenges and
share learning across the group and
was attended by 10 pharmacists
Pharmacists and
pharmacy support
staff
Not reported
Watson and
Stewart,
201148
Community
Pharmacies in
Grampian, Scotland,
UK
Two training sessions were
delivered. One evening training
session was delivered to describe
the purpose of the study,
the use of FAST and the study
documentation. One pharmacist
and up to one member of staff
from each pharmacy were invited
to attend. Pharmacies not
represented at this event received a
training visit from a research team
member. A 1-day ABI training
session was also delivered to
pharmacists in the intervention
group, attendance at which was
compulsory for participation in the
study. This training was provided by
Create Consultancy and the
research team
Quality assurance: none reported
Pharmacists and
pharmacy support
staff
Estimated cost for
delivering one ABI
was £70.90, based
on an average of
10 people screened
for each ABI delivered:
£10.20 training costs,
£50.00 staff time for
screening, £10 staff
time for delivering
ABI, £0.70 for
consumables
Smoking cessation
Bauld et al.,
201149
Bauld et al.,
200950
Boyd et al.,
200951
Community
pharmacies (90%
in Glasgow Health
Board area),
Glasgow, UK
Training of pharmacists varied from
attending a Glasgow Health Board
or online course, to observing
sessions in the pharmacy
Quality assurance: none reported
Pharmacists and
pharmacy support
staff
Details are presented
in the paper (in
appendix).
Cost-effectiveness
(52-week quitter) of
intervention per
client: one-to-one
pharmacy led
intervention £79.00;
group-based support
(control) £368.00
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Author
Type and location
of pharmacy
Staff training and quality
assurance
Experience of
intervention team
Resources and other
intervention-related
costsa
Bock et al.,
201052
Pharmacies located
within large urban
community health
centres in the USA
A 3-hour training session for the
pharmacists was conducted.
Pharmacists were trained using the
Rx for Change tobacco cessation
programme (http://rxforchange.
ucsf.edu (accessed 14 January
2015); Corelli et al.85) which
focuses on fostering
self-efficacy for counselling and
includes role-playing and a
hands-on workshop with the
various US Food and Drug
Administration-approved
medications for smoking cessation.
All counselling approaches were
aligned with the 5 A’s framework
(ask, assess, advise, assist, arrange
follow-up) as described in the
Clinical Practice Guideline (Fiore
et al.86). The pharmacists were
trained to assess readiness to quit,
to focus their counselling on
motivational issues for those not
ready to quit, and, for those ready
to quit, to offer practical advice
regarding quitting, discuss the
importance of obtaining social
support, and evaluate the
appropriateness of quit smoking
medications and make
recommendations (the primary
difference between EQ and EQ+
conditions being the availability
of free NRT). Additionally, the
training addressed (1) study aims
and the research protocol;
(2) a demonstration of the EQ
programme and examination of
tailored intervention reports for
the patient and pharmacist; and
(3) role-playing with case scenarios
that integrated output from the EQ
system
Quality assurance: none reported
Pharmacists No information
provided except for
incentivisation. All
participants were
compensated US$20
for their time and
effort for completing
the baseline survey
and for returning the
follow-up survey
Burford
et al.,
201353
Community
pharmacies located
around Perth city
centre in Western
Australia
No training details provided
Unclear whether it was the
community pharmacists (who
would have needed some training
in the use of the face ageing
software) or a single research
pharmacist
Quality assurance: none reported
Unclear whether it
was the community
pharmacists or a
single research
pharmacist
The face ageing
software (APRIL) was
provided by the
software company.
Total costs of
implementing the
intervention from a
health sector
perspective were
AU$463, or the
equivalent of AU$5.79
per participant
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Author
Type and location
of pharmacy
Staff training and quality
assurance
Experience of
intervention team
Resources and other
intervention-related
costsa
Costello
et al., 201155
Pharmacies in
Ontario, Canada
Pharmacists were trained in the
intervention methodology during a
5-hour face-to-face session or a
3-hour pre-recorded online session
plus 1-hour teleconference
conducted by the STOP study staff.
Training covered (1) the study
protocol and documentation;
(2) the ‘5-A’ model for brief
behavioural counselling; and (3) an
overview of NRT products and their
use
Quality assurance: none reported
Community
pharmacists
Resources listed (but
not costed) included
free NRT, training and
pharmacists’ time
Crealey
et al., 199856
Pharmacies in
Belfast, Northern
Ireland, UK
Each study site pharmacist was
sent a copy of the PAS model
documentation, together with a
written literature review on
smoking cessation and asked to
study the material. Between 2 and
3 weeks after receipt of the
documentation, pharmacists
attended a local workshop on
smoking cessation (including
detailed instruction on the study
methodology). These workshops
each lasted 3 hours and covered
epidemiology, smoking statistics,
the use of NRT, the cycle of change
model and the PAS model
Quality assurance: following the
training, a researcher visited the
pharmacists to provide support and
to address any queries they had in
implementing the model. This
constituted the training for the
intervention
Community
pharmacists
Fixed costs of the
intervention are
detailed in table II.
Variable costs
included pharmacist
time – an average
time of 1 hour (over
the 6-month follow-up
period) at £30 per hour
The cost per life-year
saved ranged from
£196.76 to £351.45
for men and £181.35
to £772.12 for women
(1997 values)
Hoving et al.,
201057
Pharmacies in the
Netherlands
Note that training for pharmacy
staff not relevant for this
intervention. Computer-tailored
letter (intervention) or a thank-you
letter (control)
Quality assurance: not relevant
Not relevant Not reported. One
would assume the
costs of setting up the
system would be
significant but, once
set up, costs would
be minimal (the cost
of sending a letter)
Howard-
Pitney et al.,
199944
Pharmacies in the
USA
Pharmacists were trained initially
during a 4-hour training session
with investigators and field staff.
Training included educating the
pharmacists about chewing
tobacco prevalence in their
counties, study protocol, nicotine
withdrawal symptom and role of
nicotine patches in reducing
physical withdrawal. In addition,
field staff demonstrated the
pharmacists’ role in the intervention
protocol, and each pharmacist
practised the intervention in a
role-playing exercise
Pharmacists Not reported, but NRT
was offered free of
charge
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Author
Type and location
of pharmacy
Staff training and quality
assurance
Experience of
intervention team
Resources and other
intervention-related
costsa
Quality assurance: at the end of the
training session, field staff, playing
the role of a study participant,
tested the pharmacists’ knowledge
and ability to perform their
intervention role. Pharmacists had
to perform 80% of the steps
adequately in each visit’s protocol
before being certified to intervene
with participants
Maguire
et al., 200158
Pharmacies in
London, England,
Uk and Northern
Ireland, UK
Each study site pharmacist was sent
a copy of the PAS model
documentation, together with a
written literature review on
smoking cessation and asked to
study the material. Between 2 and
3 weeks after receipt of the
documentation, pharmacists
attended a local workshop on
smoking cessation (including
detailed instruction on the study
methodology). These workshops
each lasted 3 hours and covered
epidemiology, smoking statistics,
the use of NRT, the cycle of change
model and the PAS model
Quality assurance: following the
training, a researcher visited the
pharmacists to provide support and
to address any queries they had in
implementing the model. This
constituted the training for the
intervention
Community
pharmacists
Not reported but
authors refer to their
earlier paper (Crealey
et al., 199852) which
does report on costs
and cost-effectiveness
Mochizuki
et al., 200459
Pharmacies in Japan Note that this paper is written in
Japanese and we only have the
abstract in English. There is no
mention in the abstract of
pharmacists receiving training
Assume
pharmacists
Not reported
Sinclair
et al., 199860
Non-city community
pharmacies in
Grampian, Scotland,
UK
Delivery of a 2-hour training session
to pharmacists and pharmacy
assistants. The training did not
include motivational interviewing
techniques to encourage smokers
to move from pre-contemplation to
contemplation; however, it did
include specific content and
recommendations pertaining to
preparation, action, maintenance
and relapse. The training aimed to
give participants an understanding
of the stages in the stages-of-
change model, and focused on brief
questioning which could enable
counsellors to assess the stage of
individual customers and to
subsequently increase the frequency
and effectiveness of the counselling
support by tailoring their advice to
the current stage of the customer
Quality assurance: not reported
Pharmacists and
pharmacy suport
staff
The cost of producing
one additional
successful attempt to
quit smoking by using
intensive rather
than standard
pharmaceutical
support was £300
(in 1995–7). Costs
included training
costs, NRT and
counselling costs
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Author
Type and location
of pharmacy
Staff training and quality
assurance
Experience of
intervention team
Resources and other
intervention-related
costsa
Sonderskov
et al., 199763
Community
pharmacies in the
areas of Aarhus and
Copenhagen,
Denmark
No training of pharmacists as such,
but they were given ‘instructions’
from the pharmaceutical company
concerning trial procedures
Quality assurance: pharmaceutical
company contacted pharmacies at
least once per week throughout
the study period
Pharmacists and
pharmacy support
staff
Not reported, but
nicotine patches were
provided free of
charge
Vial et al.,
200245
Community
pharmacies in
Adelaide, Australia
Before the study commenced,
participating community
pharmacies were informed of all
study-related procedures at a
seminar. Brief information about
stages of behaviour change and
recommended interventions during
smoking cessation were also
included in the seminar
Quality assurance: not reported
MSc student in
health science
Not reported, but
nicotine patches were
supplied at a reduced
price
Weight loss
Ahrens
et al., 200364
A community
pharmacy: Travis
Pharmacy in
Shenandoah,
Iowa, USA
The two pharmacists who
participated in the study received
no special training, although both
used current literature and research
to prepare themselves to be able to
counsel patients in dietary advice.
A registered dietitian reviewed
the dietary plan developed by the
pharmacist before it was used with
the patients, and was consulted as
needed during the study
Quality assurance: not reported
Community
pharmacists
Not reported, but
meal replacements
were provided free of
charge
Bush et al.,
201165
Community
pharmacies in
Birmingham,
England, UK
Pharmacists did not received
training, but intervention deliverers
(in pharmacies and GP practices)
were ‘trained health-care workers’,
for example a pharmacy assistant
working in a pharmacy, and they
did receive training
All intervention deliverers
attended a 2-day training
session organised by the PCT
which provided deliverers with
training material and
resources . . .
p. 67
The training included input from
dietitians, GP and pharmacy staff
All deliverers attended a 2-day
training session, which was
regarded as being useful and
provided deliverers with training
material and resources
Quality assurance: not reported
A trained health-care
worker (for example,
a health-care
assistant, practice
nurse or pharmacy
assistant)
Costs per participant
were higher in a
pharmacy setting than
in a GP surgery setting
initially, but by the end
of the programme
(9 months) the costs
were about the same
because of the larger
number of participants
recruited by GPs
(thus allowing for
distribution of, for
example, training costs
across a larger pool of
participants)
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Author
Type and location
of pharmacy
Staff training and quality
assurance
Experience of
intervention team
Resources and other
intervention-related
costsa
Jolly et al.,
201166
Community
pharmacies,
England, UK
There are eight arms (six
interventions) in this (Lighten Up)
Trial:
1. WW (group)
2. SW (group)
3. RC (group)
4. NHS Size Down programme (led
by food advisers recruited from
the local community, and
trained by dietitians, group)
5. GP practice (nurse-led, one
to one)
6. Pharmacy (pharmacist-led, one
to one)
7. Control (12 free vouchers for
local leisure centre)
Or a choice of one of the above
1–3: the group leaders were
trained by the respective
organisations
4–6: staff delivering these
programmes had attended a 3-day
training course on weight
management in adults delivered
by dietitians experienced in the
management of obesity. This
included key messages on diet
and physical activity, doing a
behavioural assessment,
goal-setting, plans for change,
dealing with resistance, enhancing
motivation and weight
maintenance. It included both
practical tasks and informational
components
Quality assurance: not reported
Variable depending
on intervention
For the pharmacy-led
intervention,
pharmacists
delivered the
intervention
Resources and other
intervention costs
varied between the
different weight loss
interventions.
Interventions 4–6
(primary care) were
more costly than 1–3
(commercial)
Provider costs:
l WW= £55.00
l SW= £49.50
l RC= £55.00
l NHS Size Down=
£70.00
l GP= £90.86
l Pharmacy=
£90.43
Cost per participant
(in addition to
provider costs)= £10
for call centre, £3.54
for practices to search
their lists and GPs to
screen lists, £8.33 for
invitation letters sent
by practices (£1 per
letter with 12%
response rate)
Malone and
Alger-Mayer,
200339
Community
pharmacies, USA
Pharmacists delivering the
intervention were trained (a 1-day
course) in ‘obesity management
skills’. Training included various
aspects of obesity but no mention
of any behavioural support/skill
training
Quality assurance: not reported
Community
pharmacist
Not reported
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Type and location
of pharmacy
Staff training and quality
assurance
Experience of
intervention team
Resources and other
intervention-related
costsa
Phimarn
et al., 201367
Community
pharmacy, Thailand
The two community pharmacists
who routinely provide weight loss
advice received minimal training.
The pharmacists developed the
weight loss handbook. Information
included was the same as the
group advice provided by the
primary care unit staff. The
handbook is comprised of three
parts: (1) an informational section,
which deals with healthy diet,
principles of calorie intake, food
groups, portion size and exercise;
(2) a patient profile to record
personal information and clinical
outcomes; and (3) a daily food
record for patients to record their
daily meals. Prior to the study, the
handbook was provided to the two
pharmacists as a standard guide for
their use in counselling. Both
community pharmacists practised
giving advice with simulated
patients
Quality assurance: not reported
Community
pharmacists
Not reported
Multicomponent intervention (pharmacotherapy and lifestyle changes)
Diabetes mellitus – type 2
Ali et al.,
201268
Community
pharmacies,
Hertfordshire, UK
The pharmacists who delivered the
intervention undertook an 8-hour
training programme provided by
the School of Pharmacy at the
University of Hertfordshire,
involving workshop sessions with a
consultant diabetologist and a
diabetes mellitus specialist nurse,
providing an update on diabetes
mellitus management and referrals,
an overview of the use of
diagnostic equipment and the data
collection forms
Quality assurance: not reported
Community
pharmacists
Not reported
Correr et al.,
201169
Community
pharmacies,
the Curitiba
metropolitan region
of Brazil
Pharmacists providing care for
patients with type 2 diabetes
mellitus in the PF group underwent
a specific training provided by
faculty staff of Federal University of
Parana and University of Granada
(Spain), including basic concepts
and procedures of PF as well as
diabetes mellitus care and glucose
and blood pressure measurement
Quality assurance: not reported
Community
pharmacists
An economic
evaluation of the
intervention estimated
the annual cost of the
reduction in 1% in
HbA1c values in the PF
group. However, no
such analysis was
conducted for a
reduction in body
weight or BMI
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Author
Type and location
of pharmacy
Staff training and quality
assurance
Experience of
intervention team
Resources and other
intervention-related
costsa
Fornos et al.,
200670
Community
pharmacies,
Province of
Pontevedra in Spain
All the pharmacists involved in the
study received 18 hours of training
in the PF programme and in the
proper use of the measuring tools,
and followed a protocol which
helped them to monitor patients
Quality assurance: pharmacists had
regular contact with the research
team and attended clinical sessions
where results on drug-related
problems were presented and
discussed
Community
pharmacists
Not reported
Dyslipidaemia
Paulos et al.,
200571
Community
pharmacy, Santiago,
Chile
The study was conducted by a
pharmacist who was dedicated
solely to this study and who was
trained specifically for the purposes
of this study – no further details
Quality assurance: not reported
Community
pharmacist
Not reported
Hypertension
Zaragoza-
Fernandez
et al., 201272
Community
pharmacies, Murcia,
Spain
No mention of any training for the
pharmacists
Quality assurance: not reported
Community
pharmacist
Not reported
ABI, Alcohol Brief Intervention; EQ, Exper_Quit; MSc, Master of Science; PCT, primary care trust; PF, pharmacotherapy follow-up;
RC, Rosemary Conley; STOP, Smoking Treatment for Ontario Patients; SW, Slimming World; WW, Weight Watchers.
a Sources of funding appear in Tables 2–5.
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Appendix 11 Outcomes
Study Outcomes Summary
Alcohol
Dhital et al., 201546
Brief alcohol intervention vs.
leaflet-only control
AUDIT baseline score, mean (SD):
I (n= 205), 11.93 (3.24); C (n= 202),
11.53 (3.19)
12-week AUDIT score, mean (SD):
I (n= 168), 11.80 (5.88); C (n= 158),
10.77 (5.54)
12-week AUDIT change in score:
I (n= 168), 0.11 (95% CI –0.82
to 0.61); C (n= 158) –0.74
(95% CI –1.47 to 0.00)
12-week AUDIT between-group
difference unadjusted: –0.63 (95% CI
–1.69 to 0.43)
12-week AUDIT between-group
difference adjusted for pharmacist,
sex, age, ethnicity and education:
–0.57 (95% CI –1.59 to 0.45)
12-week OR for AUDIT < 8 (control as
reference): 0.87 (95% CI 0.50 to 1.51)
Other outcomes:
l % scoring < 8 (AUDIT) at
follow-up
l Three AUDIT subscales
(consumption, problems
and dependence)
l General health status (EQ-5D)
There was no evidence of effectiveness
of community pharmacist delivery of
brief alcohol intervention. The AUDIT
total change score did not differ
significantly between the two groups
and did not change significantly
between baseline and follow-up in
either the intervention or control
group
Watson and Stewart, 201148
Brief alcohol intervention vs. control
FAST total median score baseline:
I (n= 27), 5.00 (IQR 3.00–6.00);
C (n= 42), 5.00 (IQR 4.00–6.00)
3-month FAST median score: I (n= 10),
3.00 (IQR 1.00–4.25); C (n= 23) 4.00
(IQR 2.00–6.00)
A reduction in FAST score of 0.93
(95% CI –2.84 to 0.97) was shown in
the intervention group at 3 months
(p= 0.32)
6-month FAST median score: I (n= 6)
2.50 (IQR 1.50–4.25); C (n= 14), 3.50
(IQR 2.00–7.50)
3-month FAST mean score change:
Male: I (n= 4), 0.50 (SD 1.00);
C (n= 9), –0.11 (SD 3.18)
Female: I (n= 6), 1.67 (SD 2.73);
C (n= 12), 1.17 (SD 1.90)
No significant difference was shown
between FAST scores for the
intervention group compared with
control, at 3 or at 6 months
At 6 months there was substantially
lower follow-up of intervention clients
(22.2%) compared with control clients
(33.3%). Only adjusted for baseline
FAST; not clear if there were baseline
differences for other variables
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Study Outcomes Summary
6-month FAST mean score change:
Male: I (n= 4), 2.25 (SD 3.20);
C (n= 4), –1.25 (SD 2.87)
Female: I (n= 2), 0.50 (0.71); C (n= 8),
0.75 (SD 1.67)
6-month FAST between-group
difference: –1.84 (95% CI –4.49 to
0.82)
Other outcomes:
l Self-reported alcohol consumption
l Number of alcohol-free days
during an average week
l Barriers/facilitators to delivering
intervention (by pharmacists)
l Pharmacy users opinions
l Staff and training costs
Smoking cessation
Bauld et al., 201149
Bauld et al., 200950
Boyd et al., 200951
I: pharmacy-based NHS smoking
cessation service (12-weeks one-to-one
support) moderate intensity+NRT
C: group-based NHS smoking
cessation service (community-based
7 weeks behavioural support) high
intensity +NRT/medication
Baseline number of cigarettes/day
> 21: I, 40.1% (396/987); C, 41.6%
(169/406)
4-week CO-validated quitters:
I, 255/1374; C, 146/411 of 1785 that
set a quit date
I, 255/1508; C, 146/471 of 1979 who
accessed service and agreed to data
usage but did not set quit date
52-week CO-validated quitters:
I, 38/1374; C, 26/411 of 1785 that set
a quit date
I, 38/1508; C, 26/471 of 1979 who
accessed service and agreed to data
usage but did not set quit date
Univariate analyses: in each service
more deprived smokers (those in
socioeconomic groups 5 and 6) had
lower cessation rates, although the
trend relating socioeconomic score to
cessation rate was significant only for
the pharmacy service
In a multivariate model, restricted to
participants (n= 1366) with data
allowing adjustment for
sociodemographic and behavioural
characteristics and including
interaction terms, users who accessed
the group-based services (C) were
almost twice as likely (OR 1.980, 95% CI
1.50 to 2.62) as those who used
pharmacy-based support (I) to have quit
smoking at 4-week follow-up
Much larger sample size for pharmacy
than group-based service (n= 1374 vs.
n= 411). Clients could choose service.
Group participants were older and of
higher SES
Pharmacy-based not as effective for
smoking cessation but many more
smokers access the pharmacy-based
service
All pharmacy clients had NRT, 84%
group clients had NRT/16%
medication
This is secondary data analysis of an
observational study so direct
comparison between the pharmacy-
based and group-based service is
inappropriate
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Study Outcomes Summary
Other outcomes:
l 4-week CO-validated quit rates by
socioeconomic group score and
also by Scottish deprivation
quintile
l Cost-effectiveness analysis
l Self-reported quits
l Use of cessation aids
Bock et al., 201052
I1: smoking cessation training for
pharmacists and use of a computer-
driven software system, EQ, which
provided individually tailored
interventions and matching reports to
the pharmacist to guide cessation
counselling plus 8 weeks free NRT
I2: same as above without NRT
C: observation only
Baseline number of cigarettes/day,
mean (SD): I1, 18.2 (9.1); I2, 17.7 (8.3);
C, 13.8 (8.6)
7-day point prevalence abstinence
at 2 months [verified with CO
(<10 p.p.m.)]: I1, 39% (39/100);
I2, 27% (27/100); C, 9% (9/99)
7-day point prevalence abstinence at
6 months (verified by saliva cotinine):
I1, 28% (28/100); I2, 15% (15/100);
C, 8% (8/99)
6-month quit between-group difference:
I1 vs. C: OR 3.3 (95% CI 1.9 to 5.2)
I2 vs. C: OR 1.49 (95% CI 1.2 to 3.6)
I1 vs. I2: OR 2.3 (95% CI 1.5 to 3.9)
Other outcomes:
l Quit attempts
l Predictors of cessation
Pharmacist sex (female) was positively
correlated with abstinence at 2 months
but not 6 months. Only 26% of
participants were counselled by a
female pharmacist (similar rates for
EQ and EQ+ groups). Of participants
who were counselled by a female
pharmacist, 77% set a target quit date
compared with 58% of those
counselled by males
N: EQ+, n= 100; EQ, 100; C, n= 99
Control group not randomised, but EQ
and EQ+ groups were. There were
significant baseline differences and it is
not clear if these were controlled for in
analyses of quit rates. Low attrition
A tailored intervention combined with
brief proactive counselling from
pharmacist plus pharmacist training
(EQ) was successful in increasing quit
rates, with further increases among
patients who also received free
nicotine patches (EQ+)
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Study Outcomes Summary
Burford et al., 201353
I: standardised smoking cessation
advice+ computer-generated
photoageing (demonstrating the
detrimental effects on facial physical
appearance of smoking)
C: standardised smoking cessation
advice only
Baseline number of cigarettes/day
> 21: I, 10% (8/80); C, 15% (12/80)
6-month CO-validated quitters
(95% CI): I, 11/80 (13.8%, 7.8% to
22.9%); C, 1/80 (1.3%, 0% to 6.7%)
This difference between groups
remained statistically significant after
adjustment small differences between
groups in sex and nicotine dependence
Other outcomes:
l Cost-effectiveness analysis
l Nicotine dependence
l Progression along the
transtheoretical stages-of-
change model
l Quit attempts
l Self-reported quit
Photoageing intervention was effective
in stopping young people smoking
compared with control
Costello et al., 201155
I1: 1-week then fortnightly pharmacy
visit for NRT plus three sessions of
‘5-A’ model for brief behavioural
counselling
I2: received 5-weeks NRT at initial
pharmacy visit plus one session of
‘5-A’ model for brief behavioural
counselling at initial visit
C: 5-weeks NRT mailed directly to
participants home
Baseline Heaviness of Smoking Index
score 5–6 (high): I1, 40.7%
(1459/3588); I2, 40.1% (1364/3399);
C, 39.4% (1823/4630)
Self-reported 7-day point prevalence
at 5 weeks: I1, 612/3503 (17.5%);
I2, 604/3350 (18.0%)
Self-reported 7-day point prevalence at
5 weeks (controlling for covariates):
OR= 0.96 (95% CI 0.86 to 1.08)
(n= 6809)
Other analyses:
Study models various confounders by
abstinence and intervention group and
also controls for covariates when
modelling abstinence by intervention
group
Age and education were significant
confounders: 25–39 years and
55+ years were more likely to be
abstinent than 18–24 years, those
completing some college/university
were more likely to be abstinent than
those who did not complete high
school. Sex was not significant in ‘ITT’
analyses (n= 6809)
Completer
Multivariate analysis suggest when
controlling for possible confounders
and clustering across pharmacies
group I1, three-session completers
were more likely to quit compared
with group I2 (OR 1.72, 95% CI 1.53
to 1.94)
Other outcomes:
l Predictors of abstinence
Control group not randomised, but
intervention groups were. Control
group only used in paper for baseline.
Only completer analysis showed
significant difference between groups.
When participants assessed as
assigned and with non-responders
classed as still smoking there is no
significant difference between
intervention groups
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Study Outcomes Summary
Crealey et al., 199856
I: PAS model of behavioural support,
35/52 nicotine gum
C1: Nicotine gum only
C2: Control (expressed wish to stop
smoking)
Baseline cigarettes/day: NR
3-month CO-verified abstinence (and
stopped using nicotine gum): I, 56%;
C1, 16%
6-month CO-verified abstinence (and
stopped using nicotine gum): I, 46%;
C1, 6%; C2, 0%
Other outcomes: NR
N: I1, n= 52; I2, n= 48; C: n= 60
There was a statistically significant
difference in cessation rates between
intervention and control patients
Hoving et al., 201057 Baseline cigarettes/day: I (n= 256),
22; C (n= 289), 21
3-month continued abstinence (having
refrained from smoking between
baseline and follow-up, yes/no):
I, 37/256; C, 31/289
6-month continued abstinence
(having refrained from smoking
between baseline and follow-up,
yes/no): I, 2/256; C, 2/289
Other outcomes:
l Quit attempt
l Point prevalence
At 3 and 12 months there was no
significant difference between I vs. C
in the pharmacy sample except for
quit attempts at 12 months:
responders in the experimental group
were more likely to have had a quit
attempt than the control group (OR
1.48, 95% CI 1.03 to 2.11; p< 0.05)
controlled for number of previous quit
attempts
There was a pharmacy setting and a
GP setting – treated as two separate
trials. GP sample not extracted as
follow-up is at different time periods
than pharmacy sample – there is an
intervention and control group for
both pharmacy and GP settings
(four groups)
GP surgeries and 15 pharmacies used
passive recruitment, 50 pharmacies
used active recruitment
Howard-Pitney et al., 199944
I: pharmacist advice and
support+ nicotine patch (free 6-week
15-mg patches)
C: pharmacist advice and
support+ placebo patch
Baseline number of cans/week,
mean (SD): I, 3.9 (2.4) n= 206;
C, 4.1 (2.3) n= 204
7-day point prevalence at 6 months
(verified by cotinine): I, 38% (78/206);
C, 34% (69/204)
In intervention group age was a
significant predictor of relapse (older
chewers less likely to relapse)
Other outcomes:
l Self-reported 7-day point
prevalence at 10 days
l Self-reported 7-day point
prevalence at 3 months
l Self-reported relapse (first day
chewed tobacco for 7 days in
a row)
l Predictors of relapse
Study of tobacco chewers. Abstinence
rates relatively high at 6-month
follow-up but not significantly
different between groups
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Study Outcomes Summary
Maguire et al., 200158
I: PAS model, 86% NRT
C: ad-hoc pharmacist advice on
smoking cessation, 84% NRT
Baseline number of cigarettes/day
1–10: I, 14/265; C, 26/219
10–20: I, 197/265; C, 121/219
20–30: I, 29/265; C, 33/219
> 30: I, 13/265; C, 20/219
12-month abstinence (self-reported
abstinence since the intervention for
12 months supported by a negative
urinary cotinine test at 12 months):
I, 14.3% (38/265); C, 2.7% (6/219)
Other outcomes:
l Self-reported abstinence at 3 and
6 months
The PAS intervention significantly
increased smoking cessation compared
with control. It is unclear how many of
the participants actually reached
12 months of follow-up
Pharmacists were willing to participate
before randomisation
Mochizuki et al., 200459
I: nicotine gum plus advice on usage
and initial and follow-up cessation
advice
C: nicotine gum plus advise on usage
Baseline number of cigarettes/day:
I (n= 11), 23.0 (6.75); C (n= 16),
25.7 (13.9)
Self-reported complete cessation (no
smoking and no use of nicotine gum)
at 3 months: I, 45.5% (5/11); C, 31.2
(5/16); OR 1.83 (not statistically
significant)
Other outcomes:
l Relationship between the smoker’s
ergogram and effectiveness of
the intervention
Both interventions appear to increase
cessation but not reported if
significant improvement from baseline,
no significant difference between
groups at follow-up. Very small study
Sinclair et al., 199860
I: training pharmacists and pharmacy
assistants in the stages-of-change
model of smoking cessation
C: standard professional support
Baseline number of cigarettes/day:
NR, Fagerström test for nicotine
dependence: I (n= 224), 5.2;
C (n= 263), 5.2
Self-reported continued abstinence at
9 months: I, 12% (26/217); C, 7.4%
(19/257)
Self-reported continued abstinence at
9 months between-group difference
(95% CI): 4.6% (–0.8% to 10.0%)
Outcome was not affected by sex, age
and SES (Carstairs Morris deprivation
score)69
Other outcomes:
l Self-reported point prevalence at
1 month
l Self-reported continued abstinence
at 4 months
l Perceptions of customers and
pharmacy personnel
l Cost-effectiveness analysis
The intervention was associated with a
favourable non-significant trend at
9 months, but this was based on
self-reported abstinence. Pharmacists
were willing to participate before
randomisation. The study failed to
reach its recruitment target (about
half); power was reduced to the 10%
level
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Study Outcomes Summary
Sonderskov et al., 199763
I1: free 21-mg nicotine patches
(12 weeks, dosage reduced)
I2: free 14-mg nicotine patches
(12 weeks, dosage reduced)
C1: free placebo 21-mg patches
(12 weeks, dosage reduced)
C2: free placebo 14-mg patches
(12 weeks, dosage reduced)
No psychological or behavioural
support was added to the
pharmacological treatment
Baseline number of cigarettes/day
(n/N):
10–14: I1, 2/136; I2, 51/119;
C1, 0/142; C2, 53/125
15–19: I1, 9/136; I2, 62/119;
C1, 12/142; C2, 64/125
20–24: I1, 88/136; I2, 3/119;
C1, 92/142; C2, 5/125
≥ 25: I1, 37/136; I2, 0/119;
C1, 38/142; C2, 0
Self-reported point prevalence at
26 weeks (no smoking during a
4-week treatment period or one episode
of a slip defined as <6 days of smoking
within a 4-week period) (n/N): I1, 11%
(15/132); C1, 4.2% (6/142); I2, 22.7%
(27/119); C2, 18.4% (23/125)
Prevalence proportion ratio (95% CI): I1;
C1, 2.61 (1.04 to 6.53)
Prevalence proportion ratio (95% CI): I2;
C2, 1.23 (0.75 to 2.03)
Other outcomes:
l Self-reported point prevalence at
4, 8 and 12 weeks
Self-reported point prevalence only
which also includes participants who
have one episode of smoking
(< 6 days)
Intervention effective for those
smoking ≥ 20/day at baseline
randomised to I1 (21-mg patches) vs.
C1, but not effective for lighter
smokers randomised to 12 (14-mg
patches) vs. C2. However, it appears
that both intervention and placebo
14-mg patch groups had more quitters
than the 21-mg patch intervention and
control groups (not statistically tested).
Seems to be a placebo effect,
especially in low-dose placebo group
Non-compliance among successful
quitters was low
Vial et al., 200245
I: community pharmacy-based nicotine
patches plus weekly counselling
(US$15.00 weekly patches × 16 weeks)
I2: hospital outpatient clinic nicotine
patches plus weekly counselling
(US$15.00 weekly patches × 16 weeks)
C: minimal intervention (written and
verbal information at baseline)
Baseline number of cigarettes/day:
NR, Fagerström score mean (range):
I1 (n= 34), 5.79 (3–9); I2 (n= 35),
5.94 (1–9); C (n= 33), 6.33 (1–9)
Self-reported continued abstinence
at 12 months (not smoked since
discharge): I1, 19% (4/21); I2, 24%
(5/21); C, 4.6% (1/22)
Other outcomes:
l Self-reported continuous
abstinence at 3 and 6 months
l Self-reported continuous
abstinence × compliance
l Self-reported 7-day point
prevalence at 3 and 6 months
l Self-reported 7-day point
prevalence × compliance
l Self-reported 30-day point
prevalence at 12 months
Participants were all former inpatients
of respiratory unit and intervention
commenced for all participants while
inpatients then continued after
discharge (either as outpatient or
pharmacy-based)
Point prevalence, but not continuous
abstinence, was significantly different
in favour of either active intervention
compared with control at 12-month
follow-up
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Study Outcomes Summary
Weight loss
Ahrens et al., 200364
I1: meal replacement (free products)
I2: conventional low-calorie diet both
set in community pharmacy
BMI baseline (kg/m2), mean (SD):
I (n= 45), 29.5 (2.2); C (n= 43),
29.0 (2.6)
BMI change: NR
WC baseline (cm), mean (SD): I (n=45),
89.1 (8.5); C (n=43), 87.0 (8.2)
12-week WC change (cm): I (n= 45),
–5.31; C (n= 43), –6.10
22-week WC change (cm): I (n= 45),
–8.08 C (n= 43), –7.82
12-week WC between-group difference
(95% CI): NR
Weight baseline (kg), mean (SD):
I (n= 45), 81.9 (11.1); C (n= 43),
78.3 (10.1)
Weight 12 weeks (kg): I (n= 45), 77.0
(SE 1.6); C (n= 43), 74.0 (SE 1.6)
12-week weight change (kg):
I (n= 45), −4.9 (SE 0.3); C (n= 43),
–4.3 (SE 0.3)
12-week weight change (kg):
I, −5.2 (SE 0.4); C, –4.3
(SE 0.4); n= 68 (I+C)
12-week weight between-group
difference (kg) (95% CI): –0.9 (−2.0 to
–0.1); n=68 (I+C)
12–22-week weight change (kg):
I, −0.7 (SE 0.4); C, –0.9 (SE 0.4);
n=68 (I+C)
12–22-week weight (kg) between-group
difference (95% CI): 0.3 (−0.8 to –1.4);
n=68 (I+C)
Other outcomes:
l % weight loss
l loss > 7% body weight loss
l DBP
l SBP
l Triglycerides
l HDL-C
l LDL-C
l TC
During the 12-week weight loss
phase both groups lost a significant
amount of WC and weight, the
meal replacement group also lost a
significant amount of weight between
weeks 12–22, although no significant
difference between the groups at
12 weeks or at 22 weeks
High dropout especially during
maintenance phase
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Study Outcomes Summary
Bush et al., 201165
Diet and exercise with a trained
health-care worker (health-care
assistant, practice nurse, pharmacy
assistant):
I: pharmacy-based
C: GP-based
BMI baseline (kg/m2): I (n= unclear),
33.0; C (n= unclear), 35.6
12-week BMI change (kg/m2):
I (n= 91), –0.9 (95% CI ±0.2);
C (n= 75), –1.4 (95% CI ±0.3)
15-week BMI change (kg/m2):
I (n= 60), −1.3 (95% CI ±0.4);
C (n= 22), –0.8 (95% CI ±0.7)
BMI between-group difference
(95% CI): NR
WC baseline (cm): I, 105.1; C, 108.8
12-week WC change (cm): I (n= 91),
–4.9 (95% CI ±0.9); C (n= 75),
–6.0 (95% CI ±1.3)
15-week WC change (cm): I (n= 60),
–6.5 (95% CI ±1.6); C (n= 22),
–4.9 (95% CI ±2.6)
WC between-group difference
(95% CI): NR
Weight baseline (kg): I (n= 186), 86.1;
C (n= 268), 95.8
12-week weight change (kg):
I (n= 91), −2.4 (95% CI ±0.6);
C (n= 75), –3.8 (95% CI ±0.8)
15-week weight change (kg):
I (n= 60), −3.4 (95% CI ±1.1);
C (n= 22), –2.3 (95% CI ±1.9)
Weight between-group difference
(95% CI): NR
Other outcomes:
l 12-week % weight by sex, age,
IMD and ethnicity
l Cost-effectiveness analysis
l 12-week health-related quality of
life (Short Form-12)
Significant differences between groups
at baseline. GP participants tending to
be older than pharmacy participants.
Large percentage of Asian participants
recruited in pharmacies. Large dropout
and small groups at last follow-up.
Both groups appear to reduce BMI,
WC and weight at follow-up, statistical
significance either from baseline to
follow-up or between groups is not
reported. Pharmacy group appear to
continue to improve between weeks
12–15 but the GP group outcomes
do not
There were no statistically significant
relationships between sex, age, IMD
quintile or ethnicity and per cent
weight loss at session 12 among
pharmacy or GP participants.
Completer analysis only
It is unclear which provider type
delivered the programme more
cost-effectively
At session 12 each extra kg of weight
loss per participant would cost £8.29
through pharmacy providers.
Conversely, at session 15, each extra
kg of weight loss per participant
would cost £2.91 through GP
providers
Attendance rates on the programme
were consistently better among
pharmacy participants than among GP
participants
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Study Outcomes Summary
Jolly et al., 201166
WW, SW, RC, Size Down (NHS
community-based), GP, pharmacy,
participants own choice vs. control
(exercise)
BMI baseline (kg/m2), mean (SD): WW,
33.96 (3.9); SW, 33.83 (3.8); RC,
33.38 (3.5); Size Down, 33.77 (3.9);
GP, 33.06 (3.5); pharmacy, 33.44 (3.5);
choice, 33.41 (3.4); C, 33.88 (4.4)
BOCF 12-week BMI change: NR
BOCF 1-year BMI change (kg/m2): WW,
–1.17 (95% CI –1.7 to –0.7); SW, –0.71
(95% CI –1.0 to –0.4); RC, –0.75
(95% CI –1.1 to –0.3); Size Down, –0.67
(95% CI –1.0 to –0.3); GP, –1.32
(95% CI –0.7 to 0.1); pharmacy, –0.31
(95% CI –0.7 to 0.0); choice, –0.90
(95% CI –1.3 to –0.5; C, –0.45 (95% CI
–0.8 to –0.1)
BOCF BMI between-group difference
adjusted for weight at baseline, physical
activity at baseline, age, sex, and ethnic
group (kg/m2):
WW vs. C, −2.34 (95% CI −3.56 to
–1.13); SW vs. C, −1.24 (95% CI −2.47
to –0.02); RC vs. C, −2.390 (95% CI
−3.61 to –1.16); Size Down vs. C, −0.09
(95% CI −1.31 to 1.14 ); GP vs. C, 0.61
(95% CI −0.73 to 1.96); pharmacy vs.
C, 0.12 (95% CI −1.51 to 1.27); choice
vs. C, −1.33 (95% CI −2.55 to –0.11)
WC baseline: NR
BOCF 12-week weight change (kg): WW,
–4.43 (95% CI –5.3 to –3.6); SW,
–3.56 (95% CI –4.4 to –2.7); RC, –4.23
(95% CI –5.2 to –3.2); Size Down, –2.38
(95% CI –3.1 to –1.7); GP, –1.37
(95% CI –2.3 to –0.4); pharmacy, –2.11
(95% CI –3.2 to –1.0); choice, –3.32
(95% CI –4.1 to –2.5); C, –2.01 (95% CI
–2.8 to –1.2)
BOCF 1-year weight change (kg): WW,
–3.46 (95% CI –4.8 to –2.1); SW, –1.89
(95% CI –2.9 to –0.9); RC, –2.12
(95% CI –3.4 to –0.9); Size Down, –2.45
(95% CI –3.6 to –1.3); GP, –0.82
(95% CI –2.0 to –0.4); pharmacy, –0.66
(95% CI –1.7 to –0.4); choice, –2.15
(95% CI –3.4 to –0.9); C, –1.08 (95% CI
–2.1 to –0.1)
All programmes achieved significant
weight loss ranging from –1.37 kg
(GP) to –4.43 kg (WW) at 12 weeks
All except GP and pharmacy groups
resulted in significant weight loss at
1 year. At 1 year, only the WW group
had significantly greater weight loss
than did the control (exercise only)
group (2.5 kg, 95% CI 0.8 kg to
4.2 kg)
The commercial programmes (WW,
SW and RC) achieved significantly
greater weight loss than did the
primary care programmes (general
practice and pharmacy-based
interventions) at 12 weeks and 1 year.
At 1 year, the difference was 1.6 kg
(95% CI 0.3 to 2.9 kg; p= 0.06) in the
adjusted model. Mean weight loss at
1 year, with baseline value used for
imputation was 0.8 kg (SD 4.7 kg) for
primary care and 2.5 kg (SD 6.2 kg) for
commercial programmes
The primary care programmes were
the most costly to provide. If assumed
participants randomised to this
intervention continued to weigh
1.3 kg/m2 less throughout life, then
the cost per life-year saved was £77
(€88; US$122)
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Study Outcomes Summary
Weight between-group difference
adjusted for weight at baseline,
physical activity at baseline, age, sex
and ethnic group (kg):
WW vs. C, −2.49 (95% CI −4.15 to
–0.83); SW vs. C, −0.90 (95% CI −2.57
to 0.77); RC vs. C, −1.35 (95% CI
−3.03 to 0.33); SD vs. C, −1.65 (95% CI
−3.33 to 0.04); GP vs. C, 0.12 (95% CI
−1.96 to 1.72); pharmacy vs. C, 0.06
(95% CI −1.84 to 1.96); choice vs. C,
−1.47 (95% CI −3.13 to 0.20)
Other analyses:
l Completers
l LOCF
l Unadjusted between-group
difference (BMI, weight)
Other outcomes:
l % weight loss
l > 5% body weight loss
l Costs
l Physical activity
WW, n= 100; SW, n= 100;
RC, n= 100; Size Down, n= 100;
GP, n= 70; pharmacy, n= 70;
choice, n= 100; C, n= 100
Malone and Alger-Mayer, 200339
I: orlistat+ usual outpatient
care+ community pharmacy support
C: orlistat+ usual outpatient care
BMI baseline (kg/m2), mean (SD):
I, 48.3 (14.6); C, 42.8 (8.1)
BMI change: NR
WC baseline (cm), mean (SD): I, 128 (20);
C, 127 (17)
WC change: NR
Weight baseline (kg), mean (SD):
I, 130 (39); C, 124 (30)
26 weeks weight change (kg), mean (SD):
I, −3.5 (2.9); C, –3.0 (5.2)
Weight between-group difference: NR
I, n=15; C, n=15
Other outcomes:
l % weight loss
l > 3% body weight loss
l General health status (Short Form
questionnaire-36 items)
Very small study, high dropout and
high baseline BMI. Both groups
appeared to lose similar amount of
weight at 26 weeks
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Study Outcomes Summary
Phimarn et al., 201367
I: community pharmacist individual
support
C: primary care unit group support
BMI baseline (kg/m2), mean (SD),
I, 27.48×3.14; C, 27.74×3.25
16 weeks BMI (kg/m2), mean (SD):
I, 26.68×4.88; C, 27.93×3.30
BMI change (kg/m2), mean (SD):
I, –0.80×0.07; C, 0.19×0.04
BMI between-group difference: NR
WC baseline (inches), mean (SD):
I, 36.26 × 3.50 ; C, 37.23 × 3.02
16 weeks WC (inches), mean (SD):
I, 36.30 × 3.56 ; C, 37.12 × 3.01
WC (inches) change: I, 0.04×0.01;
C, –0.11×0.03
WC change (cm), mean (SD):
I, 0.1 × 0.03; C, –0.28×0.08
WC between-group difference: NR
Weight baseline (kg), mean (SD):
I, 66.80×7.44; C, 66.66×8.03
16 weeks weight (kg), mean (SD):
I, 65.98×7.15; C, 67.58 kg×7.98
Weight change (kg), mean (SD):
I, –0.82×0.29; C, 0.92×0.19
Weight between-group difference
(95% CI): NR
I, n=33; C, n=33
Other outcomes:
l theory of planned behaviour
scores
Neither group showed significant
improvement in clinical outcomes.
Small study. Completer analysis only
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Study Outcomes Summary
Multicomponent interventions (pharmacotherapy and lifestyle changes)
Diabetes mellitus – type 2
Ali et al., 201268
I: diabetes mellitus monitoring and
lifestyle modification counselling
C: usual care
BMI baseline (kg/m2), mean (SD):
I (n= 23), 30.84 (4.95); C (n= 23),
29.82 (5.46)
12 months BMI (kg/m2), mean (SD):
I (n= 23), 26.98 (3.31); C (n= 23),
28.73 (4.06)
BMI (kg/m2) change: NR
BMI (kg/m2) between-group difference
(95% CI): NR
WC (cm) baseline: NR
Weight (kg) baseline: NR
Other outcomes:
l DBP
l SBP
l Blood glucose
l HbA1c
l HDL-cholesterol
l LDL-cholesterol
l Triglycerides
l Diabetes Quality of Life Brief
Clinical Inventory
l Satisfaction with Information
received about Medicines
l Patients’ concerns and necessities
about their medicines (BMQ)
l Health Status (Short Form-36)
l Diabetes Knowledge Test
Small study, low attrition. Significant
reductions in BMI in the intervention
group as compared with no significant
changes in the control group from
baseline to follow-up but no
significant difference between groups
at follow-up
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Study Outcomes Summary
Correr et al., 201169
I: pharmacotherapy including patient
education
C: usual care
BMI baseline (kg/m2), mean (SD):
I, 29.2 (4.9); C, 27.6 (4.4)
52-week BMI change (kg/m2), mean:
I, –0.2 (95% CI –0.8 to 0.3); C, –0.1
(95% CI –0.7 to 0.4)
BMI between-group difference (kg/m2): NR
WC baseline (cm), mean (SD): I, 95.2
(11.4); C, 94.9 (10.2)
52-week WC change (cm), mean: I, 0.8
(95% CI –0.7 to 2.4); C, 0.06 (95% CI
–2.0 to 2.1)
WC between-group difference (cm)
(95% CI): NR
Weight baseline: NR
Other outcomes:
l Glycosylated haemoglobin
l Fasting capillary glycaemia
l DBP
l SBP
l Changes in medication
l Cost per patient to reduce HbA1c
values by 1%
I, n= 50; C, n= 46
BMI and WC remained similar
between the groups at follow-up.
Pharmacists were willing to participate
before randomisation
Analyses adjusted for baseline
differences however the percentage of
women, was greater among the
drop-outs (73.3% vs. 53.1%;
p= 0.014), and the initial SBP and
DBP, were higher in the completing
patients (p= 0.026 and p= 0.019,
respectively)
Fornos et al., 200670
I: pharmacotherapy and lifestyle advice
C: usual care
BMI baseline (kg/m2), mean (SD):
I, 31.0 (4.7); C, 31.7 (5.4)
13-month BMI (kg/m2), mean (SD):
I, 30.1 (4.4); C, 31.4 (5.4)
BMI change (kg/m2): NR
BMI between-group difference (kg/m2):
NR
WC (cm) baseline: NR
Weight (kg) baseline: NR
Other outcomes:
l Albumin-to-creatinine ratio
l Blood pressure
l Drug-related problems
l Fasting blood glucose
l HbA1c
l HDL-cholesterol
l Knowledge about diabetes
l LDL-cholesterol
l TC
l Triglycerides
I, n= 56; C, n= 56
Intervention group but not control
reduced BMI from baseline to follow-up
but BMI not significantly different
between groups at follow-up
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Study Outcomes Summary
Dyslipidaemia
Paulos et al., 200571
I: medication compliance and lifestyle
modifications
C: usual care
BMI baseline (kg/m2), mean (SD): NR
16-week BMI (kg/m2) change:
I, –0.4 (0.5); C, NR
BMI between-group difference (kg/m2): NR
There was no significant difference in
baseline BMI between the two groups,
but there was a significant decrease of
0.4 kg/m2 within the intervention group
WC baseline (kg), mean (SD): NR
Weight baseline (kg), mean (SD): NR
16-week weight change (kg), mean
(SD): I, −1.0 (1.3); C, +1.1 (2.6)
Weight between-group difference (kg): NR
Smoking status:
One intervention participant smoked
throughout the intervention
(three Cigarettes per day); six control
participants smoked at baseline, four
of whom increased the number of
cigarettes smoked per day by the end
of the intervention
Alcohol status:
Fifty per cent of the intervention
group and 72% of the control group
did not drink alcoholic beverages.
These numbers persisted until the
end of the program, although
2 patients in the intervention group
stopped drinking alcohol during the
study period and 1 patient decreased
his alcohol intake
Other outcomes:
l Cholesterol
l Drug-related problems
l Physical activity
l Quality of life
l Satisfaction
l Triglycerides
I, n= 23; C, n= 19
Appears to be significant difference
from baseline to follow-up for weight
in intervention group. Paper only
reports change in BMI for intervention
group (not control, assume it remains
similar to baseline). Does not report
baseline weight or BMI, only change in
these variables. Completer analyses
only
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Study Outcomes Summary
Hypertension
Zaragoza-Fernandez et al., 201272
I: diet and exercise
C: usual care
Hypertensive participants taking
anti-hypertensive medication but not
controlled
BMI baseline (kg/m2), mean (SD):
I (n= 76), 30.8 (3.9); C (n= 74),
30.0 (4.1)
8-week BMI (kg/m2), mean (SD):
I (n= 71), 30.4 (4.0); C (n= 72),
29.8 (4.1)
BMI change (kg/m2): NR
BMI between-group difference (kg/m2):
NR
WC baseline: NR
Weight baseline (kg), mean (SD):
I (n= 76), 78.3 (14.4); C (n= 74),
74.9 (12.4)
8-week weight (kg), mean (SD):
I (n= 71), 77.6 (14.8); C (n= 72),
74.3 (12.2)
Weight change (kg): NR
Weight between-group difference
(95% CI): NR
Other outcomes:
l Lifestyle behaviours (modification
of diet, salt restriction, alcohol
intake reduction, improving
regular physical exercise)
l DBP
l SBP
Short-term study but low attrition.
Main focus is about controlling
hypertension, BMI and weight appear
fairly stable from baseline to follow-up
and between groups (slight reductions)
Reports alcohol reduction, but only for
intervention group (as measure of
adherence rather than effectiveness).
Low attrition
BOCF, baseline observation carried forward; C, control; DBP, diastolic blood pressure; EQ, Exper_Quit; EQ-5D, European
Quality of Life-5 Dimensions; HDL, high-density lipoprotein; I, intervention; IQR, interquartile range; LDL, low-density
lipoprotein; LOCF, last observation carried forward; NR, not reported; p.p.m., parts per million; RC, Rosemary Conley;
SBP, systolic blood pressure; SE, standard error; SW, Slimming World; TC, total cholesterol; WW, Weight Watchers.
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Appendix 12 UK alcohol service evaluations that
were excluded from the systematic review
Reason for exclusion: these service evaluations did not meet the inclusion criteria for the systematicreview.
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